

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
REQUEST FOR FILING APPLICATION UNDER 37 CFR 1.53(b)
WITHOUT FILING FEE OR EXECUTED INVENTOR'S DECLARATION**

Assistant Commissioner for Patents
Washington, D.C. 20231 U.S. PTO



Atty. Dkt. 620-125

Date: November 28, 2000

Sir:

11/28/00

This is a request for filing a new PATENT APPLICATION under Rule 53(b) entitled:
POLYNUCLEOTIDE AND ITS USE FOR MODULATING A DEFENCE RESPONSE IN PLANTS
without a filing fee and/or without an executed inventor's oath/declaration.

JC825 U.S. PTO
09/722377
11/28/00



This application is made by the below identified inventor(s). Attached hereto are the following papers:

An abstract together with
120 pages of specification and claims including
73 numbered claims and also attached is/are
28 sheets of accompanying drawings.

This application is based on the following prior foreign application(s):

Application No.	Country	Filing Date
9615879.5	Great Britain	29 July 1996
9622626.1	Great Britain	30 October 1996
9704789.8	Great Britain	07 March 1997
PCT/GB97/02046	PCT	29 July 1997

respectively, the entire content of which is hereby incorporated by reference in this application, and priority is hereby claimed therefrom.

This application is based on the following prior provisional application(s):

Application No.	Filing Date
------------------------	--------------------

respectively, the entire content of which is hereby incorporated by reference in this application, and priority is hereby claimed therefrom.

Certified copy/ies of foreign applications attached.

This application is a continuation/ division/ continuation-in-part of application Serial No. 09/230,728, filed January 29, 1999; which is a 371 of PCT/GB97/02046, filed July 29, 1997.

Please amend the specification by inserting before the first line: --This application is a continuation/ division/ continuation-in-part of application Serial No. 09/230,728, filed January 29, 1999; which is a 371 of PCT/GB97/02046, filed July 29, 1997, the entire content of which is hereby incorporated by reference in this application.--

The Examiner's attention is directed to the prior art cited in the parent application by applicant and/or Examiner for the reasons stated therein. The Examiner is requested to initial and return the attached PTO-1449 Form listing that art.

1.	Inventor:	Paul (first)	M.J. MI	Schulze-Lefert (last)	German (citizenship)
	Residence: (city)	Norwich	(state/country) Great Britain		
	Post Office Address:	Sainsbury Laboratory, Norwich Research Park, Colney Lane, Norwich, Great Britain			
	(Zip Code)	NR4 7UH			
2.	Inventor:	Ralph (first)	MI	Panstruga (last)	German (citizenship)
	Residence: (city)	Aachen	(state/country) Germany		
	Post Office Address:	Weberstrasse 35, Aachen, Germany			
	(Zip Code)	52065			

NOTE: FOR ADDITIONAL INVENTORS, check box and attach sheet with same information.

Address all future communications to NIXON & VANDERHYE P.C., 1100 North Glebe Road, 8th Floor, Arlington, Virginia 22201.

1100 North Glebe Road, 8th Floor
Arlington, Virginia 22201-4714

Telephone: (703) 816-4000
Facsimile: (703) 816-4100

MJW:tat

NIXON & VANDERHYE P.C.

By Atty: Mary J. Wilson, Reg. No. 32,955

Signature: Mary J. Wilson

U.S. PATENT APPLICATION

Inventor(s): Paul M.J. Schulze-Lefert
Ralph Panstruga
Rainer Buschges

Invention: POLYNUCLEOTIDE AND ITS USE FOR MODULATING A DEFENCE
RESPONSE IN PLANTS

*NIXON & VANDERHYE P.C.
ATTORNEYS AT LAW
1100 NORTH GLEBE ROAD
8TH FLOOR
ARLINGTON, VIRGINIA 22201-4714
(703) 816-4000
Facsimile (703) 816-4100*

SPECIFICATION

POLYNUCLEOTIDE AND ITS USE FOR MODULATING A DEFENCE RESPONSE IN PLANTS

The present invention relates to stimulating a defence response in plants, with a view to providing the plants with enhanced pathogen resistance. More specifically, it has resulted from cloning of the barley *Mlo* gene, various mutant *mlo* alleles, and a number of homologues from various species. The *Mlo* gene has been isolated using a positional cloning approach which has never previously been successful in Barley.

Details and discussion are provided below. Wild-type *Mlo* exerts a negative regulatory function on a pathogen defence response, such that mutants exhibit a defence response in the absence of pathogen. In accordance with the present invention, down-regulation or out-competition of *Mlo* function may be used to stimulate a defence response in transgenic plants, conferring increased pathogen resistance.

Mutations have been described in several plants in which defence responses to pathogens appear to be constitutively expressed. Mutation-induced recessive alleles (*mlo*) of the barley *Mlo* locus exhibit a leaf lesion phenotype and confer an apparently durable, broad spectrum resistance to the powdery mildew pathogen, *Erysiphe graminis* f sp *hordei*.

Resistance responses to the powdery mildew pathogen have been genetically well characterized (Wiberg, 1974; Søgaard and Jørgensen, 1988; Jørgensen, 1994). In most analyzed cases resistance is specified by race-specific resistance genes following the rules of Flor's gene-for-gene hypothesis (Flor, 1971). In this type of plant/pathogen interaction, resistance

is specified by and dependent on the presence of two complementary genes, one from the host and one from the fungal pathogen. The complementary genes have been termed operationally (pathogen) resistance ("R") gene and avirulence gene, respectively. Most of the powdery mildew resistance genes (*Mlx*) act as dominant or semidominant traits (Jørgensen, 1994).

Monogenic resistance mediated by recessive (*mlo*) alleles of the *Mlo* locus is different. Apart from being recessive, it differs from race-specific resistance to single pathogen strains in that (i) it confers broad spectrum resistance to almost all known isolates of the pathogen (ii) *mlo* resistance alleles have been obtained by mutagen treatment of any tested susceptible wild type (*Mlo*) variety, and (iii) *mlo* resistance alleles exhibit a defence mimic phenotype in the absence of the pathogen (Wolter et al., 1993). Thus, the genetic data indicate the *Mlo* wild type allele exerts a negative regulatory function on defence responses to pathogen attack.

Resistance mediated by *mlo* alleles is currently widely used in barley breeding and an estimated 10 million hectares are annually planted in Europe with seeds of this genotype. A 'mlo like' inherited resistance to powdery mildew in other cereal plants has not been reported so far although the fungus is a relevant pathogen in wheat (attacked by *Erysiphe graminis* f sp *tritici*), oat (attacked by *E. g.* f sp *avenae*), and rye (attacked by *E. g.* f sp *secalis*). Because cereals are morphologically, genetically and biochemically highly related to each other (Moore et al., 1995), one would predict the

existence of homologous genes in these species. The failure to have found a 'mlo like' inherited resistance in wheat and oat is probably due to their hexaploid genomes, making it difficult to obtain by mutagenesis defective alleles in all six gene copies, and the chance of all such mutations occurring in Nature is remote. The failure to have found a mlo equivalent in other cereals is probably due to insignificant amount of mutational analysis in these species and complications as a result of their outbreeding nature (e.g. rye).

RFLP markers closely linked to *Mlo* on barley chromosome 4 were previously identified on the basis of a *mlo* backcross line collection containing *mlo* alleles from six genetic backgrounds (Hinze et al. , 1991). The map position of *Mlo* on the basis of RFLP markers was consistent with its chromosomal localization as determined by a previous mapping with morphological markers (Jørgensen, 1977).

Having identified an ~3cM genetic interval containing *Mlo* bordered by genetic markers, we decided to attempt to isolate the gene via positional cloning.

However, there is no documented example of a successful positional cloning attempt of a barley gene. We were faced with a number of difficulties.

Firstly, the genome of barley (5.3×10^9 bp/haploid genome equivalent; Bennett and Smith, 1991) has almost double the size of the human genome and because the total genetic map covers ~1.800 cM (Becker et al., 1995) we were confronted with a very unfavourable ratio of genetic and physical distances (1 cM

corresponds to ~ 3 Mb).

Secondly, a high resolution genetic map had to be constructed around *Mlo* enabling the positioning of linked markers with a precision of better than 0.1 cM.

Thirdly, we aimed to physically delimit the target gene and both flanking DNA markers on individual large insert genomic clones, a procedure later termed "chromosome landing" (Tanksley et al., 1995). For this purpose, a complete barley YAC library from barley Megabase DNA had to be constructed with an average insert size of 500-600 kb, which was unprecedented.

Fourthly, we had to prepare unusual genetic tools that enabled us to identify the *Mlo* gene within a physically delimited region without the need for a time consuming generation of barley transgenic plants and testing of different candidate genes. We used for our studies ten characterized radiation- or chemically-induced *mlo* mutants (Jørgensen, 1992). For a conclusive chain of evidence of the gene isolation we decided to depend upon a functional restoration of the wild type *Mlo* allele starting out from characterized *mlo* defective alleles. For this purpose, we performed *mlo* heteroallelic crosses and isolated susceptible intragenic *Mlo* recombinants. The sequence analysis of these proves the function of the described gene.

The cloning of the barley *Mlo* gene and homologues, including homologues from other plant species, gives rise to a number of practical applications, reflected in the various aspects of the present invention.

According to a first aspect of the present invention there is provided a nucleic acid molecule comprising a nucleotide sequence encoding a peptide with Mlo function. Those skilled in the art will appreciate that "Mlo function" refers to the ability to suppress a defence response, said defence response being race and/or pathogen independent and autonomous of the presence of a pathogen, such as, for example, the *Mlo* gene of barley, the *Acd* gene and the *Lsd* gene of *Arabidopsis*.

mlo mutations that down-regulate or disrupt functional expression of the wild-type *Mlo* sequence are recessive, such that they are complemented by expression of a wild-type sequence. Thus "Mlo function" can be determined by assessing the level of constitutive defence response and/or susceptibility of the plant to a pathogen such as, for example, powdery mildew or rust (e.g. yellow rust). Accordingly, a putative nucleotide sequence with *Mlo* function can be tested upon complementation of a suitable *mlo* mutant. The term "*mlo* function" is used to refer to sequences which confer a *mlo* mutant phenotype on a plant.

The capitalisation of "Mlo" and non-capitalisation of "mlo" is thus used to differentiate between "wild-type" and "mutant" function.

A *mlo* mutant phenotype is characterised by the exhibition of an increased resistance against one or more pathogens, which is race and/or pathogen independent and autonomous of the presence of a pathogen.

The test plant may be monocotyledonous or dicotyledonous.

Suitable monocots include any of barley, rice, wheat, maize or oat, particularly barley. Suitable dicots include *Arabidopsis*.

Nucleic acid according to the invention may encode a
5 polypeptide comprising the amino acid sequence shown in Figure
2, or an allele, variant, derivative or mutant, or homologue,
thereof.

Nucleic acid according to the present invention may have
the sequence of a *Mlo* gene of barley, or be a mutant, variant
10 (or derivative) or allele of the sequence provided, or a
homologue thereof. Preferred mutants, variants and alleles are
those which encode a sequence which retains a functional
characteristic of the wild-type gene, especially the ability to
suppress a defence response as discussed herein. Other
15 preferred mutants, variants and alleles encode a sequence
which, in a homozygote, cause constitutive activation of a
defence response, or at least promotes activation of a defence
response (i.e. is a *mlo* mutant sequence), e.g. by reducing or
wholly or partly abolishing *Mlo* function. Preferred mutations
20 giving *mlo* mutant sequences are shown in Table 1. Changes to a
sequence, to produce a mutant, derivative or variant, may be by
one or more of addition, insertion, deletion or substitution of
one or more nucleotides in the nucleic acid, leading to the
addition, insertion, deletion and/or substitution of one or
25 more amino acids. Of course, changes to the nucleic acid which
make no difference to the encoded amino acid sequence are
included. Particular variants, mutants, alleles and

DOCUMENTS CITED IN THE SPECIFICATION

derivatives are discussed further below, as well as homologues.

A preferred nucleic acid sequence according to an aspect of the present invention is shown in Figure 2 along with the predicted amino acid sequence. Nucleic acid may be subject to alteration by way of substitution of nucleotides and/or a combination of addition, insertion and/or substitution of one or more nucleotides with or without altering the encoded amino acids sequence (by virtue of the degeneracy of the genetic code).

As discussed below, further aspects of the present invention provide homologues of the *Mlo* sequence shown in Figure 2, including from rice (genomic sequence Figure 5, bottom line, cDNA sequence Figure 10, amino acid sequence Figure 13) and barley (genomic sequence Figure 6, bottom line, cDNA sequence Figure 11, amino acid sequence Figure 14); also Table 5B (nucleotide sequences) and Figure 5A (amino acid sequences) show homologous EST's from rice and *Arabidopsis*.

The present invention also provides a vector which comprises nucleic acid with any one of the provided sequences, preferably a vector from which a product can be expressed. The vector is preferably suitable for transformation into a plant cell and/or a microbial cell. The invention further encompasses a host cell transformed with such a vector, especially a plant cell or a microbial cell (e.g. *Agrobacterium tumefaciens*). Thus, a host cell, such as a plant cell, comprising nucleic acid according to the present invention is provided. Within the cell, the nucleic acid may be incorporated within the nuclear

genome, i.e. a chromosome. There may be more than one heterologous nucleotide sequence per haploid genome.

A vector comprising nucleic acid according to the present invention need not include a promoter, particularly if the 5 vector is to be used to introduce the nucleic acid into cells for recombination into the genome.

Nucleic acid molecules and vectors according to the present invention may be provided in a form isolated and/or purified from their natural environment, in substantially pure 10 or homogeneous form, or free or substantially free of nucleic acid or genes of the species of interest or origin other than the relevant sequence. Nucleic acid according to the present invention may comprise cDNA, RNA, genomic DNA and may be wholly or partially synthetic. The term "isolate" may encompass all 15 these possibilities.

The present invention also encompasses the expression product of any of the nucleic acid sequences disclosed and methods of making the expression product by expression from encoding nucleic acid therefore under suitable conditions in 20 suitable host cells, e.g. *E. coli*. Those skilled in the art are well able to construct vectors and design protocols for expression and recovery of products of recombinant gene expression. Suitable vectors can be chosen or constructed, containing one or more appropriate regulatory sequences, 25 including promoter sequences, terminator fragments, polyadenylation sequences, enhancer sequences, marker genes and other sequences as appropriate. For further details see, for

CONFIDENTIAL

example, Molecular Cloning: a Laboratory Manual: 2nd edition, Sambrook et al, 1989, Cold Spring Harbor Laboratory Press. Transformation procedures depend on the host used, but are well known. Many known techniques and protocols for manipulation of nucleic acid, for example in preparation of nucleic acid constructs, mutagenesis, sequencing, introduction of DNA into cells and gene expression, and analysis of proteins, are described in detail in *Short Protocols in Molecular Biology*, Second Edition, Ausubel et al. eds., John Wiley & Sons, 1992.

The disclosures of Sambrook et al. and Ausubel et al. are incorporated herein by reference, along with all other documents mentioned.

Purified Mlo protein, or a fragment, mutant or variant thereof, e.g. produced recombinantly by expression from encoding nucleic acid therefor, may be used to raise antibodies employing techniques which are standard in the art. Antibodies and polypeptides comprising antigen-binding fragments of antibodies may be used in identifying homologues from other species as discussed further below.

Methods of producing antibodies include immunising a mammal (eg human, mouse, rat, rabbit, horse, goat, sheep or monkey) with the protein or a fragment thereof. Antibodies may be obtained from immunised animals using any of a variety of techniques known in the art, and might be screened, preferably using binding of antibody to antigen of interest. For instance, Western blotting techniques or immunoprecipitation may be used (Armitage et al, 1992, Nature 357: 80-82).

092232/142600

Antibodies may be polyclonal or monoclonal.

As an alternative or supplement to immunising a mammal, antibodies with appropriate binding specificity may be obtained from a recombinantly produced library of expressed 5 immunoglobulin variable domains, eg using lambda bacteriophage or filamentous bacteriophage which display functional immunoglobulin binding domains on their surfaces; for instance see WO92/01047.

Antibodies raised to a polypeptide or peptide can be used 10 in the identification and/or isolation of homologous polypeptides, and then the encoding genes. Thus, the present invention provides a method of identifying or isolating a polypeptide with Mlo or mlo function (in accordance with embodiments disclosed herein), comprising screening candidate 15 peptides or polypeptides with a polypeptide comprising the antigen-binding domain of an antibody (for example whole antibody or a fragment thereof) which is able to bind an Mlo or mlo peptide, polypeptide or fragment, variant or variant thereof or preferably has binding specificity for such a peptide or polypeptide, such as having an amino acid sequence identified herein. Specific binding members such as antibodies 20 and polypeptides comprising antigen binding domains of antibodies that bind and are preferably specific for a Mlo or mlo peptide or polypeptide or mutant, variant or derivative thereof represent further aspects of the present invention, as 25 do their use and methods which employ them.

Candidate peptides or polypeptides for screening may for

instance be the products of an expression library created using nucleic acid derived from an plant of interest, or may be the product of a purification process from a natural source.

A peptide or polypeptide found to bind the antibody may be isolated and then may be subject to amino acid sequencing. Any suitable technique may be used to sequence the peptide or polypeptide either wholly or partially (for instance a fragment of a polypeptide may be sequenced). Amino acid sequence information may be used in obtaining nucleic acid encoding the peptide or polypeptide, for instance by designing one or more oligonucleotides (e.g. a degenerate pool of oligonucleotides) for use as probes or primers in hybridisation to candidate nucleic acid, or by searching computer sequence databases, as discussed further below.

A further aspect of the present invention provides a method of identifying and cloning *Mlo* homologues from plants, including species other than Barley, which method employs a nucleotide sequence derived from that shown in Figure 2. Further similar aspects employ a nucleotide sequence derived from any of the other Figures provided herein. Nucleic acid libraries may be screened using techniques well known to those skilled in the art and homologous sequences thereby identified then tested. The provision of sequence information for the *Mlo* gene of Barley and various homologues enables the obtention of homologous sequences from Barley and other plant species, as exemplified further herein.

Also, one can easily derive PCR primers based on putative

within the sequence shown in Figure 2, a single amino acid change with respect to the sequence shown in Figure 2, or 2, 3, 4, 5, 6, 7, 8, or 9 changes, about 10, 15, 20, 30, 40 or 50 changes, or greater than about 50, 60, 70, 80 or 90 changes.

5 In addition to one or more changes within the amino acid sequence shown in Figure 2, a mutant, allele, variant or derivative amino acid sequence may include additional amino acids at the C-terminus and/or N-terminus.

As is well-understood, homology at the amino acid level is generally in terms of amino acid similarity or identity.

10 Similarity allows for "conservative variation", i.e. substitution of one hydrophobic residue such as isoleucine, valine, leucine or methionine for another, or the substitution of one polar residue for another, such as arginine for lysine, 15 glutamic for aspartic acid, or glutamine for asparagine.

Similarity may be as defined and determined by the TBLASTN program, of Altschul et al. (1990) *J. Mol. Biol.* 215: 403-10, which is in standard use in the art, or, and this may be preferred, the standard program BestFit, which is part of the 20 Wisconsin Package, Version 8, September 1994, (Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA, Wisconsin 53711). BestFit makes an optimal alignment of the best segment of similarity between two sequences. Optimal alignments are found by inserting gaps to maximize the number 25 of matches using the local homology algorithm of Smith and Waterman

Homology may be over the full-length of the relevant

exon sequences, which might be identified by comparison with the *Mlo* sequence provided in Figure 2 wherein exons are highlighted, and perform RT-PCR with total RNA from the plant of interest, e.g. barley and rice for the homologues shown in Figures 5 and 6, with cDNA and amino acid sequences shown in other figures herein.

The homologues whose nucleotide sequences are given and whose amino acid sequences are given or are deducible represent and provide further aspects of the present invention in accordance with those disclosed for the Barley gene shown in Figure 2.

The present invention also extends to nucleic acid encoding a *Mlo* homologue obtained using a nucleotide sequence derived from that shown in Figure 2, or the amino acid sequence shown in Figure 2. Preferably, the nucleotide sequence and/or amino acid sequence shares homology with the sequence encoded by the nucleotide sequence of Figure 2, preferably at least about 50%, or at least about 55%, or at least about 60%, or at least about 65%, or at least about 70%, or at least about 75%, or at least about 80% homology, or at least about 85% homology, or at least about 90% homology, most preferably at least about 95% homology. "Homology" in relation to an amino acid sequence may be used to refer to identity or similarity, preferably identity. High levels of amino acid identity may be limited to functionally significant domains or regions.

A mutant, allele, variant or derivative amino acid sequence in accordance with the present invention may include

sequence shown herein, or may more preferably be over a contiguous sequence of about or greater than about 20, 25, 30, 33, 40, 50, 67, 133, 167, 200, 233, 267, 300, 333, 400, 450, 500, 550, 600 or more amino acids or codons, compared with the relevant amino acid sequence or nucleotide sequence as the case may be.

The EST sequences provided herein, have on average 70% similarity and 50% identity with the Mlo amino acid sequence of Figure 2. We show that the rice homologue (Figure 5) and barley homologue (Figure 6) have an amino acid identity of 81% (amino acid sequences shown in Figure 13 and Figure 14).

In certain embodiments, an allele, variant, derivative, mutant or homologue of the specific sequence may show little overall homology, say about 20%, or about 25%, or about 30%, or about 35%, or about 40% or about 45%, with the specific sequence. However, in functionally significant domains or regions the amino acid homology may be much higher. Putative functionally significant domains or regions can be identified using processes of bioinformatics, including comparison of the sequences of homologues. Functionally significant domains or regions of different polypeptides may be combined for expression from encoding nucleic acid as a fusion protein. For example, particularly advantageous or desirable properties of different homologues may be combined in a hybrid protein, such that the resultant expression product, with Mlo or mlc function, may comprise fragments of various parent proteins.

The nucleotide sequence information provided herein, or

any part thereof, may be used in a data-base search to find homologous sequences, expression products of which can be tested for *Mlo* or *mlo* function. These may have ability to complement a *mlo* mutant phenotype in a plant or may, upon 5 expression in a plant, confer a *mlo* phenotype.

In public sequence databases we recently identified several homologues for the sequence of Figure 2. We have already found homologues in rice and barley, and the dicot. *Arabidopsis*.

10 By sequencing homologues, studying their expression patterns and examining the effect of altering their expression, genes carrying out a similar function to *Mlo* in Barley are obtainable. Of course, mutants, variants and alleles of these sequences are included within the scope of the present 15 invention in the same terms as discussed above for the Barley gene.

Homology between the homologues as disclosed herein, may be exploited in the identification of further homologues, for example using oligonucleotides (e.g. a degenerate pool) 20 designed on the basis of sequence conservation.

According to a further aspect, the present invention provides a method of identifying or a method of cloning a *Mlo* homologue, e.g. from a species other than Barley, the method employing a nucleotide sequence derived from that shown in 25 Figure 2 or that shown in any of the other Figures herein. For instance, such a method may employ an oligonucleotide or oligonucleotides which comprises or comprise a sequence or

sequences that are conserved between the sequences of Figures 2 and/or 5 and/or 6 and/or 10 and/or 11 and/or 12, or encoding an amino acid sequence conserved between Figure 2 and/or 7 and/or 13 and/or 14 and/or 15 to search for homologues. Thus, a
5 method of obtaining nucleic acid is provided, comprising hybridisation of an oligonucleotide or a nucleic acid molecule comprising such an oligonucleotide to target/candidate nucleic acid. Target or candidate nucleic acid may, for example, comprise a genomic or cDNA library obtainable from an organism
10 known to contain or suspected of containing such nucleic acid, either monocotyledonous or dicotyledonous. Successful hybridisation may be identified and target/candidate nucleic acid isolated for further investigation and/or use.

Hybridisation may involve probing nucleic acid and
15 identifying positive hybridisation under suitably stringent conditions (in accordance with known techniques) and/or use of oligonucleotides as primers in a method of nucleic acid amplification, such as PCR. For probing, preferred conditions are those which are stringent enough for there to be a simple
20 pattern with a small number of hybridisations identified as positive which can be investigated further. It is well known in the art to increase stringency of hybridisation gradually until only a few positive clones remain.

As an alternative to probing, though still employing
25 nucleic acid hybridisation, oligonucleotides designed to amplify DNA sequences may be used in PCR reactions or other methods involving amplification of nucleic acid, using routine

procedures. See for instance "PCR protocols; A Guide to Methods and Applications", Eds. Innis et al, 1990, Academic Press, New York.

Preferred amino acid sequences suitable for use in the design of probes or PCR primers for some purposes are sequences conserved (completely, substantially or partly) between at least two *Mlo* peptides or polypeptides encoded by genes able to suppress a defence response in a plant, e.g. with any of the amino acid sequences of any of the various figures herein and/or encoded by the nucleotide sequences of any of the various figures herein.

On the basis of amino acid sequence information oligonucleotide probes or primers may be designed, taking into account the degeneracy of the genetic code, and, where appropriate, codon usage of the organism from the candidate nucleic acid is derived.

Preferably an oligonucleotide in accordance with certain embodiments of the invention, e.g. for use in nucleic acid amplification, is up to about 50 nucleotides, or about 40 nucleotides or about 30 or fewer nucleotides in length (e.g. 18, 21 or 24).

Assessment of whether or not such a PCR product corresponds to *Mlo* homologue genes may be conducted in various ways. A PCR band from such a reaction might contain a complex mix of products. Individual products may be cloned and each one individually screened. It may be analysed by transformation to assess function on introduction into a plant

DEPARTMENT OF TRADE AND INDUSTRY

of interest.

As noted, nucleic acid according to the present invention is obtainable using oligonucleotides, designed on the basis of sequence information provided herein, as probes or primers. Nucleic acid isolated and/or purified from one or more cells of barley or another plant (see above), or a nucleic acid library derived from nucleic acid isolated and/or purified from the plant (e.g. a cDNA library derived from mRNA isolated from the plant), may be probed under conditions for selective hybridisation and/or subjected to a specific nucleic acid amplification reaction such as the polymerase chain reaction (PCR). The nucleic acid probed or used as template in the amplification reaction may be genomic DNA, cDNA or RNA. If necessary, one or more gene fragments may be ligated to generate a full-length coding sequence.

We have tested several PCR primers derived from the *Mlo* sequence disclosed herein to test their specificity for amplifying nucleic acid according to the present invention, using both barley genomic DNA and RT-PCR templates. The latter was synthesized from barley polyA⁺ RNA. In each case we were able to amplify the expected *Mlo* derived gene fragments as shown by cloning and subsequent DNA sequencing of the PCR products. Full length cDNA clones can be obtained as described by 5' and 3' RACE technology if RT-PCR products are used as templates.

Examples of primers tested include:

19

25L 5'-GTG CAT CTG CGT GTG CGT A-3'
25LN 5'-GTG TGC GTA CCT GGT AGA G-3'
25R 5'-AAC GAC GTC TGG TGC GTG-3'
33 5'-TGC AGC TAT ATG ACC TTC CCC CTC-3'
5 37 5'-GGA CAT GCT GAT GGC TCA GA-3'
38 5'-CAG AAC TTG TCT CAT CCC TG-3
38A 5'-GGC TAT ACA TTG GGA CTA ACA-3'
38B 5'-CGA ATC ATC ACA TCC TAT GTT-3'
39 5'-GCA AGT TCG ACT TCC AC-3'
10 39A 5'-TCG ACT TCC ACA AGT ACA TCA-3'
53 5'-AGC GTA CCT GCG TAC GTA G-3'

Various primer combinations have been tested:

38/39A; 38/39; 38/33; 38/37; 38A/39A; 38B/39A; 38/25L; 38/25LN;
25R/25L; 25R/25LN; 25R/53.

15

Various aspects of the present invention include the obtainable nucleic acid, methods of screening material, e.g. cell lysate, nucleic acid preparations, for the presence of nucleic acid of interest, methods of obtaining the nucleic acid, and the primers and primer combinations given above.

The sequence information provided herein also allows the design of diagnostic tests for determination of the presence of a specific mlo resistance allele, or a susceptibility allele (e.g. wild-type), in any given plant, cultivar, variety, population, landrace, part of a family or other selection in a breeding programme or other such genotype. A diagnostic test

may be based on determination of the presence or absence of a particular allele by means of nucleic acid or polypeptide determination.

At the nucleic acid level, this may involve hybridisation 5 of a suitable oligo- or poly-nucleotide, such as a fragment of the Mlo gene or a homologue thereof, including any homologue disclosed herein, or any particular allele, such as an allele which gives an *mlo* phenotype, such as any such allele disclosed herein. The hybridisation may involve PCR designed to amplify 10 a product from a given allelic version of *mlo*, with subsequent detection of an amplified product by any of a number of possible methods including but not limited to gel electrophoresis, capillary electrophoresis, direct hybridisation of nucleotide sequence probes and so on. A 15 diagnostic test may be based on PCR designed to amplify various alleles or any allele from the Mlo locus, with a test to distinguish the different possible alleles by any of a number of possible methods, including DNA fragment size, restriction site variation (e.g. CAPS - cleaved amplified polymorphic 20 sites) and so on. A diagnostic test may also be based on a great number of possible variants of nucleic acid analysis that will be apparent to those skilled in the art, such as use of a synthetic *mlo*-derived sequence as a hybridisation probe.

Broadly, the methods divide into those screening for the 25 presence of nucleic acid sequences and those that rely on detecting the presence or absence of a polypeptide. The methods may make use of biological samples from one or more

plants or cells that are suspected to contain the nucleic acid sequences or polypeptide.

Exemplary approaches for detecting nucleic acid or polypeptides include analysing a sample from the plant or plant 5 cell by:

(a) comparing the sequence of nucleic acid in the sample with all or part of the nucleotide sequence shown in Figure 7 to determine whether the sample from the patient contains a mutation;

10 (b) determining the presence in the sample of a polypeptide including the amino acid sequence shown in Figure 2 or a fragment thereof and, if present, determining whether the polypeptide is full length, and/or is mutated, and/or is expressed at the normal level;

15 (c) performing DNA fingerprinting to compare the restriction pattern produced when a restriction enzyme cuts nucleic acid in the sample with the restriction pattern obtained from the nucleotide sequence shown in Figure 7 or from a known mutant, allele or variant thereof;

20 (d) contacting the sample with a specific binding member capable of binding to nucleic acid including the nucleotide sequence as set out in Figure 7 or a fragment thereof, or a mutant, allele or variant thereof, the specific binding member including nucleic acid hybridisable with the sequence of Figure 25 7 or a polypeptide including a binding domain with specificity for nucleic acid including the sequence of Figure 7 or the polypeptide encoded by it, or a mutated form thereof, and

determining binding of the specific binding member;

(e) performing PCR involving one or more primers based on the nucleotide sequence shown in Figure 7 to screen the sample for nucleic acid including the nucleotide sequence of Figure 7 or a mutant, allele or variant thereof.

When screening for a resistance allele nucleic acid, the nucleic acid in the sample will initially be amplified, e.g. using PCR, to increase the amount of the analyte as compared to other sequences present in the sample. This allows the target sequences to be detected with a high degree of sensitivity if they are present in the sample. This initial step may be avoided by using highly sensitive array techniques that are becoming increasingly important in the art.

A variant form of the gene may contain one or more insertions, deletions, substitutions and/or additions of one or more nucleotides compared with the wild-type sequence (such as shown in Table 1) which may or may not disrupt the gene function. Differences at the nucleic acid level are not necessarily reflected by a difference in the amino acid sequence of the encoded polypeptide. However, a mutation or other difference in a gene may result in a frame-shift or stop codon, which could seriously affect the nature of the polypeptide produced (if any), or a point mutation or gross mutational change to the encoded polypeptide, including insertion, deletion, substitution and/or addition of one or more amino acids or regions in the polypeptide. A mutation in a promoter sequence or other regulatory region may prevent or

reduce expression from the gene or affect the processing or stability of the mRNA transcript.

Tests may be carried out on preparations containing genomic DNA, cDNA and/or mRNA. Testing cDNA or mRNA has the advantage of the complexity of the nucleic acid being reduced by the absence of intron sequences, but the possible disadvantage of extra time and effort being required in making the preparations. RNA is more difficult to manipulate than DNA because of the wide-spread occurrence of RN'ases.

Nucleic acid in a test sample may be sequenced and the sequence compared with the sequence shown in Figure 2, or other figure herein, to determine whether or not a difference is present. If so, the difference can be compared with known susceptibility alleles (e.g. as summarised in Table 1) to determine whether the test nucleic acid contains one or more of the variations indicated, or the difference can be investigated for association with disease resistance.

The amplified nucleic acid may then be sequenced as above, and/or tested in any other way to determine the presence or absence of a particular feature. Nucleic acid for testing may be prepared from nucleic acid removed from cells or in a library using a variety of other techniques such as restriction enzyme digest and electrophoresis.

Nucleic acid may be screened using a variant- or allele-specific probe. Such a probe corresponds in sequence to a region of the gene, or its complement, containing a sequence alteration known to be associated with disease resistance.

Under suitably stringent conditions, specific hybridisation of such a probe to test nucleic acid is indicative of the presence of the sequence alteration in the test nucleic acid. For efficient screening purposes, more than one probe may be used 5 on the same test sample.

Allele- or variant-specific oligonucleotides may similarly be used in PCR to specifically amplify particular sequences if present in a test sample. Assessment of whether a PCR band contains a gene variant may be carried out in a number of ways 10 familiar to those skilled in the art. The PCR product may for instance be treated in a way that enables one to display the mutation or polymorphism on a denaturing polyacrylamide DNA sequencing gel, with specific bands that are linked to the gene variants being selected.

15 An alternative or supplement to looking for the presence of variant sequences in a test sample is to look for the presence of the normal sequence, e.g. using a suitably specific oligonucleotide probe or primer.

Approaches which rely on hybridisation between a probe and 20 test nucleic acid and subsequent detection of a mismatch may be employed. Under appropriate conditions (temperature, pH etc.), an oligonucleotide probe will hybridise with a sequence which is not entirely complementary. The degree of base-pairing between the two molecules will be sufficient for them to anneal 25 despite a mis-match. Various approaches are well known in the art for detecting the presence of a mis-match between two annealing nucleic acid molecules.

DEPARTMENT OF TRADE AND INDUSTRY

For instance, RN'ase A cleaves at the site of a mis-match. Cleavage can be detected by electrophoresing test nucleic acid to which the relevant probe or probe has annealed and looking for smaller molecules (i.e. molecules with higher 5 electrophoretic mobility) than the full length probe/test hybrid. Other approaches rely on the use of enzymes such as resolvases or endonucleases.

Thus, an oligonucleotide probe that has the sequence of a region of the normal gene (either sense or anti-sense strand) 10 in which mutations associated with disease resistance are known to occur (e.g. see Table 1) may be annealed to test nucleic acid and the presence or absence of a mis-match determined. Detection of the presence of a mis-match may indicate the presence in the test nucleic acid of a mutation associated with 15 disease resistance. On the other hand, an oligonucleotide probe that has the sequence of a region of the gene including a mutation associated with disease resistance may be annealed to test nucleic acid and the presence or absence of a mis-match determined. The presence of a mis-match may indicate that the 20 nucleic acid in the test sample has the normal sequence, or a different mutant or allele sequence. In either case, a battery of probes to different regions of the gene may be employed.

The presence of differences in sequence of nucleic acid molecules may be detected by means of restriction enzyme 25 digestion, such as in a method of DNA fingerprinting where the restriction pattern produced when one or more restriction enzymes are used to cut a sample of nucleic acid is compared

with the pattern obtained when a sample containing the normal gene or a variant or allele is digested with the same enzyme or enzymes.

The presence or absence of a lesion in a promoter or other 5 regulatory sequence may also be assessed by determining the level of mRNA production by transcription or the level of polypeptide production by translation from the mRNA.

Nucleic acid isolated and/or purified from one or more 10 cells of a plant or a nucleic acid library derived from nucleic acid isolated and/or purified from cells (e.g. a cDNA library derived from mRNA isolated from the cells), may be probed under conditions for selective hybridisation and/or subjected to a specific nucleic acid amplification reaction such as the polymerase chain reaction (PCR).

15 A method may include hybridisation of one or more (e.g. two) probes or primers to target nucleic acid. Where the nucleic acid is double-stranded DNA, hybridisation will generally be preceded by denaturation to produce single-stranded DNA. The hybridisation may be as part of a PCR 20 procedure, or as part of a probing procedure not involving PCR. An example procedure would be a combination of PCR and low stringency hybridisation. A screening procedure, chosen from the many available to those skilled in the art, is used to identify successful hybridisation events and isolate hybridised 25 nucleic acid.

Binding of a probe to target nucleic acid (e.g. DNA) may be measured using any of a variety of techniques at the

DOCUMENT EPO

disposal of those skilled in the art. For instance, probes may be radioactively, fluorescently or enzymatically labelled. Other methods not employing labelling of probe include examination of restriction fragment length polymorphisms, 5 amplification using PCR, RNAase cleavage and allele specific oligonucleotide probing.

Probing may employ the standard Southern blotting technique. For instance DNA may be extracted from cells and digested with different restriction enzymes. Restriction 10 fragments may then be separated by electrophoresis on an agarose gel, before denaturation and transfer to a nitrocellulose filter. Labelled probe may be hybridised to the DNA fragments on the filter and binding determined. DNA for probing may be prepared from RNA preparations from cells.

15 Preliminary experiments may be performed by hybridising under low stringency conditions various probes to Southern blots of DNA digested with restriction enzymes. Suitable conditions would be achieved when a large number of hybridising fragments were obtained while the background hybridisation was 20 low. Using these conditions nucleic acid libraries, e.g. cDNA libraries representative of expressed sequences, may be searched.

As noted, those skilled in the art are well able to employ suitable conditions of the desired stringency for selective 25 hybridisation, taking into account factors such as oligonucleotide length and base composition, temperature and so on.

In some preferred embodiments of diagnostic assays according to the present invention, oligonucleotides according to the present invention that are fragments of any of the sequences shown in Figure 2, or any allele associated with disease resistance, e.g. as identified in Table 1, are at least about 10 nucleotides in length, more preferably at least about 15 nucleotides in length, more preferably at least about 20 nucleotides in length, more preferably about 30 nucleotides in length. Such fragments themselves individually represent aspects of the present invention. Fragments and other oligonucleotides may be used as primers or probes as discussed but may also be generated (e.g. by PCR) in methods concerned with determining the presence in a test sample of a sequence indicative of disease resistance.

11

There are various methods for determining the presence or absence in a test sample of a particular polypeptide, such as the polypeptide with the amino acid sequence shown in Figure 2, or other figure herein, or an amino acid sequence mutant, variant or allele thereof (e.g. including an alteration shown in Table 1).

A sample may be tested for the presence of a binding partner for a specific binding member such as an antibody (or mixture of antibodies), specific for one or more particular variants of the polypeptide shown in Figure 2, e.g. see Table 1.

In such cases, the sample may be tested by being contacted

with a specific binding member such as an antibody under appropriate conditions for specific binding, before binding is determined, for instance using a reporter system as discussed. Where a panel of antibodies is used, different reporting labels 5 may be employed for each antibody so that binding of each can be determined.

A specific binding member such as an antibody may be used to isolate and/or purify its binding partner polypeptide from a test sample, to allow for sequence and/or biochemical analysis 10 of the polypeptide to determine whether it has the sequence and/or properties of the wild-type polypeptide or a particular mutant, variant or allele thereof. Amino acid sequence is routine in the art using automated sequencing machines.

15 The use of diagnostic tests for *mlo* alleles allows the researcher or plant breeder to establish, with full confidence and independent from time consuming resistance tests, whether or not a desired allele is present in the plant of interest (or a cell thereof), whether the plant is a representative of a 20 collection of other genetically identical plants (e.g. an inbred variety or cultivar) or one individual in a sample of related (e.g. breeders' selection) or unrelated plants. The *mlo* alleles conferring the desirable disease resistance phenotype are recessive, and are not therefore detectable at 25 the whole plant phenotype level when in a heterozygous condition in the presence of a wild-type Mlo allele. Phenotypic screening for the presence of such recessive alleles

is therefore only possible on material homozygous for the *mlo* locus and so delays substantially the generation in a plant breeding programme at which selection can be reliably and cost-effectively applied. In a backcross breeding programme where, 5 for example, a breeder is aiming to introgress a desirable *mlo* allele into an elite adapted high performing target genotype, the *mlo* locus will be permanently in the heterozygous condition until selfing is carried out. Nucleic acid or polypeptide testing for the presence of the recessive allele avoids the 10 need to test selfed progeny of backcross generation individuals, thus saving considerable time and money. In other types of breeding scheme based on selection and selfing of desirable individuals, nucleic acid or polypeptide diagnostics for the desirable *mlo* alleles in high throughput, low cost assays 15 as provided by this invention, reliable selection for the desirable *mlo* alleles can be made at early generations and on more material than would otherwise be possible. This gain in reliability of selection plus the time saving by being able to test material earlier and without costly resistance phenotype 20 screening is of considerable value in plant breeding.

By way of example for nucleic acid testing, the barley *mlo-5* resistance allele is characterized by a G- to A-nucleotide substitution in the predicted start codon of the *Mlo* gene (Table 1). The mutation may easily be detected by 25 standard PCR amplification of a *Mlo* gene segment from genomic template DNA with the primers:

forward primer: 5'-GTTGCCACACTTGTCCACG-3'

DOCUMENT E223583

reverse primer: 5' -AAGCCAAGACGACAATCAGA-3'
(for example), followed by digestion with the restriction enzyme *Psh*A1. This generates a cleaved amplified polymorphic sequences (CAPS) marker which may be displayed using conventional agarose gel electrophoresis. Presence of a 769 bp fragment is indicative of the presence of the *mlo*-5 allele.

The *mlo*-9 resistance allele is characterized by a C- to T-nucleotide substitution (Table 1). This allele is of particular relevance since it is used frequently in breeding material. The mutational event may be easily detected using the primers:

forward primer 5'-GRRGCCACACTTGCCACG-3'
reverse primer 5'-AAGCCAAGACGACAATCAGA-3'
(for example) and subsequent digestion of genomic amplification products with the restriction enzyme *Hha*I. This generates a CAPS marker which may be displayed by conventional agarose gel electrophoresis. The presence of a 374 bp fragment is indicative of the presence of *mlo*-9.

A third, particularly interesting allele is *mlo*-12, characterised by a substitution at residue 240, specifically a Phe240 to leucine replacement. This may result from a C720 to A substitution in the encoding nucleotide sequence (Table 1). This is the only currently documented *mlo* allele for which conclusive evidence is available that the altered protein retains residual wild-type activity (Henrich, 1979, Arch. Züchtungsvorsch., Berlin 9, S. 283-291). *mlo*-12 exhibits no detectable spontaneous cell death reaction but confers a

32

sufficient level of resistance to pathogens such as the powdery mildew fungus. mlo-12 may therefore be the allele of choice in breeding programs if minimal pleiotropic effects (spontaneous cell death) are desirable after introgression of the mlo resistance in elite breeding lines. Furthermore, the molecular site of the amino acid substitution within the Mlo protein allows the design of alleles with a residual wild-type activity, and also the obtention of interacting and/or inhibitory molecules, reducing undesirable pleiotropic effects from a complete loss of function of the Mlo protein.

Nucleic acid-based determination of the presence or absence of mlo alleles may be combined with determination of the genotype of the flanking linked genomic DNA and other unlinked genomic DNA using established sets of markers such as RFLPs, microsatellites or SSRs, AFLPs, RAPDs etc. This enables the researcher or plant breeder to select for not only the presence of the desirable mlo allele but also for individual plant or families of plants which have the most desirable combinations of linked and unlinked genetic background. Such recombinations of desirable material may occur only rarely within a given segregating breeding population or backcross progeny. Direct assay of the mlo locus as afforded by the present invention allows the researcher to make a stepwise approach to fixing (making homozygous) the desired combination of flanking markers and mlo alleles, by first identifying individuals fixed for one flanking marker and then identifying progeny fixed on the other side of the mlo locus all the time

knowing with confidence that the desirable *mlo* allele is still present.

The present disclosure provides sufficient information for a person skilled in the art to obtain genomic DNA sequence for any given new or existing *mlo* allele and devise a suitable nucleic acid- and/or polypeptide-based diagnostic assay.

Existing *mlo* alleles to which this may be applied include, for example, *mlo-1*, *mlo-3*, *mlo-4*, *mlo-5*, *mlo-6*, *mlo-7*, *mlo-8*, *mlo-9*, *mlo-10*, *mlo-12*, *mlo-13*, *mlo-16*, *mlo-17*, *mlo-26* and *mlo-28*, for all of which sequence information is provided herein (see e.g. Figure 2 and Table 1). In designing a nucleic acid assay account is taken of the distinctive variation in sequence that characterises the particular variant allele. Thus, the present invention extends to an oligonucleotide fragment of a *mlo* allele, having a sequence which allows it to hybridise specifically to that allele as compared with other *mlo* alleles. Such an oligonucleotide spans a nucleotide at which a *mlo* mutation occurs, and may include the mutated nucleotide at or towards its 3' or 5' end. Such an oligonucleotide may hybridise with the sense or anti-sense strand. The variation may be within the coding sequence of the *mlo* gene, or may lie within an intron sequence or in an upstream or downstream non-coding sequence, wherein disruption affects or is otherwise related to the lesion in *Mlo* that results in the mildew resistant phenotype.

The *mlo-9* allele is widely but not exclusively used in plant breeding (J Helms Jorgensen - *Euphytica* (1992) 63: 141-

SEARCHED
INDEXED
MAILED

152), *mlo*-11 is also used. Use of *mlo* mutants in practical breeding has largely been restricted to spring barley, because the spontaneous cell death response associated with many of the mutant alleles appears to represent a penalty to plant growth 5 and performance when incorporated into high yielding winter barley genotypes. However different *mlo* alleles have different degrees of associated spontaneous cell death response, and thus some, either existing or newly created from mutagenesis programmes or isolated as spontaneous mutants, are 10 more suitable than others for incorporation into winter barley backgrounds. The *mlo*-11 allele may be particularly suitable since no detectable pleiotropic effects occur despite conferring a sufficient level of pathogen resistance. The use of *mlo* based mildew resistance more widely in winter barleys 15 will have significant value for barley growers as well as significant economic and environmental implications such as reduced use of fungicide inputs with their associated treatment costs. The provision of nucleic acid diagnostics as provided herein enables rapid and accurate deployment of new and 20 existing *mlo* alleles into winter barley germplasm.

Plants which include a plant cell according to the invention are also provided, along with any part or propagule thereof, seed, selfed or hybrid progeny and descendants. A 25 plant according to the present invention may be one which does not breed true in one or more properties. Plant varieties may be excluded, particularly registrable plant varieties according

to Plant Breeders' Rights. It is noted that a plant need not be considered a "plant variety" simply because it contains stably within its genome a transgene, introduced into a cell of the plant or an ancestor thereof.

5 In addition to a plant, the present invention provides any clone of such a plant, seed, selfed or hybrid progeny and descendants, and any part of any of these, such as cuttings, seed. The invention provides any plant propagule, that is any part which may be used in reproduction or propagation, sexual or asexual, including cuttings, seed and so on. Also encompassed by the invention is a plant which is a sexually or asexually propagated off-spring, clone or descendant of such a plant, or any part or propagule of said plant, off-spring, clone or descendant.

10 15 A further aspect of the present invention provides a method of making a plant cell involving introduction of the sequence (e.g. as part of a suitable vector) into a plant cell and causing or allowing recombination between the vector and the plant cell genome to introduce the sequence of nucleotides 20 into the genome.

Following transformation of a plant cell a plant may be regenerated.

25 The invention further provides a method of modulating *Mlo* expression in a plant, which may modulate a defence response in the plant, comprising expression of a heterologous *Mlo* gene sequence (or mutant, allele, variant or homologue thereof, as

discussed) within cells of the plant. As discussed further herein, modulation or alteration of the level of constitutive defence response in a plant may be by way of suppression, repression or reduction (in the manner of wild-type *Mlo*) or promotion, stimulation, activation, increase, enhancement or augmentation (in the manner of mutant *mlo*). Activation or enhancement of the defence response may confer or increase pathogen resistance of the plant, especially resistance to powdery mildew and/or rust (such as yellow rust).

The term "heterologous" may be used to indicate that the gene/sequence of nucleotides in question have been introduced into said cells of the plant or an ancestor thereof, using genetic engineering, ie by human intervention. A transgenic plant cell, i.e. transgenic for the nucleic acid in question, may be provided. The transgene may be on an extra-genomic vector or incorporated, preferably stably, into the genome. A heterologous gene may replace an endogenous equivalent gene, ie one which normally performs the same or a similar function, or the inserted sequence may be additional to the endogenous gene or other sequence. An advantage of introduction of a heterologous gene is the ability to place expression of a sequence under the control of a promoter of choice, in order to be able to influence expression according to preference, such as under particular developmental, spatial or temporal control, or under control of an inducible promoter. Furthermore, mutants, variants and derivatives of the wild-type gene, e.g. with higher or lower activity than wild-type, may be used in

CONFIDENTIAL

place of the endogenous gene. Nucleic acid heterologous, or exogenous or foreign, to a plant cell may be non-naturally occurring in cells of that type, variety or species. Thus, nucleic acid may include a coding sequence of or derived from a particular type of plant cell or species or variety of plant, placed within the context of a plant cell of a different type or species or variety of plant. A further possibility is for a nucleic acid sequence to be placed within a cell in which it or a homologue is found naturally, but wherein the nucleic acid sequence is linked and/or adjacent to nucleic acid which does not occur naturally within the cell, or cells of that type or species or variety of plant, such as operably linked to one or more regulatory sequences, such as a promoter sequence, for control of expression. A sequence within a plant or other host cell may be identifiably heterologous, exogenous or foreign.

Down-regulation of wild-type *Mlo* gene function leads to stimulation of a constitutive defence response. This may be achieved in a number of different ways, as illustrated below.

The nucleic acid according to the invention may be placed under the control of an inducible gene promoter thus placing expression under the control of the user.

In a further aspect the present invention provides a gene construct comprising an inducible promoter operatively linked to a nucleotide sequence provided by the present invention. As discussed, this enables control of expression of the gene. The invention also provides plants transformed with said gene construct and methods comprising introduction of such a

construct into a plant cell and/or induction of expression of a construct within a plant cell, e.g. by application of a suitable stimulus, such as an effective exogenous inducer or endogenous signal.

5 The term "inducible" as applied to a promoter is well understood by those skilled in the art. In essence, expression under the control of an inducible promoter is "switched on" or increased in response to an applied stimulus (which may be generated within a cell or provided exogenously). The nature of
10 the stimulus varies between promoters. Some inducible promoters cause little or undetectable levels of expression (or no expression) in the absence of the appropriate stimulus. Other inducible promoters cause detectable constitutive expression in the absence of the stimulus. Whatever the level of expression
15 is in the absence of the stimulus, expression from any inducible promoter is increased in the presence of the correct stimulus. The preferable situation is where the level of expression increases upon application of the relevant stimulus by an amount effective to alter a phenotypic characteristic.
20 Thus an inducible (or "switchable") promoter may be used which causes a basic level of expression in the absence of the stimulus which level is too low to bring about a desired phenotype (and may in fact be zero). Upon application of the stimulus, expression is increased (or switched on) to a level
25 which brings about the desired phenotype.

Suitable promoters include the Cauliflower Mosaic Virus 35S (CaMV 35S) gene promoter that is expressed at a high level

SEARCHED
INDEXED
COPIED
SERIALIZED
FILED

in virtually all plant tissues (Benfey et al, (1990a) *EMBO J* 9: 1677-1684); the cauliflower meri 5 promoter that is expressed in the vegetative apical meristem as well as several well localised positions in the plant body, eg inner phloem, flower primordia, branching points in root and shoot (Medford, J.I. (1992) *Plant Cell* 4, 1029-1039; Medford et al, (1991) *Plant Cell* 3, 359-370) and the *Arabidopsis thaliana* LEAFY promoter that is expressed very early in flower development (Weigel et al, (1992) *Cell* 69, 843-859).

An aspect of the present invention is the use of nucleic acid according to the invention in the production of a transgenic plant.

When introducing a chosen gene construct into a cell, certain considerations must be taken into account, well known to those skilled in the art. The nucleic acid to be inserted should be assembled within a construct which contains effective regulatory elements which will drive transcription. There must be available a method of transporting the construct into the cell. Once the construct is within the cell membrane, integration into the endogenous chromosomal material either will or will not occur. Finally, as far as plants are concerned the target cell type must be such that cells can be regenerated into whole plants.

Plants transformed with the DNA segment containing the sequence may be produced by standard techniques which are already known for the genetic manipulation of plants. DNA can be transformed into plant cells using any suitable technology,

such as a disarmed Ti-plasmid vector carried by Agrobacterium exploiting its natural gene transfer ability (EP-A-270355, EP-A-0116718, NAR 12(22) 8711 - 87215 1984), particle or microprojectile bombardment (US 5100792, EP-A-444882, EP-A-5 434616) microinjection (WO 92/09696, WO 94/00583, EP 331083, EP 175966, Green et al. (1987) *Plant Tissue and Cell Culture*, Academic Press), electroporation (EP 290395, WO 8706614) other forms of direct DNA uptake (DE 4005152, WO 9012096, US 4684611), liposome mediated DNA uptake (e.g. Freeman et al. 10 *Plant Cell Physiol.* 29: 1353 (1984)), or the vortexing method (e.g. Kindle, *PNAS U.S.A.* 87: 1228 (1990d) Physical methods for the transformation of plant cells are reviewed in Oard, 1991, *Biotech. Adv.* 9: 1-11.

Agrobacterium transformation is widely used by those skilled in the art to transform dicotyledonous species. Recently, there has been substantial progress towards the routine production of stable, fertile transgenic plants in almost all economically relevant monocot plants (Toriyama, et al. (1988) *Bio/Technology* 6, 1072-1074; Zhang, et al. (1988) 15 *Plant Cell Rep.* 7, 379-384; Zhang, et al. (1988) *Theor Appl Genet* 76, 835-840; Shimamoto, et al. (1989) *Nature* 338, 274-276; Datta, et al. (1990) *Bio/Technology* 8, 736-740; Christou, et al. (1991) *Bio/Technology* 9, 957-962; Peng, et al. (1991) International Rice Research Institute, Manila, Philippines 563-20 574; Cao, et al. (1992) *Plant Cell Rep.* 11, 585-591; Li, et al. (1993) *Plant Cell Rep.* 12, 250-255; Rathore, et al. (1993) *Plant Molecular Biology* 21, 871-884; Fromm, et al. (1990)

41

Bio/Technology 8, 833-839; Gordon-Kamm, et al. (1990) *Plant Cell* 2, 603-618; D'Halluin, et al. (1992) *Plant Cell* 4, 1495-1505; Walters, et al. (1992) *Plant Molecular Biology* 18, 189-200; Koziel, et al. (1993) *Biotechnology* 11, 194-200; Vasil, I.

5 K. (1994) *Plant Molecular Biology* 25, 925-937; Weeks, et al. (1993) *Plant Physiology* 102, 1077-1084; Somers, et al. (1992) *Bio/Technology* 10, 1589-1594; WO92/14828). In particular, *Agrobacterium* mediated transformation is now emerging also as an highly efficient alternative transformation method in

10 monocots (Hiei et al. (1994) *The Plant Journal* 6, 271-282).

The generation of fertile transgenic plants has been achieved in the cereals rice, maize, wheat, oat, and barley (reviewed in Shimamoto, K. (1994) *Current Opinion in Biotechnology* 5, 158-162.; Vasil, et al. (1992) *Bio/Technology* 10, 667-674; Vain et al., 1995, *Biotechnology Advances* 13 (4): 653-671; Vasil, 1996, *Nature Biotechnology* 14 page 702).

Microprojectile bombardment, electroporation and direct DNA uptake are preferred where *Agrobacterium* is inefficient or ineffective. Alternatively, a combination of different techniques may be employed to enhance the efficiency of the transformation process, eg bombardment with *Agrobacterium* coated microparticles (EP-A-486234) or microprojectile bombardment to induce wounding followed by co-cultivation with *Agrobacterium* (EP-A-486233).

25 Following transformation, a plant may be regenerated, e.g. from single cells, callus tissue or leaf discs, as is standard in the art. Almost any plant can be entirely regenerated from

cells, tissues and organs of the plant. Available techniques are reviewed in Vasil et al., *Cell Culture and Somatic Cell Genetics of Plants*, Vol I, II and III, *Laboratory Procedures and Their Applications*, Academic Press, 1984, and Weissbach and 5 Weissbach, *Methods for Plant Molecular Biology*, Academic Press, 1989.

The particular choice of a transformation technology will be determined by its efficiency to transform certain plant species as well as the experience and preference of the person 10 practising the invention with a particular methodology of choice. It will be apparent to the skilled person that the particular choice of a transformation system to introduce nucleic acid into plant cells is not essential to or a limitation of the invention, nor is the choice of technique for 15 plant regeneration.

In the present invention, expression may be achieved by introduction of the nucleotide sequence in a sense orientation. Thus, the present invention provides a method of modulation of 20 a defence response in a plant, the method comprising causing or allowing expression of nucleic acid according to the invention within cells of the plant. Generally, it will be desirable to stimulate the defence response, and this may be achieved by disrupting *Mlo* gene function.

Down-regulation of expression of a target gene may be 25 achieved using anti-sense technology or "sense regulation" ("co-suppression").

In using anti-sense genes or partial gene sequences to

down-regulate gene expression, a nucleotide sequence is placed under the control of a promoter in a "reverse orientation" such that transcription yields RNA which is complementary to normal mRNA transcribed from the "sense" strand of the target gene.

5 See, for example, Rothstein et al, 1987; Smith et al, (1988) *Nature* 334, 724-726; Zhang et al, (1992) *The Plant Cell* 4, 1575-1588, English et al., (1996) *The Plant Cell* 8, 179-188. Antisense technology is also reviewed in Bourque, (1995), *Plant Science* 105, 125-149, and Flavell, (1994) *PNAS USA* 91, 3490-3496.

10 An alternative is to use a copy of all or part of the target gene inserted in sense, that is the same, orientation as the target gene, to achieve reduction in expression of the target gene by co-suppression. See, for example, van der Krol et al., (1990) *The Plant Cell* 2, 291-299; Napoli et al., (1990) *The Plant Cell* 2, 279-289; Zhang et al., (1992) *The Plant Cell* 4, 1575-1588, and US-A-5,231,020.

15 The complete sequence corresponding to the coding sequence (in reverse orientation for anti-sense) need not be used. For example fragments of sufficient length may be used. It is a routine matter for the person skilled in the art to screen fragments of various sizes and from various parts of the coding sequence to optimise the level of anti-sense inhibition. It may be advantageous to include the initiating methionine ATG codon, and perhaps one or more nucleotides upstream of the initiating codon. A further possibility is to target a conserved sequence of a gene, e.g. a sequence that is

DRAFT PCT/GB97/02046

characteristic of one or more genes, such as a regulatory sequence. Antisense constructs may involve 3' end or 5' end sequences of *Mlo* or homologues. In cases where several *Mlo* homologues exist in a plant species, the involvement of 5'- and 5 3'-end untranslated sequences in the construct will enhance specificity of silencing.

The sequence employed may be about 500 nucleotides or less, possibly about 400 nucleotides, about 300 nucleotides, about 200 nucleotides, or about 100 nucleotides. It may be 10 possible to use oligonucleotides of much shorter lengths, 14-23 nucleotides, although longer fragments, and generally even longer than about 500 nucleotides are preferable where possible, such as longer than about 600 nucleotides, than about 700 nucleotides, than about 800 nucleotides, than about 1000 15 nucleotides, than about 1200 nucleotides, than about 1400 nucleotides, or more.

It may be preferable that there is complete sequence identity in the sequence used for down-regulation of expression of a target sequence, and the target sequence, though total 20 complementarity or similarity of sequence is not essential. One or more nucleotides may differ in the sequence used from the target gene. Thus, a sequence employed in a down-regulation of gene expression in accordance with the present invention may be a wild-type sequence (e.g. gene) selected from 25 those available, or a mutant, derivative, variant or allele, by way of insertion, addition, deletion or substitution of one or more nucleotides, of such a sequence. The sequence need not

include an open reading frame or specify an RNA that would be translatable. It may be preferred for there to be sufficient homology for the respective anti-sense and sense RNA molecules to hybridise. There may be down regulation of gene expression even where there is about 5%, 10%, 15% or 20% or more mismatch between the sequence used and the target gene.

Generally, the transcribed nucleic acid may represent a fragment of an Mlo gene, such as including a nucleotide sequence shown in Figure 2, or the complement thereof, or may be a mutant, derivative, variant or allele thereof, in similar terms as discussed above in relation to alterations being made to a coding sequence and the homology of the altered sequence. The homology may be sufficient for the transcribed anti-sense RNA to hybridise with nucleic acid within cells of the plant, though irrespective of whether hybridisation takes place the desired effect is down-regulation of gene expression.

Anti-sense regulation may itself be regulated by employing an inducible promoter in an appropriate construct.

Constructs may be expressed using the natural promoter, by a constitutively expressed promotor such as the CaMV 35S promotor, by a tissue-specific or cell-type specific promoter, or by a promoter that can be activated by an external signal or agent. The CaMV 35S promoter but also the rice actin1 and maize ubiquitin promoters have been shown to give high levels of reporter gene expression in rice (Fujimoto et al., (1993) *Bio/Technology* 11, 1151-1155; Zhang, et al., (1991) *Plant Cell* 3, 1155-1165; Cornejo et al., (1993) *Plant Molecular Biology*

23, 567-581).

For use in anti-sense regulation, nucleic acid including a nucleotide sequence complementary to a coding sequence of a *Mlo* gene (i.e. including homologues), or a fragment of a said 5 coding sequence suitable for use in anti-sense regulation of expression, is provided. This may be DNA and under control of an appropriate regulatory sequence for anti-sense transcription in cells of interest.

Thus, the present invention also provides a method of 10 conferring pathogen resistance on a plant, the method including causing or allowing anti-sense transcription from heterologous nucleic acid according to the invention within cells of the plant.

The present invention further provides the use of the 15 nucleotide sequence of Figure 2 or a fragment, mutant, derivative, allele, variant or homologue thereof, such as any sequence shown or identified herein, for down-regulation of gene expression, particularly down-regulation of expression of an *Mlo* gene or homologue thereof, preferably in order to confer 20 pathogen resistance on a plant.

When additional copies of the target gene are inserted in sense, that is the same orientation as the target gene, a range of phenotypes is produced which includes individuals where over-expression occurs and some where under-expression of 25 protein from the target gene occurs. When the inserted gene is only part of the endogenous gene the number of under-expressing individuals in the transgenic population increases. The

mechanism by which sense regulation occurs, particularly down-regulation, is not well-understood. However, this technique is well-reported in scientific and patent literature and is used routinely for gene control. See, for example, van 5 der Krol et al., (1990) *The Plant Cell* 2, 291-229; Napoli et al., (1990) *The Plant Cell* 2, 279-289; Zhang et al, 1992 *The Plant Cell* 4, 1575-1588.

Again, fragments, mutants and so on may be used in similar terms as described above for use in anti-sense regulation.

10 Thus, the present invention also provides a method of conferring pathogen resistance on a plant, the method including causing or allowing expression from nucleic acid according to the invention within cells of the plant. This may be used to suppress *Mlo* activity. Here the activity of the product is 15 preferably suppressed as a result of under-expression within the plant cells.

As noted, *Mlo* down-regulation may promote activation of a defence response, which may in turn confer or augment pathogen resistance of the plant, especially resistance to powdery 20 mildew and/or rust (e.g. yellow rust).

Thus, the present invention also provides a method of modulating *Mlo* function in a plant, the method comprising causing or allowing expression from nucleic acid according to the invention within cells of the plant to suppress endogenous 25 *Mlo* expression.

Modified versions of *Mlo* may be used to down-regulate endogenous *Mlo* function. For example mutants, variants,

derivatives etc., may be employed. For instance, expression of a *mlo* mutant sequence at a high level may out-compete activity of endogenous *Mlo*.

Reduction of *Mlo* wild type activity may be achieved by
5 using ribozymes, such as replication ribozymes, e.g. of the hammerhead class (Haseloff and Gerlach, 1988, *Nature* 334: 585-591; Feyter et al. 1996, *Gen. Genet.* 250: 329-338).

Another way to reduce *Mlo* function in a plant employs transposon mutagenesis (reviewed by Osborne et al., (1995)
10 Current Opinion in Cell Biology 7, 406-413). Inactivation of genes has been demonstrated via a 'targeted tagging' approach using either endogenous mobile elements or heterologous cloned transposons which retain their mobility in alien genomes. *Mlo* alleles carrying any insertion of known sequence could be
15 identified by using PCR primers with binding specificities both in the insertion sequence and the *Mlo* homologue. 'Two-element systems' could be used to stabilize the transposon within inactivated alleles. In the two-element approach, a T-DNA is constructed bearing a non-autonomous transposon containing
20 selectable or screenable marker gene inserted into an excision marker. Plants bearing these T-DNAs are crossed to plants bearing a second T-DNA expressing transposase function. Hybrids are double-selected for excision and for the marker within the transposon yielding F₂ plants with transposed elements. The
25 two-element approach has a particular advantage with respect to Ac/Ds of maize, as the transposed Ds is likely to be unlinked to the transposase, facilitating outcrossing and stabilization

DOCUMENT EPO FILED

of the *Ds* insertion (Jones et al., (1994) *Science* 266, 789-793; Osborne et al., (1995) *Current Opinion in Cell Biology* 7, 406-413).

5 The *mlo*-based powdery mildew resistance is caused by the inactivation of the *Mlo* wild type allele, resulting in a recessive resistance phenotype. Substances that inhibit the activity of the *Mlo* wild type protein may be used to induce the resistance phenotype.

10 An important hint that complete inactivation of *Mlo* expression is not essential and may even be detrimental is provided by the description of mutagen-induced *mlo* resistance alleles that are likely to have retained residual wild type allele activity. These alleles exhibit no detectable spontaneous leaf necrosis which negatively affects photosynthesis rates and yield (Henrich, W (1979) *Arch. Züchtungsvorsch.*, Berlin 9, S. 283-291).

15 The *Mlo* protein is predicted to be membrane-anchored by seven transmembrane helices (see e.g. Figure 7). This structure prediction has been reinforced by recent analysis of *Mlo* homologues in rice and *Arabidopsis thaliana*. Structure prediction of the *Arabidopsis thaliana* homologue also suggests the presence of seven transmembrane helices. A comparison of the *Mlo* homologues revealed in addition conserved cysteine residues in the putative extracellular loops 1 and 3 and high probabilities of amphipathic helices in the second intracellular loop adjacent to the predicted transmembrane

helices 3 and 4. These conserved structural motifs in the family of Mlo proteins are reminiscent of G protein coupled receptors (GPCR) described extensively in mammalian systems. GPCRs are known to be activated by ligands and to amplify signals intracellularly via heterotrimeric G proteins. Without in any way providing a limitation on the nature or scope of any aspect of the present invention, it is predicted that Mlo activates an inhibitory G alpha subunit of heterotrimeric G proteins, thus leading to a downregulation of as yet unknown effector proteins.

The provision herein of Mlo sequence information enables the identification of antagonists of function of the Mlo protein (e.g. GPCR function). Antagonists of Mlo may block receptor activation by its unknown genuine ligand, mimicking recessive mutations in the Mlo gene. Such Mlo antagonists may be used as crop protection compounds, for example applied externally to the plant or crop or, where the compound is peptidyl in nature, delivered internally via a biological vector (e.g. recombinant infecting viral particle expressing the antagonistic molecule within target plant cells) or via a transgenic route (plants or plant cells genetically modified to express the antagonist molecule, perhaps under control of a promoter inducible by an externally applied compound (eg GST-II promoter from maize - Jepson et al Plant Molecular Biology 26:1855-1866 (1994)) allowing control over the timing of expression of the mlo inactivation phenotype.

Leaf segments of Mlo wild type plants may be tested with a

DRAFT PCT/GB97/02046

test substance, e.g. from a random or combinatorial compound library, for resistance upon challenge with pathogen such as powdery mildew. The detached leaf segment assay is used as a standard test system to score for susceptibility/resistance upon inoculation with powdery mildew spores. Leaf segments of 7-day-old seedlings of the genotype *Mlo RorI* may be placed on agar, for example individual wells of 96-well microtiter plates containing 50 μ l agar. Different compounds may be applied to the agar surface in each well at a concentration of about 1ppm dissolved in DMSO. Around seven days after inoculation of the detached leaf segments with pathogen, such as spores of a virulent powdery mildew isolate, compounds which induce resistance may be recognised by the absence of fungal mycelium on leaf segments in the microtiter plates.

A further selection may be used to discriminate between compounds that act in the *mlo* pathway and those that confer resistance by other mechanisms, or those which exhibit a direct fungitoxic activity. For this purpose mutants in genes (*Ror* genes) which may be required for *mlo* resistance (Freialdenhoven et al., (1996), The Plant Cell 8, 5-14) may be used. Mutants of these genes confer susceptibility to powdery mildew attack despite the presence of *mlo* resistance alleles. Plants of the genotype *Mlo rorI* (wild type *Mlo* protein and defective *RorI* gene) may be used, for example, to test compounds which induce resistance on *Mlo RorI* genotypes but exhibit susceptibility on the *Mlo rorI* genotype, enabling selection of candidate *Mlo* antagonists. Testing candidate compounds identified using a

leaf segment test may be used to drastically reduce the number of candidate compounds for further *in vitro* tests.

A further selection step of candidate antagonists may involve heterologous expression of the Mlo protein or a fragment thereof (e.g. in a baculovirus insect cell system) and subsequent binding assays with labelled molecules. Specific binding of compounds to cell lines expressing wild type Mlo protein is a good indicator of their antagonistic mode of action. Analysis of the deduced Mlo protein sequence has provided strong evidence that the protein is anchored in the membrane via seven transmembrane helices and may represent a novel member of the so-called serpentine receptor family. The conclusion is supported by the sequence data derived from homologous genes identified in barley, rice and *Arabidopsis*. Seven transmembrane proteins have been shown to be expressed at high level in the Baculovirus/insect cell system (up to 10^7 molecules per cell - Tate and Grisshamer, 1996, *TIBTECH* 14: 426-430). Since the family of Mlo proteins appears to be restricted to the plant kingdom, this provides a low-background environment for compound tests. Candidate compounds which are labelled, radioactively or non-radioactively, may be tested for specific binding to Sf9 insect cells expressing the Mlo protein after infection with a recombinant baculovirus construct. Specificity of the binding may be tested further by Sf9 expression of mutant mlo proteins which carry characterised mutations (e.g. as in Table 1) leading *in vivo* to resistance.

Thus, in various further aspects the present invention relates to assays for substances able to interfere with Mlo function, i.e. confer a *mlo* mutant phenotype, such substances themselves and uses thereof.

5 The use of Mlo in identifying and/or obtaining a substance which inhibits Mlo function is further provided by the present invention, as is the use of Mlo in identifying and/or obtaining a substance which induces pathogen resistance in a plant.

10 Agents useful in accordance with the present invention may be identified by screening techniques which involve determining whether an agent under test inhibits or disrupts Mlo function to induce an *mlo* phenotype. Candidate inhibitors are substances which bind Mlo.

15 It should of course be noted that references to "Mlo" in relation to assays and screens should be taken to refer to homologues, such as in other species, including rice and wheat, not just in barley, also appropriate fragments, variants, alleles and derivatives thereof. Assessment of whether a test 20 substance is able to bind the Mlo protein does not necessarily require the use of full-length Mlo protein. A suitable fragment may be used (or a suitable analogue or variant thereof).

25 Suitable fragments of Mlo include those which include residues known to be crucial for Mlo function as identified by *mlo* mutant alleles (Table 1). Smaller fragments, and analogues and variants of this fragment may similarly be employed, e.g.

SEARCHED
SERIALIZED
INDEXED
FILED

as identified using techniques such as deletion analysis or alanine scanning.

Furthermore, one class of agents that can be used to disrupt Mlo activity are peptides fragments of it. Such peptides tend to be short, and may be about 40 amino acids in length or less, preferably about 35 amino acids in length or less, more preferably about 30 amino acids in length, or less, more preferably about 25 amino acids or less, more preferably about 20 amino acids or less, more preferably about 15 amino acids or less, more preferably about 10 amino acids or less, or 9, 8, 7, 6, 5 or less in length. The present invention also encompasses peptides which are sequence variants or derivatives of a wild type Mlo sequence, but which retain ability to interfere with Mlo function, e.g. to induce an mlo mutant phenotype. Where one or more additional amino acids are included, such amino acids may be from Mlo or may be heterologous or foreign to Mlo. A peptide may also be included within a larger fusion protein, particularly where the peptide is fused to a non-Mlo(i.e. heterologous or foreign) sequence, such as a polypeptide or protein domain.

Peptides may be generated wholly or partly by chemical synthesis. The compounds of the present invention can be readily prepared according to well-established, standard liquid or, preferably, solid-phase peptide synthesis methods, general descriptions of which are broadly available (see, for example, in J.M. Stewart and J.D. Young, Solid Phase Peptide Synthesis, 2nd edition, Pierce Chemical Company, Rockford, Illinois

1984), in M. Bodanzsky and A. Bodanzsky, *The Practice of Peptide Synthesis*, Springer Verlag, New York (1984); and Applied Biosystems 430A Users Manual, ABI Inc., Foster City, California), or they may be prepared in solution, by the liquid phase method or by any combination of solid-phase, liquid phase and solution chemistry, e.g. by first completing the respective peptide portion and then, if desired and appropriate, after removal of any protecting groups being present, by introduction of the residue X by reaction of the respective carbonic or sulfonic acid or a reactive derivative thereof.

Another convenient way of producing a peptidyl molecule according to the present invention (peptide or polypeptide) is to express nucleic acid encoding it, by use of nucleic acid in an expression system, as discussed elsewhere herein. This allows for peptide agents to be delivered to plants transgenically, by means of encoding nucleic acid. If coupled to an inducible promoter for expression under control of the user, this allows for flexibility in induction of an mlo phenotype and pathogen resistance. This may allow for any side-effects arising from interference with Mlo function to be moderated.

In one general aspect the present invention provides an assay method for a substance able to interact with the relevant region of Mlo, the method including:

- (a) bringing into contact a Mlo polypeptide or peptide fragment thereof, or a variant, derivative or analogue

56

thereof, and a test compound; and

(b) determining interaction or binding between said polypeptide or peptide and the test compound.

A test compound found to interact with the relevant portion of Mlo may be tested for ability to modulate, e.g. disrupt or interfere with, Mlo function, as discussed already above.

Another general aspect of the present invention provides 10 an assay method for a substance able to induce an mlo mutant phenotype in a plant, the method including:

(a) bringing into contact a plant or part thereof (e.g. leaf or leaf segment) and a test compound; and

(b) determining Mlo function and/or pathogen resistance 15 and/or stimulation of a defence response in the plant.

Susceptibility or resistance to a pathogen may be determined by assessing pathogen growth, e.g. for powdery mildew the presence or absence, or extent, of mycelial growth.

Binding of a test compound to a polypeptide or peptide may 20 be assessed in addition to ability of the test compound to stimulate a defence response in a plant. Such tests may be run in parallel or one test may be performed on a substance which tests positive in another test.

25 Of course, the person skilled in the art will design any appropriate control experiments with which to compare results obtained in test assays.

PCT/GB97/02046

Performance of an assay method according to the present invention may be followed by isolation and/or manufacture and/or use of a compound, substance or molecule which tests positive for ability to modulate *Mlo* function and/or induce pathogen resistance, such as resistance to powdery mildew.

The precise format of an assay of the invention may be varied by those of skill in the art using routine skill and knowledge. For example, interaction between substances may be studied *in vitro* by labelling one with a detectable label and bringing it into contact with the other which has been immobilised on a solid support. Suitable detectable labels, especially for peptidyl substances include ^{35}S -methionine which may be incorporated into recombinantly produced peptides and polypeptides. Recombinantly produced peptides and polypeptides may also be expressed as a fusion protein containing an epitope which can be labelled with an antibody.

An assay according to the present invention may also take the form of an *in vivo* assay. The *in vivo* assay may be performed in a cell line such as a yeast strain or mammalian cell line in which the relevant polypeptides or peptides are expressed from one or more vectors introduced into the cell.

For example, a polypeptide or peptide containing a fragment of *Mlo* or a peptidyl analogue or variant thereof as disclosed, may be fused to a DNA binding domain such as that of the yeast transcription factor GAL 4. The GAL 4 transcription factor includes two functional domains. These domains are the

DNA binding domain (GAL4DBD) and the GAL4 transcriptional activation domain (GAL4TAD). By fusing such a polypeptide or peptide to one of those domains and another polypeptide or peptide to the respective counterpart, a functional GAL 4 transcription factor is restored only when two polypeptides or peptides of interest interact. Thus, interaction of the polypeptides or peptides may be measured by the use of a reporter gene probably linked to a GAL 4 DNA binding site which is capable of activating transcription of said reporter gene.

This assay format is described by Fields and Song, 1989, *Nature* 340; 245-246. This type of assay format can be used in both mammalian cells and in yeast. Other combinations of DNA binding domain and transcriptional activation domain are available in the art and may be preferred, such as the LexA DNA binding domain and the VP60 transcriptional activation domain.

When looking for peptides or other substances which interact with Mlo, the Mlo polypeptide or peptide may be employed as a fusion with (e.g.) the LexA DNA binding domain, with test polypeptide or peptide (e.g. a random or combinatorial peptide library) as a fusion with (e.g.) VP60. An increase in reporter gene expression (e.g. in the case of β -galactosidase a strengthening of the blue colour) results from the presence of a peptide which interacts with Mlo, which interaction is required for transcriptional activation of the β -galactosidase gene.

The amount of test substance or compound which may be

added to an assay of the invention will normally be determined by trial and error depending upon the type of compound used. Typically, from about 0.001 nM to 1mM or more concentrations of putative inhibitor compound may be used, for example from 0.01 nM to 100 μ M, e.g. 0.1 to 50 μ M, such as about 10 μ M. Greater concentrations may be used when a peptide is the test substance. Even a molecule which has a weak effect may be a useful lead compound for further investigation and development.

Compounds which may be used may be natural or synthetic chemical compounds used in drug screening programmes. Extracts of plants which contain several characterised or uncharacterised components may also be used. Antibodies directed to Mlo or a fragment thereof form a further class of putative inhibitor compounds. Candidate inhibitor antibodies may be characterised and their binding regions determined to provide single chain antibodies and fragments thereof which are responsible for disrupting the interaction. Other candidate inhibitor compounds may be based on modelling the 3-dimensional structure of a polypeptide or peptide fragment and using rational drug design to provide potential inhibitor compounds with particular molecular shape, size and charge characteristics. It is worth noting, however, that combinatorial library technology provides an efficient way of testing a potentially vast number of different substances for ability to interact with and/or modulate the activity of a polypeptide. Such libraries and their use are known in the art, for all manner of natural products, small molecules and

peptides, among others. The use of peptide libraries may be preferred in certain circumstances.

Following identification of a substance or agent which modulates or affects *Mlo* function, the substance or agent may be investigated further. Furthermore, it may be manufactured and/or used in preparation, i.e. manufacture or formulation, of a composition for inducing pathogen resistance in a plant. These may be applied to plants, e.g. for inducing pathogen resistance, such as resistance to powdery mildew. A further aspect of the present invention provides a method of inducing pathogen resistance in a plant, the method including applying such a substance to the plant. A peptidyl molecule may be applied to a plant transgenically, by expression from encoding nucleic acid, as noted.

A polypeptide, peptide or other substance able to modulate or interfere with *Mlo* function, inducing pathogen resistance in a plant as disclosed herein, or a nucleic acid molecule encoding a peptidyl such molecule, may be provided in a kit, e.g. sealed in a suitable container which protects its contents from the external environment. Such a kit may include instructions for use.

Further aspects and embodiments of the present invention will be apparent to those skilled in the art. The present invention will now be exemplified by way of illustration with

DEPARTMENT OF TRADE & INDUSTRY
PATENT OFFICE

reference to the following figures:

Figure 1 Positional Cloning of *Mlo*. The *Mlo* locus has been mapped with increasing precision on the long arm of barley chromosome 4 using morphological, RFLP and AFLP markers. The upper part of the figure presents the genetic linkage maps of these markers relative to *Mlo*. All genetic distances are indicated in centiMorgan (cM) based on multi-point linkage analysis except for genetic distances between AFLP markers which are calculated by two-point-estimates. The morphological marker map (Jørgensen, 1977) positions *Mlo* at a distance of more than 20 cM to hairy leaf sheath (*Hs*) and glossy sheath/spike (*gsl*). The RFLP marker map is based on the analysis of 257 F₂ individuals derived from the cross Carlsberg II *Mlo* Grannenlose Zweizeilige *mlo-11*. The previously published RFLP map (Hinze et al., 1991) of the same cross was based on only 44 F₂ individuals. The gene was delimited to a 2.7 cM interval bordered by markers bAO11 and bAL88. AFLP markers were identified and mapped as described in Experimental procedures. Their genetic distance to *Mlo* is based on the cross Ingrid *Mlo* x BC₇Ingrid *mlo-3*. The crucial result of the AFLP analysis has been the identification of two markers, Bpm2 and Bpm9, defining an 0.64 cM interval containing the *Mlo* locus and one marker (Bpm16) cosegregating with *Mlo* on the basis of more than 4,000 meiotic events. Marker Bxm2 which is located 0.1 cM telomeric to *Mlo* was derived from BAC F15 template DNA (see below). One YAC clone, YAC YHV303-A6, containing the

cosegregating marker Bpm16 and two flanking loci (Bpm2 and Bpm9), is shown in the middle section of the figure. The position of marker Bpm9 was only roughly estimated within the YAC clone as indicated by the arrow. The insert of BAC F15 represents a 60 kb subfragment of this YAC as indicated in the lower part of the Figure. After the identification of AFLP marker Bpm2 in BAC F15, marker Bxm2 was discovered and positioned 0.1 cM in telomeric orientation of Mlo. The approximate physical position of AFLP markers Bpm2, Bpm16, and Bxm2 (spanning an interval of approximately 30 kb) as well as the location of some rare occurring restriction sites are indicated. Dashed lines below the schematic representation of BAC F15 DNA show the position of the largest established DNA sequence contigs. The structure of the Mlo gene is given schematically in the bottom line of the Figure. Exons are highlighted by black boxes. Positions of mutational events are indicated for the eleven tested *mlo* alleles. Mutant alleles carrying deletions in their nucleotide sequence are marked with a Δ; the remaining mutant alleles represent single nucleotide substitutions resulting in amino acid exchanges in each case.

Figure 2 shows an Mlo coding sequence and encoded amino acid sequence according to the present invention. The amino acid sequence predicted from DNA sequences of RT-PCR products from Ingrid Mlo are shown. Nucleotide numbers are given according to translational start site.

Figure 3 Northern Blot Analysis of Mlo Transcript Accumulation. Total RNA (20 µg) and poly(A)⁺ RNA (5 µg) of

seven-day-old uninjected barley primary leaves of one wild type (cultivar Ingrid *Mlo*) and two mutant (BC Ingrid *mlo-1*, BC Ingrid *mlo-3*) cultivars were isolated, separated on a 1.2% formaldehyde gel and transferred to a nitrocellulose membrane (Hybond). The filter was probed under stringent conditions (Sambrook et al., 1989) with the radioactivity labelled full size RT-PCR product derived from Ingrid *Mlo* (Figure 7). A clear signal is detected only in the lanes containing poly(A)⁺ RNA. The signal corresponds to a size of approximately 2 kb.

Figure 4 Southern Blot Analysis of Intragenic Recombinants derived from *mlo* heteroallellic crosses. The alleles of two RFLP markers flanking *Mlo* on opposite sides of either susceptible *F*₂ individuals or homozygous susceptible and homozygous resistant progeny were determined by Southern blot analysis. Plant DNA (10 µg) of the individuals were digested with *Pst* I (A) or *Hae* III (B) and hybridized with the radioactively labelled RFLP markers WG114 (upper panel; maps 3.1 cM in centromeric orientation to *Mlo*; see Figure 1) and ABG366 (lower panel; maps 0.7 cM in telomeric orientation to *Mlo*; see Figure 1) according to standard procedures (Sambrook et al., 1989).

A DNA of the parental lines *mlo-8* and *mlo-1* and two homozygous susceptible (S, *Mlo Mlo*) and two resistant (R, *mlo mlo*) progenies derived from two susceptible *F*₂ plants (designated 1 and 2) were tested. The DNAs in lanes S and R represent selection *F*₃ individuals from *F*₃ families obtained by selfing the susceptible *F*₂ individuals 1 and 2. Note that

susceptible F_2 individuals are expected to be heterozygous at Mlo in this selection scheme. Infection phenotypes were scored seven days after inoculation with the mlo avirulent isolate K1. DNA from a third susceptible individual of this heteroallellic cross (see Table 7) is not included in this Figure.

B DNA of the parental lines mlo-5 and mlo-1 and seven homozygous susceptible (S, Mlo Mlo) and seven resistant (R, mlo mlo) progeny derived from seven susceptible F_2 plants (designated 1 to 7) were tested. The DNAs in lanes S and R represent selected F_3 individuals from F_3 families obtained by selfing the susceptible F_2 individuals 1 to 7. DNA was analyzed from two further susceptible individuals of this heteroallellic cross only in the F_2 generation (8* and 9*).

Figure 5 shows an alignment of genomic sequences covering the barley Mlo gene and a rice homologue isolated via crosshybridization with a barley gene specific probe. The top line shows the barley Mlo genomic DNA sequence (exon sequences underlined). The bottom line shows the rice genomic sequence containing the rice Mlo homologue.

Figure 6 shows an alignment of genomic sequences carrying the barley Mlo gene and a barley homologue isolated via crosshybridization with a barley gene specific probe. The top line shows the barley Mlo genomic DNA sequence (exon sequences underlined). The bottom line shows the genomic sequence containing the barley Mlo homologue.

Figure 7 Nucleotide and Deduced Amino Acid Sequence of the Barley Mlo cDNA. The nucleotide and the deduced amino acid

DRAFT PCT/GB97/02046

sequence are based on the combined data of RT-PCR and RACE obtained from experiments using RNA of cultivar Ingrid Mlo. The stop codon is marked by an asterisk, the putative polyadenylation signal is underlined and the detected termini of RACE products are indicated by arrows above the sequence.

5 Positions of introns as indentified by comparison with corresponding genomic clones are labelled by triangles below the nucleic acid sequence. Six predicted transmembrane spanning helices according to the MEMSAT algorithm (Jones et al., 1994) are boxed in grey colour. A putative nuclear localization signal (K-K-K-V-R) and casein kinase II site (S-I-F-D) in the carboxy-terminal half of the protein are shown in bold type.

10 Figure 8 shows genomic sequence of rice (*Oryza sativa*) homologue including coding and flanking sequences.

15 Figure 9 shows genomic sequence of barley (*Hordeum vulgare*) homologue including coding and flanking sequences.

Figure 10 shows cDNA sequence of rice homologue.

Figure 11 shows cDNA sequence of barley homologue.

20 Figure 12 shows cDNA sequence of *Arabidopsis thaliana* homologue.

Figure 13 shows amino acid sequence of rice homologue.

Figure 14 shows amino acid sequence of barley homologue.

25 Figure 15 shows amino acid sequence of *Arabidopsis* homologue.

Figure 16 shows a pretty box of amino acid sequences of Mlo, barley, rice and *Arabidopsis* homologues.

All documents mentioned in this document are incorporated by reference.

EXAMPLE 1 - CLONING OF MLO OF BARLEY

5

Targeted search for AFLP markers tightly linked to Mlo

Efforts to increase the DNA marker density around *Mlo* were coordinated with attempts to construct a local high resolution genetic map. An alternative possibility would have been to 10 extend the population size of the characterized cross Carlsberg II *Mlo* x Grannenlose Zweizeilige *mlo-11* (Hinze et al., 1991) but it was felt to be advantageous to establish a high resolution map starting out from one of the available BC *mlo* lines and its recurrent parent line. Importantly, the 15 donor parent of the BC line represents a different genetic background in comparison to the recurrent parent line. In this way, searching for linked AFLP markers could be started in parallel with generating a large mapping population from a cross between the same genetic lines. In addition, the BC line 20 based cross allowed testing of colinearity of DNA markers in the vicinity of *Mlo* as determined from the cross Carlsberg II *Mlo* x Grannenlose Zweizeilige *mlo-11* (Hinze et al., 1991). For the new cross a *mlo-3* backcross (BC) line was used that had been backcrossed seven times into the genetic 25 background Ingrid (BC, Ingrid *mlo-3*; Hinze et al., 1991). The line was previously characterized to carry a relatively small introgressed DNA segment on barley chromosome 4. In addition,

DOCUMENT FILE NUMBER

the donor parent line Malteria Heda *mlo-3* exhibits in comparison to DNA from the recurrent parent Ingrid polymorphisms with most of the identified RFLP loci linked to *Mlo*. Thus, by searching polymorphisms only between two DNA 5 templates, from lines Ingrid *Mlo* and BC₇ Ingrid *mlo-3*, we hoped to increase the density of DNA markers with AFLPs around *Mlo* in a targeted manner.

The same two lines were crossed to establish a segregating population for high resolution mapping of DNA markers, formally 10 representing an eighth backcross. F₂ individuals were scored for *mlo* resistance after powdery mildew inoculation with isolate K1 (virulent on Ingrid *Mlo* and avirulent on BC₇ Ingrid *mlo-3*). Initially, only a small fraction of the F₂ (77 individuals) was 15 analyzed for recombination events with flanking RFLP markers. Analysis of four identified recombinants (designated 8-32-2, 7- 38-4, 1-34-1, and 1-49-4) indicated colinearity of marker order 20 in this cross compared to the previously analyzed cross Carlsberg II *Mlo* x Grannenlose Zweizeilige *mlo-11* (Hinze et al., 1991). Several of the 77 F₂ seedlings which exhibited a susceptible phenotype and heterozygosity for the tested flanking DNA marker loci (bAO11, bAL88/2, and bAP91; Hinze et 25 al., 1991) were grown to maturity to provide further selfed seed material segregating for *Mlo/mlo-3* in the F₃ generation. In total, leaf material was harvested for high resolution marker mapping from 2,026 individuals derived from either the selfed F₂ or F₃ generation.

AFLP marker candidates were identified by testing all

possible *Pst* I/*Mse* I primer combinations (1,024) extending into genomic sequences up to nucleotide positions +2 and +3, respectively. Similarly, almost 1,900 *Eco* RI/*Mse* I primer combinations (+3/+3) have been analyzed. Four DNA templates were included in this analysis: Ingrid *Mlo*, BC, Ingrid *mlo-3*, a DNA pool of two phenotypically *mlo* resistant *F*₂ individuals, and a DNA pool of nine phenotypically susceptible *F*₂ individuals. The resistant and susceptible *F*₂ individuals which were included as DNA pools in the AFLP search had been selected from the above mentioned RFLP analysis of 77 *F*₂ segregants. The pooled *F*₂ DNA enabled us to control whether candidate polymorphisms detected between template DNA from the parents were heritable traits in the *F*₂. All identified AFLP candidate markers have been re-examined with eight DNA templates: Ingrid *Mlo*, BC, Ingrid *mlo-3*, DNA pools from individuals of three *F*₃ families which were phenotypically homozygous susceptible (*MloMlo*) according to K1 inoculation experiments; DNA of three resistant *F*₂ individuals. A total of 18 *Pst* I/*Mse* I and 20 *Eco* RI/*Mse* I primers were confirmed based on the selection procedure.

The number of identified AFLP markers made it useful to assign them first roughly to marker intervals based on the RFLP map around *Mlo*. It was hoped that this approach should enable both evaluation of the distribution of AFLPs among previously identified RFLP intervals close to *Mlo* and selection of a pair of flanking AFLP markers with which recombinants could be identified among the 2,026 segregants. For AFLP assignment we

used those four recombinants that had been identified with RFLP markers out of the above mentioned small sample of 77 F₂ segregants from Ingrid *Mlo* x BC₇, Ingrid *mlo-3* (two recombinants in interval bAP91-bAL88, one in *Mlo*-bAO11, and one in bAO11-ABG366). A total of 18 AFLPs were found to be located within a genetic distance of approximately 3.5 cM including *Mlo*.

Construction of a high resolution AFLP map around Mlo

A two-step procedure was used to construct the high resolution AFLP map. First, all 2,026 segregants were screened for recombination events between two AFLP markers on opposite sides of *Mlo* and subsequently only the few identified recombinants were used to map all the identified AFLPs in the 3.5 cM target interval. AFLP markers Bpm1 and Bpm9 were chosen, detecting each allelic DNA fragments in Ingrid *Mlo* and BC₇, Ingrid *mlo-3* and located on opposite sites of *Mlo* to screen DNA templates of the segregants for recombination events.

Alternatively, the search for recombinants could have been carried out with the flanking RFLP markers bAO11 and bAL88.

However, although the conversion into cleaved amplified polymorphic sites (CAPS) was successful for both markers, difficulties to display the alleles of both loci simultaneously from crudely purified genomic DNA were encountered. A total of 2,026 individuals (F₂ or F₃ segregants) were screened simultaneously with AFLP markers Bpm1 and Bpm9 and 98 recombinants were identified. AFLP analysis was subsequently carried out with each of the 98 DNA templates of the

recombinants to identify the alleles of each of the identified of AFLP loci. The recombinants have been selfed and inoculation experiments with powdery mildew isolate K1 were performed using at least 25 individuals of each recombinant 5 family to deduce the alleles of the previous generation at the *Mlo* locus. The obtained data enabled the construction of a high resolution map around *Mlo* based on more than 4,000 meiotic events and a resolution of at least 0.025 cM derived via two-point estimates. The essential result has been the 10 identification of a DNA marker cosegregating with *Mlo* (*Bpm16*) and two flanking markers (*Bpm2* and *Bpm9*) at a distance of 0.25 and 0.4 cM respectively (Figure 1).

Construction of a large insert size barley YAC library, 15 isolation of *Bpm16* containing YACs, and physical delimitation of *Mlo*

The genetic evidence indicates that *mlo* resistance is due to loss of function in the *Mlo* wild type allele. Therefore, it was decided to establish a large insert size YAC library from 20 cultivar Ingrid *Mlo* into vector pYAC4 (Burke et al., 1987; Hieter, 1990). Megabase DNA suitable for YAC cloning experiments was prepared in mg amounts from mesophyll protoplasts of five-day-old seedlings according to a modified protocol described by Siedler and Graner (1991). The DNA was 25 partially digested with Eco RI in the presence of Eco RI methyltransferase to obtain DNA fragments after preparative pulsed-field gel electrophoresis (PFGE) in the size range of

500-600 kb. After ligation with *Eco* RI digested pYAC4, the DNA was transformed into yeast strain AB1380 and colonies carrying recombinant pYAC4 DNA were selected on solidified synthetic complete medium lacking tryptophan and uracil (Sherman et al., 5 1986). Forty randomly selected yeast colonies were tested for the presence of barley DNA using labelled barley genomic DNA in Southern experiments. The size of the YAC inserts was found after PFGE separations to vary between 500 and 800 kb. On average a genetic distance of 0.2 cM was expected to be 10 represented on the individual recombinant YAC clone. A total of ~40,000 clones representing four barley genome equivalents have been generated.

15 Four YAC clones (designated 303A6, 322G2, 400H11, and 417D1) have been isolated with marker Bpm16 cosegregating with Mlo. Their insert size was determined by PFGE to be 650, 710, 650, and 820 kb respectively. AFLP analysis had shown that three of these clones (303A6, 322G2, and 417D1) contain also both flanking marker loci whereas clone 400H11 contains only loci Bpm16 and Bpm2. These findings strongly suggested that the 20 Mlo gene had been physically delimited on recombinant YAC clones 303A6, 322G2, and 417D1.

YAC 303A6 was chosen for subcloning experiments into BAC vector pECSBAC4 containing a unique *Eco* RI site (Shizuya et al., 1992; the vector pECSBAC4 is described by Frijters and 25 Michelmore, 1996; submitted). Total yeast DNA of this clone was partially digested with *Eco* RI to obtain DNA fragments with an average size of 50 kb and ligated into *Eco* RI digested and

5 dephosphorylated BAC vector. Bacterial colonies containing YAC 303A6-derived DNA in pECSBAC4 were identified by replica colony hybridization experiments. One set of colony containing membranes was hybridized with labelled yeast AB1380 DNA and the replica set was hybridized with labelled PFGE-purified YAC303A6 DNA. Recombinant BAC clones containing the AFLP locus Bpm16 were subsequently identified using the cloned 108 bp *Pst* I/*Mse* I genomic Bpm16 fragment as a probe in colony hybridization experiments.

10 One BAC clone, BAC F15, containing an insert of ~ 60 kb
was chosen for further detailed studies. It was found that the
recombinant BAC clone contained in addition the AFLP marker
locus Bpm2, but not Bpm9. At this point the BAC F15 insert DNA
indicated successful physical delimitation in telomeric
15 orientation but it was an open question whether the insert
would contain bordering sequences in centromeric direction.
Instead of constructing a BAC contig between Bpm 16 and Bpm9,
the option to develop new polymorphic markers from BAC F15 was
chosen. An allelic *Xba* I/*Mse* I polymorphism (designated Bxm2)
20 was identified between the parental lines Ingrid Mlo and
BC₇ Ingrid mlo-3.

An analysis of the 25 recombinant individuals carrying recombination events within the *Mlo* containing interval Bpm2-Bpm9 enabled mapping of *Bxm2* in centrometric orientation at a distance of 0.1 cM from *Mlo*. Only four out of the 16 available recombinants in the interval Bpm9-*Mlo* and none of the 9 recombinants in the interval *Mlo*-Bpm2 were found to exhibit a

recombination event between Bxm2 and *Mlo*. It was concluded that *Mlo* had been physically delimited on BAC F15 between marker loci Bpm2 and Bxm2 (Figure 1).

5 *Identification of the Mlo gene and mlo mutants*

A random sequencing project was initiated to determine sequence contigs of the ~60 kb insert of BAC F15 before marker Bxm2 was identified and shown to delimit the gene in telomeric orientation. In parallel, a physical map was generated
10 (Figure 1). The physical map indicated that the flanking markers Bpm2 and Bxm2 are physically separated by ~30 kb. The sequence contigs were searched for regions of high coding probability using the UNIX versions of the STADEN program package. Only one sequence contig of almost 6 kb, including the cosegregating marker Bpm16, revealed an extensive region of
15 high coding probability.

RT-PCR reactions were performed with total leaf RNA derived from cultivar Ingrid *Mlo* using a series of primers deduced from regions which indicated high coding probabilities
20 and obtained in each case a distinct amplification product. Sequencing of the largest RT-PCR products revealed a single extensive open reading frame of 1,602 bp (Figure 2). The deduced putative protein of 533 amino acids has a molecular weight of 60.4 kDa. The ~1.7 kb RT-PCR product was used as a
25 hybridization probe and detected a single RNA transcript of ~1.9 kb length. (Figure 3). A comparison of the genomic sequence and the largest RT-PCR fragment reveals 12 exons and

11 introns, each flanked by the characteristic splice site sequences (Figure 1).

Because marker Bpm16 is located at the 3' end of the above described gene (exon 11) and cosegregates with the *Mlo* locus, we started a direct PCR sequencing of the various available mutagen-induced *mlo* resistance alleles. We identified in 14 out of 15 tested mutant alleles nucleotide alterations which result either in single amino acid alterations, deletions or frame shifts of the wild type sequence (Table 1). We suspect that mutant allele *mlo*-2 is located within the promoter- or 5' untranslated sequences. The region is notoriously difficult to be sequenced via direct PCR sequencing from genomic DNA templates but experiments using a series of nested primers are likely to solve this problem. In summary, the comparative sequencing of genomic DNA from various mutant *mlo* lines and their respective *Mlo* wild type cultivars provided strong evidence that *Mlo* has been identified.

20 *Intragenic recombinants*

It had been the intention to provide a chain of evidence for the molecular isolation of *Mlo* which did not rely upon complementation experiments via transgenic barley plants. We had chosen to develop an unusual genetic tool to confirm that the identified gene represented *Mlo*. It was reasoned that if the mutations observed in the above described gene caused resistance to the powdery mildew fungus, recombination events

DRAFT DRAFT DRAFT

between mutant allele sites should restore wild type sequences. It was predicted that those intragenic recombinants would exhibit susceptibility upon powdery mildew attack.

A crossing scheme was devised involving *mlo* resistance alleles *mlo-1*, *mlo-5*, and *mlo-8*. The mutant alleles originate from the genetic backgrounds Haisa (*mlo-1*) and Carlsberg II (*mlo-5* and *mlo-8*). Intermutant crosses were performed as shown in Table 2 generating in each case at least 10 *F*₁ plants. *F*₂ populations were obtained by self-fertilization. *F*₂ seedlings were screened for rare susceptible individuals after inoculation with powdery mildew isolate K1 which is virulent on each of the parental *Mlo* wild type cultivars. Susceptible *F*₂ individuals were identified with a frequency of ~6 × 10⁻⁴. In contrast, if comparable numbers of progenies from selfings of each of the *mlo* mutants were tested for resistance to K1, no susceptible seedling was identified. This finding strongly indicated that the majority of the susceptible individuals derived from the intermutant crosses were not due to spontaneous reversion events of the mutant *mlo* alleles.

Inheritance of the susceptible *F*₂ individuals was tested after selfing in *F*₃ families. Each of the *F*₂ individuals segregated susceptible and resistant *F*₃ individuals indicating heterozygosity for alleles conferring resistance/susceptibility in the *F*₂. Homozygous susceptible *F*₃ progeny were isolated for the majority of susceptible *F*₂ individuals by selfing of *F*₃ individuals and subsequent identification of *F*₄ families in which only susceptible individuals were detected.

A molecular analysis of the susceptible individuals has been performed using RFLP markers known to be tightly linked (< 3 cM) on each side of the *Mlo* locus (Figure 4). RFLP marker WG114 maps in centromeric orientation relative to *Mlo*, marker 5 ABG366 maps in the direction of the telomere. Detected RFLP alleles are shown for the intermutant crosses *mlo-8* x *mlo-1* (A) and *mlo-1* x *mlo-5* (B). DNA was analyzed either from susceptible 10 *F*₂ individuals (indicated by *) or from homozygous susceptible (S) and homozygous resistant (R) *F*₃ progeny obtained from selfed susceptible *F*₂ individuals.

The homozygous susceptible *F*₃ progeny from the susceptible *F*₂ plant #1 of cross 15 *mlo-8* x *mlo-1* (Figure 4) reveals the WG114 allele derived from the *mlo-1* parent in centromeric orientation next to *Mlo* and the ABG366 allele from the *mlo-8* parent in telomeric orientation to *Mlo*. The homozygous resistant *F*₃ progeny from *F*₂ plant #1 of 20 this cross reveals in contrast only the flanking marker alleles derived from parent *mlo-1*. The finding strongly suggested that susceptibility in *F*₂ plant #1 is caused by a cross-over type of recombination in the preceding meiosis of one chromosome which results in a restoration of the *Mlo* wild type allele whereas the second *F*₂ chromosome of individual 1 contains a functionally unaltered *mlo-1* allele. The allelotypes of the RFLP loci of the homozygous susceptible *F*₃ progeny from 25 susceptible *F*₂ plant #2 are identical to the one described above. However, flanking marker alleles from the homozygous resistant *F*₃ progeny of this individual are in both cases

derived from the *mlo-8* parent. It is concluded that again a cross-over type of recombination restored one *Mlo* wild type allele in the susceptible F_2 individual #2.

Nine susceptible F_2 individuals were recovered from the cross *mlo-1* x *mlo-5* (Figure 4). For susceptible F_2 individuals #1 to #7 both homozygous susceptible and homozygous resistant F_3 progeny were analyzed at the DNA level. Note that only DNA from the heterozygous susceptible F_2 individuals was analyzed in the case of individuals #8 and #9 (marked by a *). The following allele patterns with respect to the flanking RFLP loci were observed: (i) homozygous resistant F_3 progeny showed on both sides of *Mlo* either only the allelotypes of loci WG114 and ABG366 derived from the *mlo-1* parent (individuals #1, #3, #6, #7) or only the allelotypes derived from the *mlo-5* parent (individuals #2, #4, #5). (ii) Homozygous susceptible F_3 progeny showed in contrast either only the allelotypes of both loci derived from the *mlo-5* parent (no. #3, #5, #6) or they showed different allelotypes on both sides of *Mlo* (individuals #1, #2, #4, #7). (iii) The homozygous susceptible F_3 progeny with different allelotypes on both sides always contain in centromeric orientation the *mlo-1* derived WG114 allele and in telomeric orientation the *mlo-5* derived ABG366 allele. (iv) The heterozygous susceptible F_2 individual #8 reveals on either side next to *Mlo* only the alleles derived from parent *mlo-5*. The heterozygous susceptible individual #9 reveals in centromeric orientation alleles derived from both parents *mlo-1* and *mlo-5* whereas only the *mlo-5* derived allele is detected in

telomeric orientation. A comprehensive interpretation of the data suggests that susceptibility in F_2 individuals no. #1, #2, #4, #7, and #9 is caused by a cross-over type of recombination restoring the *Mlo* wild type allele. Non cross-over types of recombination may have restored the *Mlo* wild type allele in individuals no. #3, #5, #6, and #8.

A compilation of the detected flanking RFLP alleles of all isolated susceptible F_2 individuals or homozygous F_3 progeny is shown in Table 3. Note that individual #3 of the cross *mlo-8* x *mlo-1* is not shown in Figure 4. The compilation reveals that (i) cross-over types of recombination (CO) and non cross-over types of recombination (NCO) are found with a ratio of 7 : 5, (ii) cross-over types of recombination are resolved unidirectional, and (iii) NCO recombinants were not observed with parental *mlo-1*-linked RFLP alleles.

The CO type intragenic recombinants isolated from heteroallelic *mlo* crosses were used to test whether wild type sequences of the *Mlo* candidate gene had been restored. For the three relevant alleles *mlo-1*, *mlo-5*, *mlo-8* alleles candidate mutation sites have been identified (Table 1 and 4). Direct PCR sequencing of genomic DNA of susceptible intragenic recombinants derived from both heteroallelic crosses *mlo-1* x *mlo-8* and *mlo-1* x *mlo-5* revealed restoration of wild type sequences (Table 4). This observation strongly suggests that the intragenic cross over event occurred between nucleotide -1 and +483 in the former and +3 and +483 in the latter cross (according to translational start site). Thus, the molecular

analysis of seven intragenic recombinants from two heteroallellic crosses provides final proof that the above described candidate gene represents *Mlo*.

5 EXAMPLE 2 - HOMOLOGUES OF THE IDENTIFIED MLO GENE

The available expressed sequence tag (EST) databases of *Oryzae sativa* (rice) and *Arabidopsis thaliana* were searched for homologous protein sequences. Five *Arabidopsis* cDNA clones were identified whose deduced amino acid sequences show substantial similarity to the *Mlo* protein. Remarkable is cDNA clone 10 205N12T7 which reveals a chance probability of 1.2×10^{-45} . In addition, at least one significant homologue was found in rice (OSR16381A).

15 A rice BAC library (Wang et al., 1995) has also been screened with a labelled barley genomic fragment containing *Mlo*. A BAC clone containing an insert of ~23 kb was isolated. Subsequent subcloning enabled isolation of a 2.5 kb *Pst* I 20 genomic rice fragment showing strong cross-hybridization with the barley *Mlo* gene probe. DNA sequencing of this fragment revealed remarkable DNA sequence similarities within exon sequences of the barley *Mlo* gene (Figure 5).

Finally, a 13 kb λ genomic barley clone derived from 25 cultivar Igri (Stratagene) was isolated with a labelled barley genomic fragment containing *Mlo*. The nucleotide sequence derived from a subcloned 2.6 kb *Sac* I fragment reveals again extensive sequence similarities to the *Mlo* gene (Fig. 6). The

location of the barley *Mlo* homologue within the genome is not within BAC F15 DNA.

In summary, there is conclusive evidence for *Mlo* homologues both in a monocotyledonous and a dicotyledonous 5 plant species.

Discussion

Any speculation as to mode of action of *Mlo* and *mlo* nucleic acid and polypeptides should provide no limitation on 10 the nature or scope of any aspect or embodiment of the present invention.

In plants, resistance to pathogens is frequently determined by dominant resistance genes, whose products are assumed to recognize pathogen-derived avirulence gene products. 15 This mode of pathogen defence follows Flor's gene-for-gene hypothesis (Flor, 1971). Recently, several 'gene-for-gene' type resistance genes have been molecularly isolated (Martin et al., 1993; Bent et al., 1994; Jones et al., 1994; Mindrinos et al., 1994; Whitham et al., 1994; Grant et al., 1995; Lawrence et 20 al., 1995; Song et al., 1995). The surprising finding is that the deduced proteins share remarkable similar structural domains although they trigger resistance reactions to pathogens such as viruses, fungi, and bacteria (Dangl, 1995; Staskawicz et al., 1995). The isolated genes code for proteins that either 25 contain a leucine-rich region (LRR), with or without an attached nucleotide binding site (NBS), indicative of ligand-binding and protein-protein interaction or encode a simple

serine/threonine kinase. A structural combination of LRR and the kinase domain has been reported in the deduced protein from the rice *Xa21* resistance gene (Song et al., 1995). The structural similarity of resistance genes in 'gene-for-gene' defence makes the existence of a common underlying resistance mechanisms likely.

Resistance mediated by recessive resistance alleles of the *Mlo* gene differs in various aspects from 'gene-for-gene' resistance (see introductory comments above). The molecular isolation of the *Mlo* gene and the sequencing of various mutation-induced *mlo* alleles described here, confirms previous interpretations from combined mutational and Mendelian genetic studies (Henrich, 1979; Jørgensen, 1983). It is concluded that defective alleles of the *Mlo* locus mediate broad spectrum resistance to pathogens such as the powdery mildew pathogen. This is inconsistent with the involvement of a specific recognition event of a pathogen-derived product as has been proposed for race-specific resistance genes.

Pleiotropic effects of *mlo* alleles have provided some clues towards the development of a molecular concept of the observed broad spectrum resistance response.

Firstly, aseptically grown *mlo* plants exhibit at a high frequency a spontaneous formation of cell wall appositions (CWAs) in leaf epidermal cells (Wolter et al., 1993). Those CWAs are usually formed in response to attempted pathogen penetration directly beneath the fungal appressorium. CWAs are believed to form a physical barrier against pathogen ingress

and have been implicated repeatedly in *mlo* mediated resistance (Bayles, 1990).

Secondly, at a later stage, the plants develop macroscopically detectable leaf necrotic flecks. The 5 spontaneous leaf necrosis response has been extensively studied with a unique collection of 95 chemically-induced *mlo* alleles (Henrich, 1979). The alleles were classified as either showing a gradually different infection phenotype upon infection of a mixture of nine powdery mildew isolates. Those *mlo* alleles which give rise to an intermediate infection phenotype (i.e. development of a considerable number of sporulating fungal colonies upon inoculation) showed no detectable spontaneous leaf necrosis whereas the category of the most effective resistance alleles exhibits pronounced necrosis in the absence of the pathogen. Thus, there is solid evidence that the former category of *mlo* alleles retain residual wild type allele activity and those alleles appear to exhibit no detectable spontaneous leaf necrosis.

Thirdly, a constitutive expression of defence-related genes has been observed in *mlo* seedlings grown under mildew-free conditions - in primary leaves when 10-11 days old; this includes genes of the PR-1 family, chitinases and peroxidases.

We have shown that *mlo* in barley confers increased resistance to different types of yellow rust (*Puccinia struciformis*) when a one to one mixture of talcum powder and spores were aviblown onto leaves of *mlo* barley plants after onset of constitutive expression of defence related genes (10-

SEARCHED
SERIALIZED
INDEXED
FILED

11 day old *mlo* seedlings).

Thus, it appears that multiple defence-associated responses are constitutively expressed in *mlo* plants.

The temporal relationship of these events is interesting:
5 the onset of constitutive defence-related transcript accumulation is detected in 11 day-old seedlings and precedes CWA formation which is followed by the appearance of macroscopically visible leaf necrosis. Importantly, however, *mlo* resistance can be experimentally tested as early as in five
10 day-old seedlings and is fully functional at this time. We conclude that the *Mlo* protein has a negative regulatory function in plant defence and that plants with a defective protein are 'primed' for the onset of defence responses.

The deduced amino acid sequence of *Mlo* reveals no
15 significant homologies to any of the described plant resistance genes so far, supporting the idea of a distinct molecular resistance mechanism. The *Mlo* gene shows also no striking similarities to any characterized plant or mammalian gene sequence in the various data bases. However, highly significant
20 homologous sequences have been identified in the EST and genomic databases both from rice and *Arabidopsis thaliana* (Table 5 and Figure 5). This strongly suggests that the *Mlo* protein represents a member of a novel protein family. A putative nuclear localization motif (NLS) is found within exon
25 12 providing indication of nuclear localization of the protein (KEKKKVR; Nigg et al., 1991). The significance of this motif is supported by a casein kinase II motif located 14 amino acids

into direction of the NH₂-terminus (SIFD; Rihs et al., 1991). Functional tests may examine the putative subcellular localization of the Mlo protein.

Mutations have been described also in other plant species in which defence responses to pathogens appear to be constitutively expressed (Walbot et al., 1983; Pryor, 1987; Jones, 1994). It has been suggested that this class of mutants, termed lesion mimics (*Les*) or necrotic mutants (*nec*), affect the control of plant defence responses. Recessively inherited lesion mimic mutants have been systematically analysed in *Arabidopsis thaliana* (Greenberg and Ausubel, 1993; Dietrich et al., 1994; Greenberg et al., 1994; Weymann et al. 1995). The affected genes have been designated *acd* (accelerated cell death; *acd1* and *acd2*) or *lsd* (lesions simulating disease resistance response; *lsd1* to *lsd7*).

Each of the mutants exhibits, in the absence of pathogens, HR characteristics such as plant cell wall modifications and the accumulation of defence-related gene transcripts. Leaves of the *acd2* mutant have been shown to accumulate high levels of salicylic acid and of the *Arabidopsis* phytoalexin, camelexin (Tsuji et al., 1992). Importantly, *acd* and *lsd* mutants exhibit elevated resistance to a bacterial (*P. syringae*) and fungal (*P. parasitica*) pathogen. The *lsd1* mutant is exceptional in that it confers heightened pathogen resistance at a prelesion state, in contrast to the other defective loci which exhibit elevated pathogen resistance only in the lesion-positive state. In this respect, *lsd1* resembles the *mlo* mutants in barley. Another

SEARCHED
INDEXED
FILED
JULY 1998
199804586

striking feature of *lsd1* is the indeterminate spread of lesions in contrast to the other mutants where lesion growth is determinate.

5 EXPERIMENTAL PROCEDURES

Plant Material

A compilation of the *mlo* mutants and their mother varieties analyzed in this study has been described by Jørgensen (1992) [*mlo-1*, *mlo-3*, *mlo-4*, *mlo-5*, *mlo-7*, *mlo-8*, *mlo-9*, *mlo-10*, *mlo-11*] and by Habekuss and Henrich (1988) [mutants in cultivar Plena 2018 (*mlo-13*), 2034 (*mlo-17*), 2118]. Since mutant 2118 has not been assigned to an allele number so far, we designate the allele here as *mlo-26*, according to current numbering in the GrainGene database (<gopher://greengenes.cit.cornell.edu:70/77/.graingenes.ndx/index?mlo>).

The high resolution map is based on a cross between Ingrid *Mlo* x BC₇ Ingrid *mlo-3*. *F*₁ plants were selfed generating a segregating *F*₂ population of approximately 600 plants. Phenotypically susceptible *F*₂ plants which showed heterozygosity for RFLP markers on opposite sites of *Mlo* were selfed and generated further segregants in the *F*₃ generation for high resolution mapping.

25

Powdery Mildew Infection Tests

The fungal isolate K1 (Hinze et al., 1991) is virulent on

all cultivars used in this study carrying the *Mlo* allele and avirulent on all tested *mlo* genotypes. Plant growth and inoculation with *Erysiphe graminis* f sp *hordei* were carried out as described previously (Freialdenhoven et al., 1996). The genotype at *Mlo* of recombinants used for the high resolution map were determined after selfing and subsequent inoculation experiments in *F*₃ or *F*₄ families comprising at least 24 individuals.

10 AFLP Analysis

Genomic DNA for AFLP analysis was isolated according to Stewart and Via (1993). AFLP analysis was carried out with minor modifications as described by Vos et al. (1995). For screening of AFLP markers linked to *Mlo* we used the enzyme combinations *Pst* I/*Mse* I with amplification primers carrying +2 and +3 selective bases respectively in genomic sequences of amplified fragments. For *Eco* RI/*Mse* I amplification primers we used +3 and +3 selective bases respectively. A set of four DNA templates has been used: from the susceptible parent cultivar Ingrid *Mlo*, the resistant parent BC₇Ingrid *mlo*-3, a pool of two resistant *F*₂ individuals (*mlo*-3 *mlo*-3) and a pool of nine susceptible *F*₂ individuals (*Mlo Mlo*) derived from the cross Ingrid *Mlo* x BC₇ Ingrid *mlo*-3. Amplified genomic fragments representing AFLP markers Bpm2, Bpm9, and Bpm16 (Figure 1) were cloned and sequenced as follows: gel pieces (fixed by vacuum drying to Whatman 3MM paper) containing the amplified genomic fragments were identified via autoradiography and subsequently

excised. 100 μ l water were added, boiled for 10 min. and after centrifugation 5 μ l of the supernatant were used as a template for non-radioactive reamplification (30 cycles) with the selective AFLP primers. Amplification products were isolated after agarose gel using a DNA isolation kit (Jetsorb, Genomed Inc., USA). DNA was treated with Klenow polymerase and T4 polynucleotide kinase and subsequently cloned in the EcoRV site of pBluescript SK (Stratagene). Sequencing reactions were performed using a dye terminator cycle sequencing reaction kit (Perkin Elmer) and resolved either on an ABI 373 or 377 (Applied Biosystems) automated sequencer.

Barley YAC Library and BAC Sublibrary Construction of YAC YHV303-A6

The YAC library of barley cultivar Ingrid was established using the pYAC4 vector (Burke et al., 1987; Kuhn and Ludwig 1994) and yeast strain AB 1380. Details of the library construction and its characterization will be described elsewhere. Screening for YAC clones containing marker Bpm16 was done by AFLP analysis. For construction of a BAC sublibrary of YAC YHV303-A6, total DNA of this yeast clone was used. After partial Eco RI digestion and preparative pulsed-field gel electrophoresis, DNA fragments in the size range of 50 kb were recovered and subcloned in the pECSBAC4 vector. Clones carrying YHV303-A6 derived inserts were identified by a two-step colony hybridization procedure. First total labelled DNA of the non-recombinant yeast strain AB 1380 was used as a

probe to eliminate most of the clones carrying insert DNA derived from the host strain. In a subsequent hybridization step the remaining clones were probed with the labelled recombinant chromosome YHV303-A6 after enrichment by 5 preparative pulsed-field gel electrophoresis.

DNA Sequencing of BAC F15

DNA of BAC F15 was isolated by an alkaline lysis large scale plasmid preparation according to Sambrook et al. (1989). 10 50 µg of purified DNA were nebulized by high pressure treatment with argon gas in a reaction chamber for 150 seconds. The ends of the sheared and reprecipitated DNA were blunt-ended by a T4 DNA polymerase-mediated fill in reaction. DNA fragments in the size range between 800 bp and 3 kb were isolated from agarose 15 gels using a DNA isolation kit (Jetsorb, Genomed Inc., U.S.A.), subcloned into the pBluescript SK vector (Stratagene) and propagated in *E. coli* DN5α. Clones carrying BAC F15 derived inserts were selected by hybridization using the sheared DNA of BAC F15 as a probe. Sequencing reactions were performed as 20 described above. Evaluation of the sequencing data, construction of sequence contigs, and estimation of coding probabilities were done by means of the STADEN software package for Unix users (4th edition, 1994). Assessment of coding 25 probabilities was based on a combined evaluation of uneven positional base frequencies, positional base preference and barley codon usage in the investigated contigs. Homology searches were done using the BLAST software.

PCR-based Sequencing of Alleles at Mlo

Plant chromosomal DNA for this purpose was isolated according to Chunwongse et al. (1993). DNA sequences of *Mlo* alleles of the different barley varieties, *mlo* mutants, BC lines, and intragenic recombinants used in this study were obtained by PCR-based sequencing. Seven overlapping subfragments of the gene (each 400 bp-600 bp in length) were amplified by PCR (35 cycles, 60°C annealing temperature) using sets of specific primers. After preparative agarose gel electrophoresis and isolation of the amplification products using the Jetsorb kit (Genomed Inc., U.S.A.) fragments were reamplified to increase specificity. The resulting products were subsequently purified from nucleotides and oligonucleotides (Jettpure, Genomed Inc., U.S.A.) and used as a template in DNA sequencing reactions (see above). All DNA sequences of mutant alleles and corresponding regions of the parental lines and the intragenic recombinants were derived from both strands and confirmed two times in independent sets of experiments. In addition, mutant alleles *mlo-1*, *mlo-3*, *mlo-4*, *mlo-5*, *mlo-7*, *mlo-8*, *mlo-9*, and *mlo-10* were also verified in the corresponding BC lines in cultivar Ingrid.

RT-PCR and Rapid Amplification of cDNA Ends (RACE)

RT-PCR was performed using the SUPERSCRIPT preamplification system for first strand cDNA synthesis (Gibco BRL). Total RNA (1 µg) of seven-day-old primary barley leaves (cultivar Ingrid) served as template. First strand cDNA

synthesis was primed by an oligo(dT) primer. The putative coding region of the *Mlo* gene was subsequently amplified using oligonucleotides 25L (GTGCATCTGCGTGTGCGTA) and 38 (CAGAAACTTGTCTCATCCCTG) in a single amplification step (35 cycles, 60°C annealing temperature). The resulting product was analyzed by direct sequencing. 5'- and 3'-ends of the *Mlo* cDNA were determined by RACE (Frohman et al., 1988) using the MARATHON cDNA amplification kit (Clontech). Corresponding experimental procedures were mainly carried out according to the instructions of the manufacturer. To obtain specific RACE products, two consecutive rounds of amplification (35 cycles, 55°C annealing temperature) were necessary. For this purpose, two sets of nested primers were used in combination with the adapter primers of the kit: oligonucleotides 46 (AGGGTCAGGATCGCCAC) and 55 (TTGTGGAGGCCGTGTTCC) for the 5'-end and primers 33 (TGCAGCTATATGACCTTCCCCCTC) and 37 (GGACATGCTGATGGCTCAGA) for the 3'-end. RACE products were subcloned into pBluescript SK (Stratagene). Ten 5'-end and eight 3' end clones were chosen for DNA sequence analysis.

20

The term "AFLPs" is used herein to refer to "AFLP markers".

Table 1 summarizes the identified mutation sites of various mutants within the *Mlo* gene. The origin, the mutagen and the predicted effect of the mutation at the amino acid level are indicated.

5 Table 2 shows the results of heteroallelic *mlo* crosses and selfings of the respective *mlo* lines to isolate intragenic recombination events.

Table 3 summarizes the genotypes at flanking RFLP markers in susceptible F_2 or homozygous F_3 progeny from the intermutant crosses. CO and NCO indicate crossover type and non crossover type recombinants deduced from flanking molecular marker exchange. Table 3 summarizes DNA sequence analysis of susceptible intragenic crossover type recombinants (from homozygous susceptible F_3 progeny) and the corresponding parental *mlo* mutant lines. Sequences flanking the identified mutation sites are shown.

Table 4 shows the results of direct PCR sequencing of genomic DNA of susceptible intragenic recombinants derived from both heteroallelic crosses *mlo-1* x *mlo-8* and *mlo-1* x *mlo-5*, revealing restoration of wild type sequences.

Table 5 shows several *Arabidopsis thaliana* and two rice expressed sequence tags (ESTs) with homology to the *Mlo* protein.

Table 5A show amino acid sequences, with "query" indicating part of the *Mlo* protein sequence to which homology has been found, with the predicted amino acid sequence of each identified EST marked with "subject".

Table 5B shows EST nucleotide sequences encoding the amino acid sequences shown in Table 5A. GenBank Accession number T22145 (definition 4153 *Arabidopsis thaliana* cDNA clone 97N8T7, NCBI Seq ID 932185), number T22146 (definition 4153 *Arabidopsis thaliana* cDNA clone 97N9T7, NCBI Seq ID 932186), number N37544 (definition 18771 *Arabidopsis thaliana* cDNA clone 205N12T7, NCBI Seq ID 1158686), number T88073 (definition 11769 *Arabidopsis thaliana* cDNA clone 155I23T7, NCBI Seq ID 935932) number H76041 (definition 17746 *Arabidopsis thaliana* cDNA clone 193P6T7, NCBI seq ID 1053292), number D24287 (rice cDNA partial sequence R1638_1A, nID g428139) and D24131 (rice cDNA partial sequence R1408_1A, nID g427985) are shown. The *Arabidopsis* sequences are from Newman et al. (1994) *Plant Physiol.* 106 1241-55. The rice sequences are from Minobe, Y. and Sasaki, T. submitted 2 Nov 1993 to DDBJ.

Table 1. *mlo* Mutant Alleles

Allele	Mother Variety	Mutagen	Mutational Event at <i>Mlo</i>	Effect on Amino Acid Level
<i>mlo-1</i>	Haisa	X-rays	T ⁴⁸⁴ → A	Itp ¹⁸² → Arg
<i>mlo-3</i>	Malteria Heda	γ-rays	deletion of 2 nucleotides (1188-1189)	frame shift after phe ³⁹⁵
<i>mlo-4</i>	Foma	X-rays	deletion of 11 nucleotides (478-488)	frame shift after Itp ¹⁵⁹
<i>mlo-5</i>	Carlsberg II	EMS	G ³ → A	met ¹ → ile ^a
<i>mlo-7</i>	Carlsberg II	EMS	G ⁶⁷⁷ → A	Gly ²²⁶ → Asp
<i>mlo-8</i>	Carlsberg II	EMS	A ¹ → G	met ¹ → Val ^a
<i>mlo-9</i>	Diamant	EMS	C ²⁸ → T	arg ¹⁰ → trp
<i>mlo-10</i>	Foma	γ-rays	deletion of 6 nucleotides (543-548)	2 amino acids (phe ¹⁸² , thr ¹⁸³) missing
<i>mlo-12</i>	Elgina	NMU	C ⁷²⁰ → A	phe ²⁴⁰ → leu
<i>mlo-13</i>	Plena	EMS	T ⁸⁹ → A	val ³⁰ → glu
<i>mlo-16</i>	Alsa	EMS	G ¹⁹¹⁷ → A	alteration in 3' splice border of intron 9
<i>mlo-17</i>	Plena	EMS	C ⁹² → T	ser ³¹ → phe
<i>mlo-26</i>	Plena	EMS	T ⁸⁰⁹ → A	leu ²⁷⁰ → his
<i>mlo-28</i>	Nadja	NaN ₃	C ⁶⁶⁵ → T	thr ²²² → ile

Numbers of nucleotides and amino acids are given according to the translational start site of the *Mlo* cDNA sequence.

Nucleotide number according to the translational start site of the genomic *Mlo* DNA sequence.

EMS = ethyl/methane sulfonate, NMU = nitrosomethylurea, NaN₃ = sodium azide.

^a Next start codon is at nucleotide positions 79-81 and is in frame with the coding sequence.

Table 2

 F_2 progeny from intermutant crosses and selfings

Testcrosses	resistant	susceptible	frequency of susceptible F_2 progeny	
<i>mlo-8 x mlo-1</i>	5,281	3	$5,7 \times 10^{-4}$	
<i>mlo-5 x mlo-1</i>	915	0	---	
<i>mlo-5 x mlo-1</i>	14,474	9	$6,2 \times 10^{-4}$	
selfings	resistant	susceptible		
<i>mlo-1</i>	12,634	0		
<i>mlo-5</i>	5,498	0		
<i>mlo-8</i>	8,435	0		

Table 3. Genotypes at Flanking RFLP Markers in Susceptible Progeny Derived from Heteroallelic *mlo* Crosses

Testcross	Susceptible Plant	Parental Genotype in Centromeric Orientation to <i>Mlo</i> 1	Parental Genotype in Telomeric Orientation to <i>Mlo</i> 2	Type of Recombination
<i>mlo</i> -8 x <i>mlo</i> -1	1	<i>mlo</i> -1	<i>mlo</i> -8	CO
	2	<i>mlo</i> -1	<i>mlo</i> -8	CO
	3	<i>mlo</i> -8	<i>mlo</i> -8	NCO
<i>mlo</i> -1 x <i>mlo</i> -5	1	<i>mlo</i> -1	<i>mlo</i> -5	CO
	2	<i>mlo</i> -1	<i>mlo</i> -5	CO
	3	<i>mlo</i> -5	<i>mlo</i> -5	NCO
	4	<i>mlo</i> -1	<i>mlo</i> -5	CO
	5	<i>mlo</i> -5	<i>mlo</i> -5	NCO
	6	<i>mlo</i> -5	<i>mlo</i> -5	NCO
	7	<i>mlo</i> -1	<i>mlo</i> -5	CO
	8*	<i>mlo</i> -5	<i>mlo</i> -5	NCO
	9*	<i>mlo</i> -1 + <i>mlo</i> -5	<i>mlo</i> -5	CO

1 deduced from alleles of RFLP marker WG114 (see Figure 1)

2 deduced from alleles of RFLP marker ABG366 (see Figure 1)

CO = cross over type, NCO = non cross over type of recombination

*Genotypes of flanking RFLP markers have been determined in heterozygous susceptible F₂ individuals; in all other cases homozygous susceptible F₃ progeny derived from the susceptible F₂ individuals were tested

Table 4. Restoration of *Mlo* Wild Type Sequences by Intragenic Recombination Events

	Genotypes	Nucleotide Sequences Flanking Mutant Sites ¹	
		Nucleotides -3 to +3	Nucleotides 481 to 486
Haisa	<i>Mlo</i>	CCGATG	AATGGG
	<i>mlo-1</i>	CCGAT <u>G</u>	AA <u>AG</u> GG
Carlsberg II	<i>Mlo</i>	CCGATG	AATGGG
	<i>mlo-5</i>	CCGATA <u>A</u>	AATGGG
	<i>mlo-8</i>	CCGG <u>TG</u>	AATGGG
Intragenic recombinant	<i>mlo-1</i> × <i>mlo-8</i>	1 CCGATG 2 CCGATG 1 CCGATG	AATGGG AATGGG AATGGG
	<i>mlo-1</i> × <i>mlo-5</i>	2 CCGATG 4 CCGATG 7 CCGATG 9 CCGATG	AATGGG AATGGG AATGGG AATGGG

¹ Numbers of nucleotides are given according to the translational start site (see Figure 2.)

TABLE 5A

>EM EST1:AT1452 T22145 4153 Arabidopsis thaliana cDNA clone 97N8T7. 11/95
Length = 382

Plus Strand HSPs:

Score = 248 (115.9 bits), Expect = 2.9e-27, P = 2.9e-27
Identities = 47/100 (47%), Positives = 67/100 (67%), Frame = +2

Query: 242 KYIKRSMEDDFKVVVGISLPLWGVAILTLFLDINGVGTIWIISFIPLVILLCVGKLEMI 301
KY+ R++EDDFK VVGIS LW ++ L++NG T WI+FIP +LL VGTKLE +

Sbjct: 2 KYMMRALEDDFKQVVVGISWYLWXFVVIFXLLNVNGWHTYFWIAFIPFXLLLAVGKLEHV 181

Query: 302 IMEMALEIQDRASVIKGAPVVEPSNKFFWFHRPDWVLFFI 341

I ++A E+ ++ I+G VV+P . + FWF +P VL+ I

Sbjct: 182 IAQLAHEVAEKHVAIEGDLVVKPxXEHWFSKPQIVLYLI 301

>EM EST1:AT1462 T22146 4154 Arabidopsis thaliana cDNA clone 97N9T7. 11/95
Length = 390

Plus Strand HSPs:

Score = 212 (99.1 bits), Expect = 4.2e-26, Sum P(2) = 4.2e-26
Identities = 41/83 (49%), Positives = 58/83 (69%), Frame = +2

Query: 242 KYIKRSMEDDFKVVVGISLPLWGVAILTLFLDINGVGTIWIISFIPLVILLCVGKLEMI 301
KY+ R++EDDFK VVGIS LW ++ L++NG T WI+FIP +LL VGTKLE +

Sbjct: 2 KYMMRALEDDFKQVVVGISWYLWXFVVIFLLLNVNGWHTYFWIAFIPFALLAVGKLEHV 181

Query: 302 IMEMALEIQDRASVIKGAPVVEP 324

I ++A E+ ++ I+G VV+P

Sbjct: 182 IAQLAHEVAEKHVAIEGDLVVKP 250

Score = 52 (24.3 bits), Expect = 1.9, Sum P(2) = 0.85
Identities = 9/32 (28%), Positives = 16/32 (50%), Frame = +2

Query: 18 WAVAVVFAAMVLVSVLMEHGLHLGHWFQHRH 49

W + FA ++ V +EH + +L H +H

Sbjct: 122 WIAFIPFALLAVGKLEHVIAQLAHEVAEKH 217

Score = 49 (22.9 bits), Expect = 4.2e-26, Sum P(2) = 4.2e-26
Identities = 8/17 (47%), Positives = 12/17 (70%), Frame = +1

Query: 323 EPSNKFFWFHRPDWLF 339

E S++ FWF +P VL+

Sbjct: 244 ETSDEHFWFPSKPQXVLY 294

TABLE 5A cont'd

>EM EST1:AT54418 N37544 18771 Arabidopsis thaliana cDNA clone 205N12T7. 1/96
 Length = 585

Plus Strand HSPs:

Score = 277 (129.5 bits), Expect = 1.2e-45, Sum P(2) = 1.2e-45
 Identities = 51/96 (53%), Positives = 71/96 (73%), Frame = +1

Query: 236 SKDFDHKYIKRSMEDDFKVVVGISLPLWGVAILTLFLDINGVGTLIWIISFIPLVILLCVG 295
 S+FDF KYI+RS+E DFK VV. IS +W VA+L L + G+ + +W+ FIPLV++L VG

Sbjct: 127 SRDFDRKYIQRSLEKDFKTVVEISPVIWFVAVLFLNTNSYGLRSYLNLPFIPLVVVILVG 306

Query: 296 TKLEMIIMEMALEIQDRASVIKGAPVVEPSNKFFWF 331

TKLE+II ++ L IQ+ V++GAPVV+P + FWF

Sbjct: 307 TKLEVITKLGLRIQEEGDVVRGAPVVQPGDDXFWF 414

Score = 121 (56.6 bits), Expect = 1.2e-45, Sum P(2) = 1.2e-45
 Identities = 25/45 (55%), Positives = 29/45 (64%), Frame = +1

Query: 196 SSTPGIRWVVAFFRQFRSVTKVVDYLTLRAGFINAHLSQNSKFDF 240.

S T W+V FFRQFF SVTKVVDYL L GFT AH + ++ F

Sbjct: 1 SKTRVTLWIVCFRQFFGSVTKVVDYLALXHGFIMAHFAPGNESRF 135

>EM EST1:AT04117 H76041 17746 Arabidopsis thaliana cDNA clone 193P6T7. 11/95
 Length = 476

Plus Strand HSPs:

Score = 210 (98.2 bits), Expect = 9.0e-36, Sum P(2) = 9.0e-36
 Identities = 43/86 (50%), Positives = 58/86 (67%), Frame = +1

Query: 196 SSTPGIRWVVAFFRQFRSVTKVVDYLTLRAGFINAHLSQNSKFDFHKYIKRSMEDDFKVV 255
 ++TP V FFRQFF SV + DYLTLL GF +AHL+ KF+F +YIK S+EDDFK+V

Sbjct: 124 TTTPFXFNVGCFFRQFFVSVERTDYLTLRAGFXSAHLAPGRKFNFQRYIKXSLEDDFKLV 303

Query: 256 VGISLPLWGVAILTLFLDINGVGTLI 281

VGI LW ++ L + +GT++

Sbjct: 304 VGIXPVLWASFVIFLAVQX*WLGTIV 381

Score = 119 (55.6 bits), Expect = 9.0e-36, Sum P(2) = 9.0e-36
 Identities = 24/57 (42%), Positives = 32/57 (56%), Frame = +1

Query: 156 MRTWKKWETETTSLEYQFANDPARFRFTHQTSFVKRHLGLSSTPGIRWVVAFFRQFF 212

+R WKKWE T S +Y F D +R R TH+TSFV+ H +T + V F + F

Sbjct: 1 IRGWKKWEQXTLSNDYXFIDHSRLRLTHETSFVREHTSFWTTPFXFNGCFFRQF 171

Score = 40 (18.7 bits), Expect = 1.2e-08, Sum P(2) = 1.2e-08
 Identities = 8/19 (42%), Positives = 10/19 (52%), Frame = +2

Query: 269 TLFILDINGVGTLIWIISFIP 287

+L + NG G L W S P

Sbjct: 344 SLLFNXNGWGPLFWASVPP 400

99

TABLE 5A cont'd

>EM EST1:AT0739 T88073 11769 *Arabidopsis thaliana* cDNA clone 155I23T7. 11/95
 Length = 460

Plus Strand HSPs:

Score = 175 (81.8 bits), Expect = 1.2e-24, Sum P(2) = 1.2e-24
 Identities = 31/67 (46%), Positives = 43/67 (64%), Frame = +1

Query: 146 VITIALSRLKMRITWKKWETETTSLEYQFANDPARFRETHQTSFYKRHLGLSSTPGIRWVV 205
 S+T A ++KMRTWK WE ET ++BYQ++NDP RFRF TSF +RHL S + +
 Sbjct: 4 IVTYAFGKIKMRITWKSWEETKTIEYQYSNDPERFRFARDTSFGRRHLNFWSKTRVTLWI 183

Score = 121 (56.6 bits), Expect = 1.4e-14, Sum P(2) = 1.4e-14
 Identities = 25/45 (55%), Positives = 29/45 (64%), Frame = +1

Query: 196 SSTPGIRWVVAFFRQFFRSVTKVVDYLTLRAGFINAHLSQNSKFDF 240
 S T W+V FFRQFF SVTKVVDYL L GFI AH + ++ F
 Sbjct: 157 SKTRVTLWIVCFRQFFGSVTKVVDYLALXHGFIMAHFAPGNESRF 291

Score = 75 (35.1 bits), Expect = 1.2e-24, Sum P(2) = 1.2e-24
 Identities = 14/21 (66%), Positives = 17/21 (80%), Frame = +1

Query: 236 SKFDFHKYIKRSMEDDFKVVV 256
 S+FDF KYI+RS+ DFK VV
 Sbjct: 283 SRFDFRKYIQRSLXXDFKTVV 345

>EM EST5:OSR16381A D24287 Rice cDNA, partial sequence (R1638_1A). 5/95
 Length = 400

Plus Strand HSPs:

Score = 147 (68.7 bits), Expect = 1.9e-16, Sum P(2) = 1.9e-16
 Identities = 26/53 (49%), Positives = 35/53 (66%), Frame = +1

Query: 236 SKFDFHKYIKRSMEDDFKVVVGISLPLWGVALTLFLDINGVGTLIWIIFIPL 288
 ++F+F KYIKR +EDDFK VVGIS P W A+ + ++G L W S PL
 Sbjct: 202 TRFNFTRKYIKRXLEDDFKTVVGISAPXWASALAIMLFNVHGWHNLFWESTXPL 360

Score = 45 (21.0 bits), Expect = 1.9e-16, Sum P(2) = 1.9e-16
 Identities = 9/15 (60%), Positives = 11/15 (73%), Frame = +2

Query: 287 PLVILLCVGKLEMI 301
 PL + L VGTKL+ I
 Sbjct: 356 PLXVTLAVGTKLQAI 400

>EM EST5:OSS1692A D39989 Rice cDNA, partial sequence (S1692_1A). 11/94
 Length = 343

Plus Strand HSPs:

Score = 95 (44.4 bits), Expect = 0.00059, P = 0.00059
 Identities = 24/58 (41%), Positives = 31/58 (53%), Frame = +3

Query: 43 HWFQHRHKKALWEALEKMKMAELMLVGFISLLLIVTQDPPIIAKICISEDAADVMPCKR 100
 H + H+ L +A+EKM E+ML+GFISLLL T I S+ PC R
 Sbjct: 3 HXSEKTHRNPLHKAMEKMKCEMMLLGFISLLAATSRIISGICIDSKYNSNFSPCTR 176

TABLE 5B

100

GenBank Accession Number T22145

1 caagtatatg atgcgcgctc tagaggatga tttcaaaca gttgttggta ttagttggta
 61 tctttggntc tttgtcgta tcttttntc gctaaatgtt aacggatggc acacatattt
 121 ctggatagca tttattccct ttnctttgtc tcttgctgtg ggaacaaaagt tggagcatgt
 181 nattgcacag ttagctcatg aagttgcaga gaaacatgt a gccattgaag gagacttagt
 241 ggtgaaaacctc ncanatgagc atttctggtt cagcaaacct caaattgttc tctacttcatgt
 301 cccattttat cctctttccc agaatgcntt ttnagantgc nttnnnnt tttggnnntt
 361 gggtaanan annggttcg nc

GenBank Accession Number T22146

1 caagtatatg atgcgcgctc tagaggatga tttcaaaca gttgttggta ttagttggta
 61 tctttggntc tttgtcgta tcttttgc gctaaatgtt aacggatggc acacatattt
 121 ctggatagca tttattccct ttgtttgtc tcttgctgtg ggaacaaaagt tggagcatgt
 181 nattgcacag ttagctcatg aagttgcaga gaaacatgt a gccattgaag gagacttagt
 241 ggtgaaaacctc cagatgagca tttctggttc agcaaacctc aaantgttct ctactngatc
 301 cnctttatcc cccttccaga atgcctttt nangattcnn nttnnnctt ntgganntt
 361 ttgggnnnnc aaacgggnntt nggacctccg

GenBank Accession Number N37544

1 agcaagacga gagtcacact atggattgtt tgaaaaata gacagttctt tggatctgtc
 61 accaaagttt attacttagc actaagnat ggtttcatca tggcgatctt tgctcccggt
 121 aacgaatcaa gattcgattt ccgcaagtat attcagagat cattagagaa agacttcaaa
 181 accgttgttggaaatcagtc ggttatctgg tttgtcgctg tgctattctt cttgaccaat
 241 tcatatggat tacgttctt ccctctggta ccattcattt cactagtctg aattctaata
 301 gttggaaacaa agcttgaagt cataataaca aaattgggtc taaggatcca agaggaaggt
 361 gatgttgtga gaggcgcccc agtgggtcag cctgggtatg accncttctg gtttngnaan
 421 cacgnntcaaa tntttccnt antacttng gccttttan gggtaattt caacttcatn
 481 ctttncctgg ggnccgtatga ttcaatccaa naatnttccc ctgaagnctn caagtttgggg
 541 cataggctt nngtgggnntt ttcaganttt nagtttggct tnccc

101

TABLE 5B (Continued)

GenBank Accession Number T88073

1 tgcattgtta cttatgttt cgaaaagatc aagatgagga cgtggaaagt gtggaggaa
 61 gagacaaaaga caatacgatc tcagtattcc aacgatcctg agaggttcag gtttgcnagg
 121 gacacatctt ttgggagaag acatctcaat ttctggagca agacgagagt cacactatgg
 181 attgtttgtt ttttagaca gttctttgga tctgtcacca aagtgttta cttagcacta
 241 agncatggtt tcatacatggc gcattttgtc cccggtaacg aatcaagatt cgattccgc
 301 aagtatattc agagatcatt agnnaagac ttcaaaaaccg ttgtttgaaa tcagtcgggt
 361 tatctggttt gtcggctgtg ctattccnct tgaccaattc atatggntnc ggtnntncnc
 421 tggtaccatt attcncttagc ggaatntaaa agttggcnga

GenBank Accession Number H76041

1 attcgtggat ggaaaaagtgggagcaagan acatttatcta atgactatna gtttnctatt
 61 gatcattcaa gacttaggtc cactcatgag acttcttttgnagagaaca tacaaggtttc
 121 tggacaacaa cncccttctn ctttaacgtc ggatgcttctttaggcagtt ctttgtatct
 181 gtngaaagaa ccgactactt gactctgcgc catggattca nctctgcccatttagctcca
 241 ggaagaaaagt tcaacttcca gagatatac aaangatctc tcgaggatga tttcaagtttg
 301 gtagttggaa taagnccagt tctttggca tcatttgtaa tcttccttgc tgttcaatgn
 361 taatggctgg ggaccattgt tttggcncntc ggtaccgcct ntactcanaa ncccaggcctt
 421 ttggccaagg ttcaaggaat ttngggacaa tgggttagaa tcgtggcnc atnngg

GenBank Accession Number D24287

1 tcntntttnn ttttcgnntn cntccacccc tnnnnntnctc nanncnntn nnnttatctc
 61 tnttnntntc ncntntccnn ncaccacnn ncgacgggn tggactnngc ccnnnngttcg
 121 aggctgcucca ctgnctgtctg agacctaccc tgnccatttga cggcacngga cttcancgtgc
 181 tgctcaacttt atctctacgg gacttaggttc aattttcggaa aatacatcaa aaggncactg
 241 gaggacgatc ttaagacagt tggtaggcatt agtgcacccn tatggccttc tgcgttggcc
 301 attatgtctt tcaatgttca tggatggcat aacttggctt ggttctctac aatnccctt
 361 gntagtaact ttagcagggtt gaacaaagct gcaggctata

GenBank Accession Number D24131

1 cagactaccc gactttgagg cacggattca ttgctgtca tttatctctta gggacttaggt
 61 tcaatttcg gaaatacatac aaaaggtcac tggaggacga ttttaagaca gttgttggca
 121 ttagtgcacc cttatgggtc tctgcgttgg ccattatgtc cttnaatgtt catggatggc
 181 ataacttggtt ctgggtcttcc acaatcccccc ttgttagtaac ttttagcagggtt ggaacaaagc
 241 tgcaggctat aatttgcattt atggctgttg aaattaaaga gaggcataca gtaattcaag
 301 gaatgccgggt ggtgaactca gtgtat

REFERENCES

1. Bayles, et al. (1990). *Physiol. Mol. Plant Pathol.* 36, 63-72.
2. Becker, et al. (1995). *Mol. and Gen. Genet.* 249, 65-73.
- 5 3. Bennet, et al. (1991). *Phil. Trans. R. Soc. London (Biol)* 334, 309-345.
4. Bent, et al. (1994). *Science* 265, 1856-1860.
5. Boyd, et al. (1995). *Plant. J.*, 7, 959-968.
6. Bourque, J. E. (1995). *Plant Science* 105, 125-149.
- 10 7. Burke, et al. (1987). *Science* 236, 806-812.
8. Cao, et al. (1992). *Plant Cell Rep.* 11, 585-591.
9. Christou, et al. (1991). *Bio/Technology* 9, 957-962.
10. Chunwongse, et al. (1993). *Ther. Appl. Genet.*, 86, 694-698.
- 15 11. Civardi (1994).
12. Cornejo, et al. (1993). *Plant Molecular Biology* 23, 567-581.
13. Dangl, J. L. (1995). *Cell* 80, 363-366.
14. Dangl, J. L., et al. (1996). *Plant Cell (in press)*.
- 20 15. Datta, et al. (1990). *Bio/Technology* 8, 736-740.
16. de Feyter, et al. (1996). *Molecular and General Genetics* 250, 329-338.
17. D'Halluin, et al. (1992). *Plant Cell* 4, 1495-1505.
18. Dietrich, et al. (1994). *Cell* 77, 565-577.
- 25 19. Doke, N. (1983). *Physiol. Plant Pathol.*, 23, 345-357.
20. Doke, N. and Ohashi, Y. (1988). *Physiol. Mol. Plant Path.*, 32, 163-175.

21. Dooner, H.K. and Kermicle, J.L. (1986). *Genetics*, 113, 135-143.

22. Dujon, B. (1996). *Trends Genet.*, 12, 263-270.

23. Flavell, R. B. (1994). *Proc. Natl. Acad. Sci. USA* 91, 5 3490-3496.

24. Flor, H. H. (1971). *Annu. Rev. Phytopathol.* 9, 275-296.

25. Freeling, M. (1978). *Genetics*, 89, 211-224.

26. Freialdenhoven, A., et al. (1996). *Plant Cell*, 8, 5-14.

27. Frohman, N.A., et al. (1988). *Proc. Natl. Acad. Sci.*, 85, 10 8998-9002.

28. Fromm, et al. (1990). *Bio/Technology* 8, 833-839.

29. Fugimoto, et al. (1993). *Bio/Technology* 11, 1151-1155.

30. Giovannoni, J.J., et al. (1991). *Nucl. Acids Res.*, 19, 6553-6558.

31. Gordon-Kamm, et al. (1990). *Plant Cell* 2, 603-618.

32. Görg, R., et al. (1993). *Plant J.*, 3, 857-866.

33. Grant, et al. (1995). *Science* 269, 843-846.

34. Greenberg, et al. (1993). *The Plant Journal* 4, 327-341.

35. Greenberg, et al. (1994). *Cell* 77, 551-563.

20 36. Habekuss, A. and Henrich, W. (1988). *Tag. Ber., Akad. Lanwirtsch.-Wiss. DDR, Berlin*, 272: 229-237.

37. Hammond-Kosack, K.E. and Jones, J.D.G. (1996). *The Plant Cell* (in press).

38. Hartmann, E., et al. (1989). *Proc. Natl. Acad. Sci.*, 86: 25 5786-5790.

39. Haselhoff, et al. (1988). *Nature* 334, 585-491.

40. Heath, M.C. (1980). *Annu. Rev. Phytopathol.*, 18: 211-236.

41. Henrich, W. (1979). Arch. Züchtungsvorsch., Berlin 9, S. 283-291.

42. Heslop-Harrison, J.S. (1991). J. Cell Sci., 100, 15-21.

43. Hiei, et al. (1994). The Plant Journal 6, 271-282.

5 44. Hieter, et al. (1990). Cold Spring Harbor, NY, Col Spring Harbor Press.

45. Hinze, et al. (1991). Proc. Natl. Acad. Sci. USA 88, 3691-3695.

46. Jabs, T., et al. (1996). Science, 273, 1853-55.

10 47. Jones, D.T., et al. (1994). Biochemistry, 33, 3038-3049.

48. Jones, et al. (1994). Science 266, 789-793.

49. Jones, J. D. G. (1994). Current Biology 4, 749-751.

50. Jørgensen, J. H. (1977). Induced mutations against plant diseases (Crop Symposium Vienna) 533-547.

15 51. Jørgensen, J. H. (1983). Induced mutations for disease resistance in crop plants II (International Atomic Energy Agency, Vienna) 73-87.

52. Jørgensen, J. H. (1992). Euphytica 63, 141-152.

53. Jørgensen, J. H. (1994). Critical Reviews in Plant Sciences 13, 97-119.

20 54. Jørgensen, J.H. and Mortensen, K. (1977). Phytopathology, 67, 678-685.

55. Klein, P., et al. (1985). Biochim. Biophys. Acta, 815, 468-476.

25 56. Koga, H., et al. (1990). Can. J. Bot., 68, 2344-2352.

57. Koornneef, M., et al. (1983). Genet. Res. Camb., 41, 57-68.

58. Kosslak, R., et al. (1996). J. Hered (in press).

59. Kuhn, R.M. and Ludwig, R.A. (1994). Gene, 141, 125-127.

60. Künzel, G. (1982). Theor. Appl. Genet., 64, 25-29.

5 61. Koziel, et al. (1993). Biotechnology 11, 194-200.

62. Lamb, C.J. (1994). Cell, 76: 419-422.

63. Lawrence, et al. (1995). The Plant Cell 7, 1195-1206.

64. Levine, A., et al. (1994). Cell, 79: 583-593.

65. Li, et al. (1993). Plant Cell Rep. 12, 250-255.

10 66. Linde-Laursen, I., et al. (1982). Z. Pflanzenzüchtg., 81, 191-219.

67. Lundqvist, U., et al. (1991). Hereditas, 115, 227-239.

68. Martin, et al. (1993). Science 262, 1432-1436.

69. McClintock, B. (1984). Science, 226, 792-801.

15 70. Mindrinos, et al. (1994). Cell 78, 1089-1099.

71. Moore, et al. (1995). Current Biology 5, 737-739.

72. Mourad, G., et al. (1994). Mol. Gen. Genet., 243, 178-184.

73. Negassa, M. (1985). Hereditas, 102, 113-121.

20 74. Nigg, et al. (1991). Cell 66, 15-22.

75. Osborne, et al. (1995). Current Opinion in Cell Biology 7, 406-413.

76. Olsen, O., et al. (1993). Proc. Natl. Acad. Sci. USA, 90, 8043-8047.

25 77. Peng, et al. (1992). Theor Appl Genet 83, 855-863.

78. Peng, et al. (1991). International Rice Research Institute, Manila, Philippines. 563-574.

106

79. Pryor, A. J. (1987). Trends in Genetics 3, 157-161.

80. Raff, M.C. (1992). Nature, 356, 397-400.

81. Raff, M.C., et al. (1993). Science, 262, 695-700.

82. Rathore, et al. (1993). Plant Molecular Biology 21, 871-
5 884.

83. Rihs, et al. (1991). EMBO J. 10, 633-639.

84. Ryerson, D.E. and Heath, M.C. (1996). Plant Cell, 8, 393-
402.

85. Salamini, F., and Lorenzoni, C. (1970). Mol. Gen. Genet.,
10 108, 225-232.

86. Sambrook, J., et al. (1989). Cold Spring Harbor
Laboratory Press, New York.

87. Schmidt, R., et al. (1995). Science, 270, 480-483.

88. Sherman, et al. (1986). Cold Spring Harbor, NY, Cold
15 Spring Harbor Laboratory Press.

89. Shimamoto, K. (1994). Current Opinion in Biotechnology 5,
158-162.

90. Shimamoto, et al. (1989). Nature 338, 274-276.

91. Shirley, B.W., et al. (1992). Plant Cell, 4, 333-347.

92. Shizuya, et al. (1992). Proc. Natl. Acad. Sci. USA 89,
20 8794-8797.

93. Siedler, et al. (1991). Molecular and General Genetics
226, 117-181.

94. Søgaard, et al. (1988). Barley Genet. Newslett. 17, 120-
25 134.

95. Somers, et al. (1992). Bio/Technology 10, 1589-1594.

96. Song, et al. (1995). Science 270, 1804-1806.

97. Stakman, E.C. (1915). *J. Ag. Research*, 4: 193-199.

98. Staskawicz, et al. (1995). *Science* 268, 661-667.

99. Stewart, C.N. and Via, L.E. (1993). *BioTechniques*, 14: 748-750.

5 100. Szostak, J.W., et al. (1983). *Cell*, 33: 25-35.

101. Tanksley, et al. (1995). *Trends in Genetics* 11, 63-68.

102. Thomas, C.M., et al. (1995). *Plant J.*, 8: 785-794.

103. Toriyama, et al. (1988). *Bio/Technology* 6, 1072-1074.

104. Tsuji, et al. (1992). *Plant Physiology* 98, 1304-1309.

105. Vasil, I. K. (1994). *Plant Molecular Biology* 25, 925-937.

106. Vasil, et al. (1992). *Bio/Technology* 10, 667-674.

107. Vos, et al. (1995). *Nucleic Acids Research* 23, 4407-4414.

108. Walbot, et al. (1983). New York, Plenum Press 431-442.

109. Walters, et al. (1992). *Plant Molecular Biology* 18, 189-200.

110. Wang, et al. (1995). *Plant Journal* 7, 525-533.

111. Weeks, et al. (1993). *Plant Physiology* 102, 1077-1084.

112. Weymann, et al. (1995). *The Plant Cell* 7, 2013-2022.

113. White, E. (1996). *Genes & Development*, 10: 1-15.

20 114. Whitham, et al. (1994). *Cell* 78, 1011-1115.

115. Wiberg, A. (1974). *Hereditas* 77, 89-148.

116. Wolter, et al. (1993). *Mol. Gen. Genet.* 239, 122-128.

117. Wyllie, A.H. (1995). *Current Biology*, 5: 97-104.

118. Zhang, et al. (1988). *Plant Cell Rep.* 7, 379-384.

25 119. Zhang, et al. (1991). *Plant Cell* 3, 1155-1165.

120. Zhang, et al. (1988). *Theor Appl Genet* 76, 835-840.

CLAIMS:

1. An isolated polynucleotide encoding a polypeptide which includes the amino acid sequence shown in Figure 2.

5

2. A polynucleotide according to claim 1 wherein the coding sequence is the coding sequence shown in Figure 2.

3. A polynucleotide according to claim 1 wherein the coding sequence is a mutant, allele, variant or derivative of the coding sequence shown in Figure 2, by way of addition, deletion, substitution and/or insertion of one or more nucleotides.

4. An isolated polynucleotide which on expression in a transgenic plant exerts a negative regulatory effect on a pathogen defence response of the plant, which defence response is pathogen independent and autonomous of the presence of pathogen, the polynucleotide encoding a polypeptide which includes an amino acid sequence which is a mutant, allele, variant or derivative of the Barley Mlo sequence shown in Figure 2, or is a homologue of another species or a mutant, allele, variant or derivative thereof, the amino acid sequence differing from that shown in Figure 2 by way of addition, substitution, deletion and/or insertion of one or more amino acids.

10
15
20
25

5. A polynucleotide according to claim 4 encoding a polypeptide which includes the amino acid sequence shown in Figure 13.

5 6. A polynucleotide according to claim 5 wherein the coding sequence is that shown in Figure 10.

10 7. A polynucleotide according to claim 5 wherein the coding sequence is a mutant, allele, variant or derivative of the coding sequence shown in Figure 10, by way of addition, deletion, substitution and/or insertion of one or more nucleotides.

15 8. A polynucleotide according to claim 4 encoding a polypeptide which includes the amino acid sequence shown in Figure 14.

20 9. A polynucleotide according to claim 8 wherein the coding sequence is that shown in Figure 11.

10. A polynucleotide according to claim 8 wherein the coding sequence is a mutant, allele, variant or derivative of the coding sequence shown in Figure 11, by way of addition, deletion, substitution and/or insertion of one or more nucleotides.

25 11. A polynucleotide according to claim 4 encoding a

110

polypeptide which includes the amino acid sequence shown in Figure 15.

12. A polynucleotide according to claim 11 wherein the coding 5 sequence is that shown in Figure 12.

13. A polynucleotide according to claim 11 wherein the coding sequence is a mutant, allele, variant or derivative of the coding sequence shown in Figure 12, by way of addition, deletion, substitution and/or insertion of one or more nucleotides.

14. A polynucleotide according to any preceding claim operably linked to a regulatory sequence for expression.

15. An isolated polynucleotide encoding a polypeptide which on expression in a transgenic plant produces a polypeptide which can stimulate or maintain a defence response of the plant, the encoded polypeptide including an amino acid sequence which is a mutant, allele, variant or derivative of the Barley *Mlo* sequence shown in Figure 2 or of a homologue of another species, the amino acid sequence differing from that shown in Figure 2 by way of addition, substitution, deletion and/or insertion of one or more amino acids.

25
16. A polynucleotide according to claim 15 which stimulates or maintains said defence response of the plant on homozygous

111

expression in the plant.

17. A polynucleotide according to claim 15 wherein the amino acid sequence includes an alteration identified in Table 1.

5

18. A polynucleotide according to claim 17 wherein the amino acid sequence is that of Figure 2 including a substitution at residue 240.

10 19. A polynucleotide according to claim 17 wherein the amino acid sequence includes Leucine at residue 240.

20. A polynucleotide according to any of claims 15 to 19 operably linked to a regulatory sequence for expression.

15 21. An isolated polynucleotide which has at least about 600 contiguous nucleotides of the nucleotide sequence of any of claims 1 to 13 or complement thereof

20 22. A polynucleotide according to claim 21 operably linked to a regulatory sequence for transcription.

25 23. An isolated polynucleotide which has at least about 300 contiguous nucleotides of the sequence of any of claims 1 to 13, or complement thereof, operably linked to a regulatory sequence for transcription.

112

24. A polynucleotide according to claim 22 or claim 23 wherein the regulatory sequence includes an inducible promoter.

25. A nucleic acid vector suitable for transformation of a host cell and including a polynucleotide according to any preceding claim.

26. A nucleic acid vector according to claim 25 wherein said host cell is a microbial cell.

27. A nucleic acid vector according to claim 25 wherein said host cell is a plant cell.

28. A host cell containing a heterologous polynucleotide or nucleic acid vector according to any preceding claim.

29. A cell according to claim 28 which is microbial.

30. A cell according to claim 28 which is a plant cell.

31. A cell according to claim 30 having said heterologous polynucleotide incorporated within its genome.

32. A cell according to claim 31 having more than one said polynucleotide per haploid genome.

33. A cell according to any of claims 30 to 32 which is

comprised in a plant.

34. A plant including a cell according to any of claims 30 to 32.

5

35. A plant which is a sexually or asexually propagated off-spring, clone or descendant of a plant according to claim 34, or any part or propagule of said plant, off-spring, clone or descendant.

10
15
20
25
30
35
40

36. A part or propagule of a plant according to claim 35.

37. A plant according to claim 34 which does not breed true.

38. A method of producing a plant, the method including incorporating a heterologous polynucleotide according to any of claims 1 to 14 into a plant cell and regenerating a plant from said plant cell.

20 39. A method of producing a plant, the method including incorporating a heterologous polynucleotide according to any of claims 15 to 20 into a plant cell and regenerating a plant from said plant cell.

25 40. A method of producing a plant, the method including incorporating a heterologous polynucleotide according to any of claims 21 to 24 into a plant cell and regenerating a plant from

said plant cell.

41. A method according to any of claims 38 to 40 including
sexually or asexually propagating or growing off-spring or a
5 descendant of said plant.

42. A method of stimulating a defence response in a plant, the
method including causing or allowing transcription from a
heterologous polynucleotide according to any of claims 1 to 14
within cells of the plant.
0

43. A method of stimulating a defence response in a plant, the
method including causing or allowing transcription from a
heterologous polynucleotide according to any of claims 15 to 20
within cells of the plant.
15

44. A method of stimulating a defence response in a plant, the
method including causing or allowing transcription from a
heterologous polynucleotide according to any of claims 21 to 24
20 within cells of the plant.

45. A method of producing a polynucleotide encoding a
polypeptide which on expression in a transgenic plant produces
a polypeptide which can stimulate or maintain a defence
25 response of the plant, the method including alteration of the
nucleotide sequence of a polynucleotide according to any of
claims 1 to 14.

115

46. A method according to claim 45 involving site-specific sequence mutation.

47. A method according to claim 45 involving intracellular 5 homologous recombination.

48. A method wherein following alteration of a nucleotide sequence in accordance with the method of claim 45 a polynucleotide including the altered nucleotide sequence is introduced into a host cell.

49. A method according to claim 48 wherein the host cell is a plant cell.

50. A method wherein following introduction of a polynucleotide into a plant cell in accordance with claim 49 a plant is regenerated from the cell or descendants thereof including the altered nucleotide sequence.

20 51. Use of a polynucleotide according to any of claims 1 to 14 for stimulating a defence response in a plant.

52. Use of a polynucleotide according to any of claims 15 to 20 for stimulating a defence response in a plant.

25

53. Use of a polynucleotide according to any of claims 21 to 24 for stimulating a defence response in a plant.

54. Use of a polynucleotide according to any of claims 21 to 24 for down-regulation of expression of a gene encoded a polypeptide encoded by a polynucleotide according to any of claims 1 to 14.

5

55. Use of a polynucleotide according to any of claims 1 to 14 in the production of a transgenic plant.

56. Use of a polynucleotide according to any of claims 15 to 20 in the production of a transgenic plant.

57. Use of a polynucleotide according to any of claims 21 to 24 in the production of a transgenic plant.

58. A method of determining the presence of a pathogen resistance or susceptibility allele in a plant or plant cell, the method including analysing a sample from the plant or plant cell by:

20 (a) comparing the sequence of nucleic acid in the sample with all or part of the nucleotide sequence shown in Figure 7 to determine whether the sample from the patient contains a mutation;

25 (b) determining the presence in the sample of a polypeptide including the amino acid sequence shown in Figure 7 or a fragment thereof and, if present, determining whether the polypeptide is full length, and/or is mutated, and/or is expressed at the normal level;

(c) performing DNA fingerprinting to compare the restriction pattern produced when a restriction enzyme cuts nucleic acid in the sample with the restriction pattern obtained from the nucleotide sequence shown in Figure 7 or from
5 a known mutant, allele or variant thereof;

(d) contacting the sample with a specific binding member capable of binding to nucleic acid including the nucleotide sequence as set out in Figure 7 or a fragment thereof, or a mutant, allele or variant thereof, the specific binding member including nucleic acid hybridisable with the sequence of Figure 7 or a polypeptide including a binding domain with specificity for nucleic acid including the sequence of Figure 7 or the polypeptide encoded by it, or a mutated form thereof, and determining binding of the specific binding member;

(e) performing PCR involving one or more primers based on the nucleotide sequence shown in Figure 7 to screen the sample for nucleic acid including the nucleotide sequence of Figure 7 or a mutant, allele or variant thereof.

10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95

20 59. A method of determining the presence of target nucleic acid in a plant or plant cell, the method including contacting a nucleic acid molecule which includes the nucleotide sequence shown in Figure 7 or an oligonucleotide fragment thereof with nucleic acid in a sample from the plant or plant cell and
25 assessing hybridisation of said nucleic acid molecule with nucleic acid in the sample.

60. A method according to claim 59 which involves amplification of nucleic acid to which said nucleic acid molecule hybridises.

5 61. A method according to claim 59 or claim 60 wherein said nucleic acid molecule includes an alteration in sequence compared with the nucleotide sequence shown in Figure 7 or corresponding fragment thereof.

10 62. A method according to claim 61 wherein said alteration is selected from those shown in Table 1.

15 63. An assay method for identifying a compound able to bind the polypeptide encoded by the polynucleotide of any of claims 1 to 14 or any of claims 15 to 20, the method including:

(a) bringing into contact said polypeptide or a fragment thereof, and a test compound; and
(b) determining interaction or binding between said polypeptide or fragment thereof and the test compound.

20

64. An assay method according to claim 63 wherein a compound is identified which is able to bind the polypeptide for which the amino acid sequence is shown in Figure 2.

25 65. An assay method for identifying a compound able to stimulate a defence response in a plant by interaction with the polypeptide encoded by the polynucleotide of any of claims 1 to

14 or any of claims 15 to 20, the method including:

(a) contacting a plant or plant part with a test compound and determining stimulation of a defence response; and

(b) bringing into contact said polypeptide or a fragment

5 thereof with a test compound and determining interaction or binding between said polypeptide or a fragment thereof and the test compound;

step (b) being performed with a test compound which tests positive in step (a), or step (a) being performed with a test 10 compound which tests positive in step (b), or steps (a) and (b) being performed in parallel.

15 66. An assay method according to claim 65 wherein stimulation of a defence response is determined by monitoring pathogen growth and/or viability on the plant or plant part.

67. An assay method according to claim 65 or claim 66 wherein a compound is identified which is able to bind the polypeptide for which the amino acid sequence is shown in Figure 2.

20 68. An assay method according to any of claims 65 to 67 wherein a compound is identified which is able to stimulate resistance to powdery mildew in barley.

25 69. A method which includes following identification of a compound as being able to stimulate a defence response in a plant in accordance with any of claims 65 to 68 formulation of

120

the compound, or optionally if the compound is peptidyl nucleic acid encoding it, into a composition including at least one additional component.

5 70. A method which includes following identification of a compound as being able to stimulate a defence response in a plant in accordance with any of claims 56 to 58 application of the compound, or optionally if the compound is peptidyl nucleic acid encoding it, to a plant.


10 71. Use of a polypeptide encoded by a polynucleotide according to any of claims 1 to 14, in screening for compounds able to stimulate a defence response in a plant.

15 72. Use of a polypeptide encoded by a polynucleotide according to any of claims 15 to 20, in screening for compounds able to stimulate a defence response in a plant.

20 73. A compound able to stimulate a defence response in a plant identified by a method according to any of claims 63 to 68.


1 / 28

Morphological
marker map




RFLP map

(CarlsbergII *Mlo* x
Grannenlose Zweizellige *mlo-11*)




AFLP map

(Ingrid *Mlo* x BC Ingrid *mlo-3*)




YAC YHV303-A6



BAC F15

Sequence contigs



Mlo gene structure




Figure 1

2/28

M S D K K G V P A R E L P E T P S W A V ATGTCGGACAAAAAAGGGGTGCCGGCGGGAGCTGCCGGAGACGCCGTCTGGCGGTG	60
A V V F A A M V L V S V L M E H G L H K GCGGTGGTCTTCGCCGCATGGTGCCTCGTCCTCATGGAACACGGCCTCCACAAG	120
L G H W F Q H R H K K A L W E A L E K M CTCGGCCATTGGTCCAGCACCGGCACAAGAAGGCCCTGTGGGAGGCCTGGAGAAGATG	180
K A E L M L V G F I S L L L I V T Q D P AAGGCGGAGCTCATGCTGGTGGGCTTCATATCCCTGCTCCTCATCGCACGCAGGACCCC	240
I I A K I C I S E D A A D V M W P C K R ATCATGCCAACAGATATGCATCTCCAGGATGCCGCCACGTATGTGGCCCTGCAAGCGC	300
G T E G R K P S K Y V D Y C P E G K V A GGCACCGAGGGCCGCAAGCCCAGCAAGTACGTTGACTACTGCCGGAGGGCAAGGTGGCG	360
L M S T G S L H Q L H V F I F V L A V F CTCATGTCCACGGGCAGCTGCACCAGCTGCACGTCTTCATCTTCTGCTCGCGGTCTTC	420
H V T Y S V I T I A L S R L K M R T W K CATGTCACCTACAGCGTCATCACCATAGCTCTAACCGCTCTCAAATGAGAACATGGAAG	480
K W E T E T T S L E Y Q F A N D P A R F AAATGGGAGACAGAGACCACCTCTTCCAATACAGTTCGCAAATGATCCTGCACGGTTC	540
R F T H Q T S F V K R H L G L S S T P G CGGTTCACGCCACCAGACGTCGTTGTGAAGGCCACCTGGGCTCTCCAGCACCCCTGGC	600
I R W V V V A F F R Q F F R S V T K V D Y ATCAGATGGGTGGTGGCCTTCTTCAGGCAGTTCTCAGGTCAAGTCACCAAGGTGGACTAC	660
L T L R A G F I N A H L S Q N S K F D F CTGACCTTGAGGGCAGGCTTCATCAACCGCGCATTTGTCGCAAAACAGCAAGTTCGACTTC	720
H K Y I K R S M E D D F K V V V V G I S L CACAAAGTACATCAAGAGGTGATGGAGGACGACTTCAGGTGTCGTGGCATCACGCTC	780
P L W G V A I L T L F L D I N G V G T L CCGCTGTGGGTGTGGCATTCTCACCCCTCTCGTGTGACATCAATGGGGTGGCACGCTC	840
I W I S F I P L V I L L C V G T K L E M ATCTGGATTCTTCATCCCTCTCGTGTGACATCAATGGGGTGGCACGCTGAGATG	900
I I M E M A L E I Q D R A S V I K G A P ATCATCATGGAGATGCCCTGGAGATCCAGGACCGGGCAGCGTCATCAAGGGGCC	960
V V E P S N K F F W F H R P D W V L F F GTGGTCGAGCCCAGCAACAGTTCTCTGGTCTGCCACCGCCCGACTGGTCTCTTC	1020
I H L T L F Q N A F Q M A H F V W T V A ATACACCTGACGTTGTCAGAACCGCTTCAGATGGCGATTTGTTGGACAGTGGCC	1080
T P G L K K C Y H T Q I G L S I M K V V ACGCCCGGCTTGAGAAATGCTACCAACACGCAAGATCGGGCTGAGCATCATGAAGGTGGTG	1140
V G L A L Q F L C S Y M T F P L Y A L V GTGGGGCTAGCTCTCCAGTTCTGCAGCTATGACCTTCCCCCTCTACGGCCTCGTC	1200
T Q M G S N M K R S I F D E Q T S K A L ACACAGATGGGATCAAACATGAAGAGGTCCATTCGACGAGCACGTCAAGGGCCTC	1260
T N W R N T A K E K K K V R D T D M L M ACCAACTGGCGAACACGCCAACAGGAGAAGAAGAAGTCCGAGACACGGACATGCTGATG	1320
A Q M I G D A T P S R G S S P M P S R G GCTCAGATGATCGGGCACGCCAACACGAGGCCAGGCTCGTCGCCATGCCGAGGCCGGGCG	1380

Figure 2

Figure 2 (Continued)


S S P V H L L H K G M G R S D D P Q S A
TCATCACCGTGACCTGCTTCACAAGGGCATGGGGCGGTGGACGACCCCCAGAGCGCG 1440

P T S P R T Q Q E A R D M Y P V V V A H
CCCACCTCGCCAAGGACCCAGCAGGAGGCTAGGGACATGTACCCGGTTGTGGTGGCAC 1500

P V H R L N P N D R R R S A S S S A L E
CCGGTGCACAGACTAAATCTAACGACAGGAGGAGGTCCGCCCTCGTCGTCCGCCCTCGAA 1560

A D I P S A D F S F S Q G *
GCCGACATCCCCAGTGCAGATTTCTTCAGCCAGGGATGA 1602

4 / 28

Figure 3

5/28


Figure 4

FIGURE 5

292 GCGGAGCTCATGCCTGGTGGCTTCATATCCCTGCTCCTCATCGTCACGCA 341
 || :
 80 GCANAGCTGATGCTGCTGGCTTCATNTCCCTGCTTCACCGTGGCACA 129
 || :
 342 GGACCCCCATCATGCCAAGATATGCATCTCCGAGGATGCCGCCGACGTCA 391
 || :
 130 GGCGCC...CATCTCCAANATCTGCATCCCAAGTCGGCTGCCAACATCT 176
 || :
 392 TGTGGCCCTGCAAGCGCGGCCACCGAGGGCCGC AAGCCCAGCAAGTACGT 440
 || :
 177 TGTTGCCGTGCAAGGCAGGCCNAGATGCCATCGAAGAANAAGCAGCAAGT 226
 || :
 441 TGACTACTGCCGGAGGTGAGCAGCAGAGCCGGACCAGCAGCTTCACGA 490
 || :
 227 GGTCNCNCNGTCC. TTGGCCGGCGCCGCCGGCGGGACTACTGCTCNAART 275
 || :
 491 TGATGAAGAAATCAATACC.....GAACCTTTCTTGTTTCT 528
 || :
 276 TCGATGTGAGAATAACNCCAGCTGCCGCAAGCACAACCTCGATNCNATN 325
 || :
 529 TCTGATTGTCGTCTGGCTTGGCTTAATTGGTGTGTGTGTGTGTTGC 578
 || :
 326 ACTNATT.....TAACTATAATTGATTTTCTTGGGTTTCTGC 364
 || :
 579 AGGGCAAGGTGGCGCTCATGTCACGGGCAGCTGCACCAAGCTGCACGTC 628
 || :
 365 AGGGCAAGGTGGCGCTGATGTCGGCAAAGAGCATGCACCAAGCTGCACATT 414
 || :
 629 TTCATCTTCGTGCTCGCGGTCTCCATGTCACCTACAGCGTCATCACCAT 678
 || :
 415 TTCATCTTCGTGCTCGCGTGTCCATGTTACCTACTGCATCATCACCAT 464
 || :
 579 AGCTCTAAGCGTCTCAAAGTGAGCCTTGCTTCT....TCTTCTTCTT 723
 || :
 465 GGGTTTAGGGCGCCTCAAAGTGAGTTGTCGTTCTGTCCTCATGCACAT 514
 || :
 724 CTTTTACC.....GCACGTCTGTCGTCAGGCGTACCTACCTGTTCA 765
 || :
 515 GTTTTCTCTAGTTCTAGCAANATTGTCAGTCCTTCAAATGGATTGTTCG 564
 || :
 766 TCAGGCTTGAGTAAAACGTGTCATAATCTGC.....TCCGGCATAA 807
 || :
 565 ACA.....AGAAACCCAATTTATTAAATTGCCAGTTAAATATATAATAA 608
 || :
 808 TCCTCTCCTCTG....CAGATGAGAACATGGAAGAAAATGGGAGACAGAG 853
 || :
 609 TTGATCTTCTTGGTTTAGATGAAGAAATGGAAGAAGTGGGAGTCACAG 658
 || :
 854 ACCACCTCCCTGGAATACCAAGTTGCAAATGGTCAGGATCCCCACTCTG 903
 || :
 659 ACCAACTCATTGGAGTATCAGTTGCAATCGGTAGTG.....AATTAA 701
 || :
 904 CAATCTCCC...CTTCTTCGAAACCAAAC...TGATGATCCATTAAA 946
 || :
 702 GAATCTCCCTAACTATTTCATTGCAAACCTTTATGATAATGTCTTGAAA 751
 || :
 947 GACGCAGGCACGATCAGAGTGAGTGAACGTGATGTATGTTCACTTTTG 996
 || :
 752 GAGGAGGAGCAAATCAG.CTGAAAAAATATGATCGA..... 785
 || :
 997 TCCTTTCAGATCCTGACGGTTCCGGTTCAAGCACCAAGACGTCGTTCTG 1046
 || :
 786 TCCATGCAGATCCTCACGATTCAAGGTCACGCATCAGACGTCGTTCTG 835

FIGURE 5 cont'd

7/28

1047 AAGCGCCACCTGGG.....CCTCTCCAGCACCCCTGGCATCAGATGGGTGGT 1093
836 AAGCGGCATCTGGATCATTCTCAAGCACCCTGGCTCAGATGGATCGT 885
1094 GAGTTTTTAGCTCTTATCTGCCCTCATCTGTGTGAATGTT..... 1137
886 GAGTTATCAATCTCCGAAT.....ACATGCTGTTTTTATTCTTGCA 928
1138 ..TGGCGTA.....TGGAGTCAGGTGATT.....ACCTT 1165
929 ACTGGCCTAGCTGTTCCAATTCAATCCATATTGGAAAAAAATAT 978
1166 GCCTGTGATGTTGTCCTGTCAGGTGGCCTTCAGGCAGTTCTTC 1215
979 TCATGCCGTGTTG.....TTGTTAGGTAGCATTCTTCAGGCAGTTCTT 1023
1216 AGGTCA GT CACCAAGGTGGACTACCTGACCTTGAGGGCAGGCTTCATCAA 1265
1024 GGGTCCGTACCAAGGTGGACTACCTGACCATGCGGCAAGGCTTCATCAA 1073
1266 QGTACGTGC...CTCCCCCTCTAGCTCCGCCATTGCTGCCGCGATGTAG 1311
1074 TGTATATACTAATCAAACCTGACCAATTCAACATTGATGATGC.AAACAG 1122
1312 CAGCAAAGCTTCT.....CAAGTTATCCTCTGACGCTAAAGTCCC 1354
1123 AAGACCAGGTTTTTTCCGAGTTGTGCAT.TGAAGTTAATG..... 1165
1355 TGTTTTCTCAAATTATTCTGCGCAGGCG.CATTGTCGAAAACAGC 1403
1166 .GTTTTAGCTTC...TTCTCTTTGCAGGGGCCATTGTCGAGAAATAGC 1211
1404 AAGTTCGACTTCCACAAGTACATCAAGAGGTGATGGAGGACGACTTCAA 1453
1212 AAGTTCGACTTCCACAATACATCAAGAGGTCTTGGAGGACGACTTCAA 1261
1454 GGTGCGTGTGGCATCAGGTACGTTCCATTCTCTCTGCACCAAGACCA 1503
1262 AGTTGTCGTGGCATCAGGTCCG.....TCCTCGCTT..... 1294
1504 CACCCCATGGATAGATTAAACAATTGCTGTCAGGTTCCACATGATAACA 1553
1295ATTAATTATAGGA....CTCTTATATTCAACATTTTTT 1330
1554 ATATACTATGA.ACTTGGTCTTGCTCCTGTCCTT.....CACGATCA 1597
1331 ATAAAGAAACATATTAGTCT...CCAGTTGTTATGTGTATGTGGATCT 1377
1598 TGACACATTGGCTGTTCGCAGCCTCCCGCTGTGGGGTGTGGCGATC 1647
1378 TGACACATTGG..CTGGTTTGCAAGCCTCCCTGTGGTCGTGGAATC 1426
1648 CTCACCCCTCTTGCACATCAATGGTATGGACCTTCTCCCTCTCCGGTT 1697
1427 CTTGTACTCTTCCCTCGATATCCACGGTA..ATCCTTGTCTT.....ATT 1469
1698 CTCTATTGTTGCAGCTAAATAAAACACTTGCAATTGTCCTGATCA 1747
1470 CATTCTTTTTTACTCTAAAACCTTGTCTGAATTGGTCTTATAATCA 1519
1748 CCGCTCATTTCAACCATTCTTTCTACTCATAGGGTTGGCACGCT 1797
1520 CCATCGATTTTTCAACTT.TTCCCCCGTGTAGGTCTTGGCACACT 1568
1798 CATCTGGATTCTTCATCCCTCTCGTGGTAAGTGC.AGATTCTCC.AT 1845
1569 TATTTGGATCTCTTGTCTCATCGTAAGAGCGAAATTCCCCCTGT 1618

FIGURE 5 cont'd

1846 CGAAAGCAACAGCAAACCCAATT.....TGATCGCAAT 1878
 1619 CCAAAGAAACAGTTAACATAATTAAATTATGCTTTAATTATCATGAAAAT 1668
 1879 GGAAACCCCACACCTAATATTAACACTAAAATGTCAATTGTCGGTGCCT 1928
 1669 TAATATGATCATATAACTAATGAACAAACATTCA..TGTGAATGCCACCG 1716
 1929 CCTCAACAGATCCTCTTGTGTGGAACCAAGCTGGAGATGATCATCAT 1978
 1717 TTGTCTCAGATCGTCTTGTAGTTGGGACCAAGCTAGAGATGGTGATCAT 1766
 1979 GGAGATGGCCCTGGAGATCCAGGACCGGGCGAGCGTCATCAAGGGGGCCC 2028
 1767 GGAGATGGCCCAAGAGATAACAGGACAGGGCCACTGTGATCCAGGGAGCAC 1816
 2029 CCGTGGTCGAGCCCAGCAACAAGTTCTCTGGTTCCACCGCCCCGACTGG 2078
 1817 CTATGGTTGAACCAAGCAACAAGTACTTCTGGTCACCGCCCTGACTGG 1866
 2079 GTCCCTCTTCTTCATACACCTGACGTT..... 2107
 1867 GTCTTGTCTTCATACACCTGACACTCTTCCCATGTACATGTTAAAACC 1916
 .
 .
 2108CCAGAACGC GTTTCAGATGGGGCATTTG 2136
 2017 GACGGACGGATCGATCATCACAGAACGCATTTCAGATGGCGCATTCG 2066
 2137 TGTGGACAGTG....GTACGCCAC.....CGATGAACCTGTCAGTT 2173
 2067 TATGGACTATGGTGTGTACTGCTACTGCTTAGTTGGCCTTACAGTT 2116
 2174AACATGGGTGTCA...AGGCACCGAGTGCCGCTGATGA..... 2208
 2117 CTTAACCAAATTAAAGTGTGATGCATGCACTGA.....CTAATGAGACAA 2160
 2209ACTGCTCTGACGGAGATTACTTGTGTTGT.....AGGCC 2243
 2161 AAAATGACACAGCTTGTTCATCGATCTGGTTGTTGTGACAGGCA 2210
 2244 ACGCCGGCTTGAAGAAATGCTACCAACACGCAGATCGGGCTGAGCATCAT 2293
 2211 ACACCTGGTCTGAAGAAATGCTTCCATGAAAATATTGGCTGAGCATCGT 2260
 2294 GAAGGTGGTGGTGGGGCTAGCTCTCCAGTTCTCTGCAGCTATATGACCT 2343
 2261 GGAAGTCATTGTGGGGATCTCTCTCAGGTGCTATGCAGCTACATCACCT 2310
 2344 TCCCCCTCTACCGCGCTCGTCACACAGGTAAATAAAACGTCCAGGAA 2389
 2311 TCCCGCTCTACCGCGCTCGTCACACAGGTGAACAAAGCCATTACAAA 2356

9/28

FIGURE 6

295 GAGCTCATGCTGGTGGGCTTCATATCCCTGCTCCTCATCGTCACGCAGGA 344
 |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
 1 GAGCTCNTGCTGGTGGGCTTCATATCCCTGCTCCTCATCGTCACGCAGGA 50

345 CCCCATCATGCCAAGATATGCATCTCCGAGGATGCCGCCACGTCATGT 394
 |||:|||||:|||||:|||||:|||||:|||||:|||||:
 51 TCC...CGTCTCCAGGATCTGCATCTCCAAGGAGGCCGGCGANAANATGC 97

395 GGCCCTGCAAG.....CGGGCACCGAGGGCCGCAAGCCA 430
 |||:|||||:|||||:|||||:|||||:
 98 TCCCGTGCAAGCCTTACNACGGCGCCGGTGGCAAAGGCAATGACAAT 147

431GCAAGTACGTTGACTACTGCCCGGA 455
 |||:|||:|||:|||:|||:
 148 CACCGGAGGCTTCTCTGGCTCCAAGGCGANAGCGANACCCACCGCCGGTT 197

456 GGTAGCAGCAGAGGCCGGACCAAG 479
 |||:|||||:|||||:
 198 CCTG.GCTGCCCGGCCGGANTGGACGTCTGCCCAAACAGGTGAGCACC 246

480 CAGCTTCACGATGATGAAGAAA.TCAATACCGAACCTTTCTTGTGTTCT 528
 |:|||:|||:|||:|||:|||:|||:
 247 TANCCTCNCCACAAACCACAAACTANCTAATGAGCATGGACCTGAATTTC 296

529 TCTGATTGTCGTCTGGCTTGGCTTAATTGGTGTGTGTGTGTTGC 578
 |:|||:|||:|||:|||:
 297 TTCTCTTCTTGGCTTGGCTTGACTAAATTGGT.....TGTGC 333

579 AGGGCAAGGTGGCGCTCATGTCACGGCAGCTTGACCCAGTCACGTC 628
 |:|||||:|||||:|||||:|||||:
 334 ACGGCAAGGTGGCGCTGATGTCNNCGGAANCATGCACCAACTGCACATA 383

629 TTCATCTCGTGTGCTGCCGGTCTTCCATGTCACCTACAGCGTCATCACC 678
 |:|||||:|||||:|||||:
 384 TTCATCTCGTGTGCTGCCGTCTTCCACGTCCTGTACAGCGTCGTACCAT 433

679 AGCTCTAAGCCGTCAAAGTGAGCCTTGCTTCTTCTTCTTCTT 728
 |:|||||:|||||:
 434 GACCCTAAGCCGTCCTCAAAGTGAGCATCATACTC..... 467

729 ACCGCACGTCTGTCAGGCGTACCTACCTGTTCATCAGGCTTGAGTA 778
 |:|||||:|||||:
 468GAGCTTTGTCATAATCCTT...GGTTCCAATCCAATTCCA 508

779 AAACTGTTCCATAATCTGCTCCGGCATAATCCTCTCCTGAGATGAG 828
 |:|||||:
 509 AAGCTGGCACTGATCCTGCTCCGG.....CTTCCTGCAGATGAA 547

829 AACATGGAAGAAATGGGAGACAGAGACCCACCTCTTGGAAATACCAAGTCG 878
 |:|||||:
 548 GCAATGGAAGAAGTGGGAGTCGGAGACCGCCTCGCTGGAGTATCAGTCG 597

879 CAAATGGTCAGGATCCCCACTCTGCAATCTCCCTTCTCGAAACCAA 928
 |:|||||:
 598 CGAATGGTCAG.....CTTCAACTTTCTTACTGAAA 629

929 CCTGATGATCCATT...AAAGACGCAGGCACGATCA....GAGTGAGT 970
 |:|||||:
 630 CCGGATG...CATTACAAACACGACGCACGATCAATCATCACAGTGT 676

971 GAACTGAT.GTATGTTCATTTTGTGTCT.TTCAGATCC..TGCACGG 1016
 |:|||||:
 677 GAGCCGATACGTTGAACCCGATTGAAATCCTCCGAGATCCCATGCCGG 726

10/28

FIGURE 6 cont'd

1017 TTCCGGTTCACGCACCAGACGTCGT ..CGTGAAGCGCACCTGGGCCTCT 1065
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 727 TGCGGGTTCACGCACCAGACGACGTTGGGTGAGGCGGCACCTGGGCCTCT 776

 1066 CCAGCACCCTGGCATCAGATGGTGGTGAGTTTTAGCTTCTTATCTG 1115
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 777 CCAGCACCCTGGCGTCAGATGGT..... 801

1166 GCCTGTGATGTTGTTGCCTTGTCAAGGTGGCCTTCTTCAGGCAGTTCTTC 1215
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 802GGTGGCCTTCTTCAGGCAGTTCTTC 826

 1216 AGGTCAAGTCACCAAGGTGGACTACCTGACCTTGAGGGCAGGCTTCATCAA 1265
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 827 ACgtCGGTGACCAAGGTGGACTACCTGACCTTGCGGCAGGGCTTCATCAA 876

 1266 CGTACGTGCCCTCCCTCTAGCTCCGCCATTGCTGCCGCGATGTAGCAGC 1315
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 877 C..... 877

1366 CAAATTATTCTGCCAGGGCATTGCGAAAAACAGCAAGTTGACTTC 1415
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 878GCGCATCTCTCGCAGGGCAACAGGTTGACTTC 910

 1416 CACAAGTACATCAAGAGGTGATGGAGGACGACTTCAAGGTGTCGTGCGG 1465
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 911 CACAAGTACATCAAGAGGTGTTGGAGGACGACTTCAAGGTGTCGTGCGG 960

 1466 CATCAGGTACGTTCCATTCTCCTCTGCAC.....CACACACAC 1506
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 961 CATCAGGTACGCCATTCTCTGCACAAAATTAAATACATCCACAC 1010

 1507 CCCATGGATAGATTTAACATTGCTGTCAGGTTCCACATGATAACAATA 1556
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 1011 CACATANGTAGATAGATAGA.....TCGATANATANATTA 1045

 1557 TACTATGAACCTGGTCTTGCTCCTTGTGCACGATCATGACACATT 1606
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 1046 TAC.AAGTGCCTGTACGTACGTACGTCTCAT...ATGATCTTGACACATC 1091

 1607 TGGCCTGTTTCGCAAGCCTCCCGCTGTGGGGTGTGGCGATCCTCACCCCTC 1656
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 1092 TGTCTCTTGGCGCAATCTCAAGCTCTGGTCTGTGGCGGTCTCATCCTC 1141

 1657 TTCTTGACATCAATGGTATGGACCTTCTCC.TCTCCGGTTCTCTATTG 1705
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 1142 TTCTTGATTTCGACGGTAGCCGCCTGTCCATGCCCTGCTCGCCCTCTC 1191

 1706 CTTTGAGCTAAATAAAACACTTGCATTCTCGTGTGATCACCGCTCAT 1755
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 1192 CTCCGCTTCTCCATAATTGTG.AACTTGTCCCCT.....AT 1229

 1756 TTTCAACCATTCTTTCTACTCATAGGG..TTGGCACGCTCATCTGG 1804
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 1230 ATAACCACACCACCGTCTTCTCGCAGGGATCGGCACTCTCTCTGG 1279

 1805 ATTTCTTCATCCCTCTCGTGGTAAGTGCAGATTCTCCATCGAAAGCAA 1854
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 1280 ATGTCCTGTGGTCTCTCGTGGTAAGTCCA.....CAATTGAAATAGA 1322

 1855 CAGCAAACCAATTGATCGCAATGAAACCCACACCTAATATTAACCTCA 1904
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 1323 CAACCTGTCCAATTGTGATGTACAGTACCTCCAAACTTAA.....TTA 1365

11/28

FIGURE 6 cont'd

1905 AAATGTCAATTGTCGGTGCCTTCC.....TCAACAGATCCTCTTGTGT 1949
 1366 ACATGTCAATTGCTGAT..GTCTTGCCTGTAACATTAGATCCTCTTGTGG 1413
 1950 GTTGGAACCAAGCTGGAGATGATCATCATGGAGATGGCCCTGGAGATCCA 1999
 1414 GTTGGGACCAAGCTGGAGATGGTATCATGGAGATGGCCAGGANATCCA 1463
 2000 GGACCGGGCGAGCGTCATCAAGGGGGCCCCCGTGGTCAGGCCAGCAACA 2049
 1464 TGACCGGGAGAGCGTCGTCAAGGGTGCCTCCGCCGTGAGGCCAGCAACA 1513
 2050 AGTTCTCTGGTTCACCGCCCCGACTGGTCCTCTTCTTCATAACACCTG 2099
 1514 AGTACTCTGGTCAACCGGCTGACTGGTCCTCTTCATGCACCTC 1563
 2100 ACGTTGTTCCAGAACGCGTTCAAGATGGCCTGACTGGTCCTCTTCATGCACCTC 2149
 1564 ACACCTTCCAGAACGCGTTCAAGATGGCTCATTCTGTGGACAGTGGT 1613
 2150 ACGCCACCGATGAACCTGTCAAGTTAACATGGG..... 2181
 1614 A...CNTACAAGTACTTGTCACTTCACTTANGCTAACTCCAACAAACGAA 1660
 .
 2182TGTCAAGGCACCGAGTGCCGCTGATGAACTGCTCTGACGGAG 2223
 1711 GACACAAAACCTCAATCCAACCGCGCGTAGCAAACGAACGTTTCCGTAC 1760
 2224 ATTTAC.....TTG 2232
 1761 GTTTCGTCCGTTCGCCCCATCCCAGCCAAATTGTTGACGTTGTTG 1810
 2233 TGTGTAGGCCACGCCGGCTTGAAGAAATGCTACCAACACGAGATCGGG 2282
 1811 CATCGCAGGCCACGCCGGCTTGAAGAAATGCTACCAACGAGAAAATGGCA 1860
 2283 CTGAGCATCATGAAGGTGGTGGGGCTAGCTCTCCAGTTCTCTGCAG 2332
 1861 ATGAGCATCGCCAAGGTGCGTGGGGTAGCCGCCAGATCTGTGCAG 1910
 2333 CTATATGACCTCCCCCTCACGGCTCGTCACACAGGTAATAAAACCGT 2382
 1911 NTACATCACCTCCCGCTNTACGGCTCGTCAC..... 1943
 .
 2433 AATCATCTGTGTGCTGGCTTGTATGCAGATGGGATCAAACATGAAGA 2482
 1944GCAGATGGGCTCACACATGAAGA 1966
 2483 GGTCCATCTCGACGGAGCAGACGTCCAAGGC GCTCACCAACTGGCGGAA 2531
 1967 GAAGCANCTTCGACGAGCAGACGGCCAAGGCGGCTGACCAACTGGCGAAA 2016
 2532 CACGGCCAAGGAGAAGAAGAAGTCCGAGACACGGACATGCTGATGGCTC 2581
 2017 GATGGCCAAGGAGAAGAAGAAGGCCGAGACGCCGCGCATGCTGATGGCGC 2066
 2582 AGATGATCGGGCGAGCAGCACCCGAGCCGAGGCTCGTCGCCGATGCCGAGC 2631
 2067 AGATGGGCGGGCGCGACGCCGAGCGCTGGCTNGTCGCCG..... 2107

12/28

FIGURE 6 cont'd

2632 CGGGGCTCATCACCGTGCACCTGCTTCACAAGGGCATGGGGCGGTGGGA 2681
2108 GTGCACCTGCTCCACAAGGCCGGGCGCGGTCCGA 2142
2682 CGACCCCCAGAGCGCGCCCACCTCGCCAAGGACCCAGCAGGAGGCTAGGG 2731
2143 CGACCCCCAGAGCGTGCCGGCGTCCCCGAGGGCCGAGAAGGAAGGCGGCG 2192
2732 ACATGTACCCGGTTGTGGTGGCGACCCGGTGCACAGACTAAATCCTAAC 2781
2193 GC..... GTGCAGCATCCGGCGCGCAAGGTACCTCCTTGT 2227
2782 GACAGGAGGAGGTCCGCCCTCGTCGTCGGCCCTCGAAGGCCGACATCCCCAG 2831
2228 GACGGGTGGAGGTCCGCCCTCGTCGCCGGCGCTCGACGCTCACATCCCCGG 2277
2832 TGCAGATTTCCTTCAGC CAGGGATGAGACAAGTTCTG 2871
2278 TGCAGATTGGCTTCAGCACGCAACGTTGACCGATCAGACAAGTTCCCTT 2327
2872 TATT 2875
2328 TTTT 2331

Figure 7

13/28

GGCTGGCTCGGCCAGCAACCAGACACRCAAGCAGCGTACCTCGCT
 ACGTAGCGTCCGGCTTTCTTTTTCTTCGCTCTTGCTGCTCCGGCGGCCAG
 TCGATAGCGGCCACGGCCAGGCACCTCGGGTTGCGTCGCTGCATCTGCCTGTGCGTA
 CCTGGTAGAGGGCGGCCCTGCTTGCTCCGGCAAGGARGGAGGTTGCGGGGTCGACCG
 M S D K K G V P A R E L P E T P S **W-A-A-V-A-V** 20
 helix I ATGCGGACAAAAAGGGTGCCTGGCGCGGGAGCTGCGGAGRCGCCGTCGTGGCGGTG 60
A-X-V-A-V-F-A-A-M-V-L-V-S-V-L-H-E-H-G-L-H-K 40
 GCGGTGGCTTCGGCCATGGTCTCGTCGCTCCATGGAAACACGGCTCCAGAAC 120
 L G H W F Q H R H K K A L W E A L E K M 60
 CTCGGCATTGGTTCAGCACGGCAACAAGAAGGCCCTGTCGGAGGCGCTGGAGAAGATG 180
 K A E **L-M-L-V-G-F-I-S-L-W-L-I-V-N-T-E-Q-D-E** 80
 RAGGGGGAGCTCATGCTGGCTTCATATCCCTGCTCCATCGTCACGGCAGGGACCCC 240
I-W-I-P-A-A-K-M-T-C-I-S-E-D-A-A-D-V-M-W-P-C-K-R 100
 ATCATCGCAAGATAATGCATCTCGAGGATGCGCCGAGCTCATGTCGGCCCTGCAAGCGC 300
 G T E G R K P S K Y V D Y C P E G X V A 120
 GGCACCGAGGGCCSRAAGCCAGCAAGTACGTTGACTCTGCCGGAGGGCAAGGGTGGCG 360
 L M S T G S L H Q L H **V-F-E-I-V-F-V-L-E-A-S-V-E-F** 140
 CTCATGTCCACGGGCAGCTTGCAACCAGTCGACGTCATGTCATCTGCTCGGGCTTC 420
H-V-T-Y-S-V-I-T-I-A-L-S-R-L-K-M-R-T-W-X 160
 CATGTCACCTACAGCGTCACTACCATAGCTTAAGCGCTCTCAAATGAGAACATGGAAG 480
 K W E T E T T S L E Y Q F A N O D P A R F 180
 AAATGGGAGACAGAGACCACTCTTGGAAATACAGTCGCAATGATCTGACCGGTT 540
 R F T H Q T S F V K R H L G L S S T P G 200
 CGGTTACGCACAGAGCTCGTCGAGGCGACCTGGCCACCTGGGCTCTCCAGCACCCCTGGC 600
 I R W V V A F F R Q F F R S V T X V D Y 220
 ATCAGATGGGTGGCTGGCCTCTTCAGGCACTTCAGGTCAGTCACCAAGGTGGACTAC 660
 L T L R A G F I N A R L S Q N S X F D F 240
 CTGACCTTGAGGGCAGGCTTCATCAACCGCATTGTCGCAAAACAGCAAGTTCGACTTC 720
 H K Y I K R S M E D D O F K **V-V-V-G-I-S-L** 260
 CACAAGTACATCAAGAGGTGCAAGGAGGACGACTCAAGGTCGTCGCGCATCGCCTC 780
P-L-W-G-V-A-I-L-T-L-F-L-D-I-N-G-V-G-T-E-L 280
 CCCCTGTTGGGATCTGGGATCTCCTACCCCTTCTGACATCATGGGTTGGCACGGCTC 840
I-W-I-S-F-I-P-L-V-I-L-L-C-V-G-T-X-L-S-M 300
 ATCTGGATTTCTTCATCCCTCTCGTCTCTGTTGAGGATCTGGGATCTGGGAGATG 900
 I I M E M A L E I Q D R A S V I K G A P 320
 ATCATCATGGAGATGGCCCTGGAGATCCAGGACGGCGAGCTCATCAAGGGGCC 960
 V V E P S N K F F W F H R P D W V L F F 340
 GTGGTCGAGGCCAGCAACAAGTCTCTGGTCCACCGCCCCGACTGGGCTCTTCTTC 1020
 I H L T L F Q N A F Q M A H F V W T V A 360
 ATACACCTGACGTTGTCAGACCGCTTCAGATGGCGCATTTGTGGACAGTGGCC 1080
 T P G L K K C Y H T Q I G L S I M K **V-E-V** 380
 ACGCCCGCTTGAAGAAATGCTACCAACACGCAAGTGGCTGACGGCATCATGAAGGTGGTG 1140
V-G-L-A-B-O-F-L-C-S-Y-M-T-F-P-L-Y-A-L-E-S-V 400
 GTGGGGCTAGCTCCAGTTCTCTGCAAGCTATAGACCTTCCCTCTACGGCGCTCGTC 1200
T-Q-M-G-S-N-M-X-R-S-I-F-D-E-Q-T-S-K-A-L 420
 ACACAGATGGGATCAAACATGAAGAGGTCATCTCGACGAGCGAGCTCAAGGGCGCTC 1260
 T N W R N T A K E **K-K-K-V-R-D-T-D-M-L-M** 440
 ACCAACTGGCGGAACACGGCCAGGGAGAAGAAGAAGATGCTGGAGACACGGCATGCTGATG 1320
 A Q M I G D A T P S R G S S P M P S R G 460
 GCTCAGATGATCGCGACGGCAACACCGAGGCCAGGGCTCGTCGCCGATGCCGAGCCGGC 1380
 S S P V H L L H K G M G R S D D P Q S A 480
 TCATCACCCGTGCACCTGCTTCACAGGGCATGGGGCGGCTGGAGACCCCCAGAGCGCG 1440
 P T S P R T Q Q S E A R D M Y P V V V A H 500
 CCCACCTGCCAACGGACCGAGGGCTAGGGACATGATCCCGTTGTGGTGGCCAC 1500
 P V H R L N P N D R R R S A S S S A L E 520
 CCGGTGACAGACTAAATCTAACGACAGGGAGGCTGGGCTGCTCGTCGCCCTCGAA 1560
 A D I P S A D F S F S Q G *
 GCCGACATCCCCAGTCAGATTTTCTTCAGCCAGGGATGAGACAAAGTCTGTATTCA
 TGTAGTCCCAATGTATAGCCAACATAGGATGTRATGATTGCTACAAATAAGAAATACAAAT
 TTTTACTGAGTC

Figure 8

14 / 28

1 GAATTCAATT AAGGACAAACA ACGGATGATA GGCTTAAGCT AGAGAGGATT
 51 CATATGGATT AATTAACTGT ACTTAAAGTTG AGGTAAAACCT CTATCGATTG
 101 CTTTGGACAC CGGCTCTCCC ATGATCTGCC AAGTTGAGCC GGCCTACCTA
 151 ATTTTCTTCG AAAGCACACA ACAAACGAAG GTAACCACCA ATCTAGACAC
 201 CACGCCCTAAG TTATCAATTAA CTACTCTAGT CTCGCGTAGA AACTTCATTC
 251 TTTATGGAGA GTGCTAGTAC TAGAGTACTT AATATAATAG TAAGCGACAA
 301 ACCCACGACG ATGAGAATGT ACCTCACTTA CGTAGTCAT TAAGTCGAAA
 351 AGGAAATCTT GAACACTTAC TTTATTAAG AAGTATTCCC CGAGGTACAG
 401 GAGAGGAGAG CACGCCAATA ACTCCAGCAC TCCTCCGAAA CCTTTCTCAC
 451 TCTCTACCCCT TTTTCTCCAC ACAACTAAAA TGATGTCTAA TGTATGAAAG
 501 TGAGTTGTAC TCTATTTGT TGTGTGTTG GAAGTGAAT TAGTCATCC
 551 TTTTATAGCA ACTTAATGGT CGGTTGTAGG TTGGTAAATTAA ACTCCGTAAA
 601 CACTCACAAAC CACCATCGTC AACCAATAGG AGATGCCAC ATGATCGAAA
 651 GCTGACAGTT AGGGGTGCCA ACCCTGTTT GTCCGAACCA ACCAAACAAAC
 701 CTCTATCTAG GACCTCTCTT CTATCTCTGA CAAGTCGGCC CATATGGCGG
 751 TGCACATATGG ATTAAGTCAA TTTCAAGTCGT TTTGGACTGT CATGTGGGCC
 801 CTTCCAATCC TTGTGCTCCC ATATGATTGG TCGAAAGTAC ATTAAATTCC
 851 TGGGTGAGTG CTAGAACTAA TATGATAGAT GTGCTCCGGC TCCTGGGAAA
 901 GAGGCCACTM GACATACTTG GGGTACTGCC CCAGGGTAT TCCCTATCGC
 951 TTTTCATAAA TTTTCTCTCT CCAAAATCGG ACGGAAACAA TAAAAAAGAG
 1001 AGGCGATGTT CATCGCAAA TATCTATTTT TTTGATAGTC TCTTCCCTTA
 1051 AAACCTGATT TTTGCGAAGA CTTCCGGCTA AAACCATGAA ATCAGAGTT
 1101 CTTGTAACAA ATTAAATTG CCTAAATACA AAAAAGATCG AATGGAGATA
 1151 GCATTAACACT TGCTCCATAC GAATCATATT AGTTGGACCG TAACTCATAG
 1201 AAAAAGTTGC AAGTTGGTTG ACCTATCAAC CCTCTTATGT TGACCGTAAA
 1251 CCTGTTATGC ATTAAGGATT AAGTACCGGC AGATCGTCAC TACTCACCGAA
 1301 TGCACAAATT TCCGGTAACG TAGGATGGGA TGAGTTGGTC AGAAACGGGT
 1351 CACCACGTGCG CCCAACCTGC CGCGATCGAG CCATGGCCG GCGATGCACG
 1401 CCCTTTGACA CAGCCGCCCG CGGCCCCCCCG GCCCGCCCCC GTTTTTAATA
 1451 AAAACCGGCC GCCCCCTGTC AAAGGTCTCA AAGTGTCAAG TGCATCAGAG
 1501 CTAAGCTAGC GGTCACCCAG TCAGCTCACC CCGAGACGCA CCAGGGGATC
 1551 TATCGGATCA TGGCAGGTGG GAGATCGGGA TCGCGGGACT TGCCGGAGAC
 1601 GCGCAGCTGG CGGGTGGCCG TCGTCTGCCG CGTCCTCGTG CTCCCTCCG
 1651 CCGCCATGGA GCACGGCCTC CACAACCTCA GCCATGTACG CGCGCGCGCA
 1701 CGCGGTGTGC TCATCTCTCG AGTTAAATTG GTTGTGTTG TTGTGTGTT
 1751 CTTGTCACAT CTCAATTAAAC ATCCGATCGT GGTGATCGA TCGCCCTGTG
 1801 GTGGCGATAC TGCTTGCATT GCACTGGCTTC CGTAGGGGGC AGAAGAAGGC
 1851 CATGGCGAC GCCCTCCACAGC AGATCAAGC AGTCACCCCT CAGCCTCAGC

09720374-1292000

15/28

FIGURE 8 cont'd

1901 TCACCCCTCAG CCTCCATCTC TAAATATTTG ACGCCGTTGA CTTTTTTAAA
 1951 TATGTTTGAC CATTGTCTT ATTTAAAAAA TTTAAGTAAT TATTAATTCT
 2001 TTTTCTACCA TTTGATTCAT TGCTAAATAT ACTATTATGT ATACATATAG
 2051 TTTTACATAT TTCACTAAAG TTTTTAAATA AGACGAATGG TCAAACATGT
 2101 TTAAAAAAAGT CAACGGCGTC AAACATTAG GAAGAAGAGA ATATTATATT
 2151 GCTGCTCCCC TCTAGCCACT TTGCTGCCTC CCTCGTCATT TTTTCAAGTA
 2201 TTTTACGCAA GACTGGTCCT CCAAATCAA CGTCACAAAT AAGCCATTAA
 2251 TAGTTTCCCTT TCGCTTTTA AGGGGGACTA CTTGTATTAA ATCATGGAGG
 2301 AAACTACCAG TCGGATGTCC GATTACTTAA AAAAAAATTC GGGGGACTAA
 2351 TTTTTTGGC TGATCATCGG TGAAATATTA GGTTATATAT GTTGAAAAAA
 2401 AATCAGCCAC AAACAATGAA ATATTTGTG AAACACATAT TAGACACGTT
 2451 GAAACGTATC ATTGTTACGT ATAAAACATC GAATGTTAAC AGATTAAAAC
 2501 ATATGTTTTT TTTTAATCAG AATATAATCA TGCGATATAT TATTGTAAAG
 2551 ATATAATTAC AACGAATACA ACAGTGCGAT CGGATTATAT ATATATTAGT
 2601 AGTTTAAGAG AAAAATCATT TTGAAGATTA CTAGATACAT ACACGTATAG
 2651 ATGGATGAAG TGGAGAGAGA TTAGAGATAA GTAGTTATAT GAATTTGTG
 2701 AAACACACTT AAGACATATG TTCAAACATA CTGCTATTAT GTATGAAATA
 2751 TTGAGTTTTA ACGGTTAAA ACACATATTC TTTAATTAG AATGTAATAA
 2801 TGTGATATCT TGGTGTAAAA TTTAATTACA TCTAATATAA CGGTGTGATT
 2851 AGATTGTATG TTGGATAACA TGCCCATCGG TTGGCTTATT TAGGGAATAA
 2901 GCCAAATGGT ATATTTGCAA ACGAAAAATA ATTTGTAAAT AAAACTTTA
 2951 TGTATGTATT CTTAACGATC TAGCAGCAAA GGCTGAAAAA TAAACTTCGA
 3001 TGAAAATCT CAAAATCAAC TCTTAAAATT TAAATTTGG CTTATAAGTA
 3051 TAGTTCTAA CTAGTTAGA AGAAAAAATA TTTAAAGCGG GGAAGAGGAA
 3101 AAGGAATAAA CTAATAGCTA AATTATTGCA TGCATGTAGC GATTTGAGGA
 3151 CGACCGAGTT GTTTGTCTG GATCAGCCGA CCGAGACAGA GCAATCTCT
 3201 TTAATCATAA ATAACCAGAA AAACCATACC AGTCATCAC AATGGACCGA
 3251 GTCAGAGTCA TTACATATTTC TTCAATTGTTG CGCACAGGAT TCACCATGTT
 3301 CTTATGGGAA ATATTTTAA CTCTCAAATG GTTATGATT TGAACTCTCA
 3351 TTTTGAGAG AGAATTAACA AGCGAGCGAG CAATCAGGCC AAAAAGGGAG
 3401 AAAGAAAATT ATTTTGTAA ATTTTTTTT AAGGTAGGGT GGAGGAGTCA
 3451 TTACATGATT TTTTTTATA TTCCCTCGTT GATTATATGC TGTTCAAATG
 3501 GTTATGATT TTTAAAAGA TAACAACAAT ACAAAATTAGT ATGTGATAGA
 3551 TCATTCACG AGCATATAGG ATTAAATTAA ACTTCTGTAA ATTACAAAAC
 3601 AAACAAGTTT AACTGTTAAT ATACATTAAA TTTGTTTTT TCAACTTAGG
 3651 AATTGAATT TATGTATATA TTTGTAAAAT GATATATTAA TTTATTTTT
 3701 TAAAAAATA ATTATTTAGA TAACACGCAA ACTAGAAAAC CACCGCAGAA
 3751 GTTCTCATAT TTCTTGTCTT ATCTGCACCT GCAGAGCTGA TGCTGCTGGG
 3801 CTTCATATCC CTGCTTCTCA CGGTGGCACA GGCGCCCATC TCCAAGATCT

0920037-412300

16/28

FIGURE 8 cont'd

3851 GCATCCCCAA GTCGGCTGCC AACATCTTGT TGCCGTGCAA GGCAGGCCAA
 3901 GATGCCATCG AAGAAAGAAG CAGCAAGTGG TCGCCGGTCC TTGGCCGGCG
 3951 CCGGCAGCGG GGACTACTGC TCGAAATTG ATGTGAGAAT AACACCAGCT
 4001 GCCGGCAAGC ACAACCTCGA TGCAATAACT AATTTAACTA TAATTGATTT
 4051 TTCTTGGGTT TTCTGCAGGG CAAGGTGGCG CTGATGTCGG CAAAGAGCAT
 4101 GCACCAGCTG CACATTTICA TCTTCGTGCT CGCCGTGTT CATGTTACCT
 4151 ACTGCATCAT CACCATGGGT TTAGGGGCC TCAAAGTGAG TTTGTCGTT
 4201 TGTCCCTCAT GCACATGTTT TCTCTAGTTC TAGCAAGATT GTCAGTCCTT
 4251 CAAATGGATT GTTTCGACAA GAAACCCAAT TTATTAATTG GCCAGTAAAT
 4301 ATATAATAAT TGATCTTCT TGGTTTTAGA TGAAGAAATG GAAGAAGTGG
 4351 GAGTCACAGA CCAACTCATT GGAGTATCAG TTCGCAATCG GTAGTGAATT
 4401 AAAAATCTCC CTAACTATTT CATTTCAGAA CCTTTATGAT AATGTCTTGA
 4451 AAAGAGGAGGA GCAAATCAGC TGAAAAATAT GATCGATCCA TGCAGATCCT
 4501 TCACGATTCA GGTTCACGCA TCAGACGTCG TTGCTGAAGC GGCATCTGGG
 4551 ATCATTCTCA AGCACCCCTG GGCTCAGATG GATCGTGAGT TATCAATCTC
 4601 CGAATAACATG CTTGTTTTT ATTCTTGAA CTGGCCTAGC TGTTCCAATT
 4651 CAATCCATAT TTTTGAAAAA AAAAAATATT CATGCCGTGT TTGTTGTTAG
 4701 GTAGCATTCT TCAGGCAGTT CTTGGGTCC GTCACCAAGG TGGACTACCT
 4751 GACCATGCGG CAAGGCTTCA TCAATGTATA TACTAATCAA ACCTGACCAA
 4801 TTCAACATTG ATGATGAAA CAGAGACCAG GTTTTTTTT TCGAGTGTGC
 4851 ATTGAGTAAT GGTTTAGCT TCTTCTCTT TGCAGGCGCA TTTGTCGCGAG
 4901 AATAGCAAGT TCGACTTCCA CAAATACATC AAGAGGTCTT TGGAGGACGA
 4951 CTTCAAAGTT GTCGTTGGCA TCAGGTCCGT CCTCGCTTTA TTAATTATAG
 5001 GACTCTTATA TTCAACATTG TTTTTATAAA GAAACATATT TAGTCTCCAG
 5051 TTGTGTATGT GTATGTGGAT CTTGACACAT TTGGCTGGTT TTGCAGCCTC
 5101 CCTCTGTGGT TCGTCGGAAT CCTTGTAATC TTCCCTCGATA TCCACGGTAA
 5151 TCCTTGTCCCT ATTTCATTCT TTTTTTTACT CTCAAAACCT TGTTCTGAAT
 5201 TGGTCTTATA ATCACCATCG ATTTTTTTTC AACTTTTCC CCGCGTGTAG
 5251 GTCTTGGCAC ACTTATTG ATCTCTTTG TTCCCTCTCAT CGTAAGAGCG
 5301 AAATTCCT GTCCAAAGAA ACAGTTAACAA TAATTAATT TGCTTTAATT
 5351 TATCATGAAA ATTAATATGA TCATATAACT AATGAACAAA CATTCATGTG
 5401 AATGCCACCG TTGTCTCAGA TCGTCTTGT AGTTGGGACC AAGCTAGAGA
 5451 TGGTGATCAT GGAGATGGCC CAAGAGATAC AGGACAGGGC CACTGTGATC
 5501 CAGGGAGCAC CTATGGTTGA ACCAAGCAAC AAGTACTTCT GGTTCAACCG
 5551 CCCTGACTGG GTCTTGTCT TCATACACCT GACACTCTTC CATGTACATG
 5601 TTTAAACCT AAACCTTGCT GCTCAACTAC AAATAGTACT TTATCTTCA
 5651 CAATTAACAC CTAATTAACT AACATAGGCAT CCATCCATT GTGGCTACTG
 5701 ATCGATGGGA CGACGGATCG ATCATCACCA GAACGCATTT CAGATGGCGC
 5751 ATTTCGTATG GACTATGGTG TGTATGCTAC TTGCTTAGTT GTGCCATTAA

17/28

Figure 8 cont'd

5801 TCAGTTCTTA AGCAAATTAA GTGTGATGCA TGCACTGACT AATGAGACAA
 5851 AAAATGACAC AGCTTGTTC TCGATCTGGT TGTTTGTGT GTGACAGGCA
 5901 ACACCTGGTC TGAAGAAATG CTTCCATGAA AATATTTGGC TGAGCATCGT
 5951 GGAAGTCATT GTGGGGATCT CTCTTCAGGT GCTATGCAGC TACATCACCT
 6001 TCCCCGCTCTA CGCGCTCGTC ACACAGGTGA ACAAGCCATT CACAAATTCT
 6051 ATTAGCCGTT TCTTAATTGA TGACACTGTT AATTTTTAGA CACACGTTTT
 6101 GACCATTGT CTTATTAAAA ATATTATGT AATTATCATT TGAGTTGT
 6151 TATCACTAAA AGTACTTTTT AAATAATTAA TATTTTGAT TTGTACAATT
 6201 CTTTTAATAA GATAATGGTC AACATGTGT CCAAAAGTTA ACAGCATCAT
 6251 CTATTAAGAA AAGGAGGGT TTTTTTTTTT TGGAAATTTC CAAATTTGT
 6301 TCAAAATCAG TCCAAAACCT TTTTTTTTTT CGAAATTTC TCA GTTTCACTAC
 6351 CAGTCCCCAT AAAATGTCTT TTCTTTATTT CCACAAGRTT GAACCCATGA
 6401 GATGCCCTTT GTGTTGGTAT GTGTTTGGC CATCACTTGC AGATGGGATC
 6451 GAACATGAAG AAGACAATT TCGAGGAGCA AACGATGAAG GCGCTGATCA
 6501 ACTGGAGGAA GAAGGCCATG GAGAAGAAGA AGGTCCGGGA CGCCGACGCG
 6551 TTCCTGGCGC AGATGAGCGT CGACTTCGCG ACGCCGGCGT CGAGCCGGTC
 6601 CGCGTCGCCG GTGCACCTGC TGCAGGTAC AGGGCGGGTC GGACGCCCGC
 6651 CGAGCCCAAT CACGGTGGCC TCACCAACGG CACCGGAGGG GACATGTACC
 6701 CGGTGCCGGC GGCAGCTGCG TCTCGCCAGC TGCTAGACGA CCCGCCGGAC
 6751 AGGAGGTGGA TGGCATCTTC GTCGGCCGAC ATCGCCGATT CTGATTTTC
 6801 CTTCAAGCGCA CAACGCTGAC GGGGGCGATC GGTTTCTGTA TTGATGCTGT
 6851 ACCAAACATA CGAGTTAAC ATATATATAA TTGTTACGGT AAAATCTAAT
 6901 TATTGTGCGC GCACCTTATAT TAGTCTTATA GCGCGACTGG TTCGTGATTA
 6951 GACAAGGTGA TGCATGCTGT TTAGTTATAA AGGATATCAG CGCAGCTAAA
 7001 AAAACTTAAT CCTACTTAA TAGATGACCT CGTTGATTT TAACATTATT
 7051 CGTCTTATTT AAAAATTAA TGCAAATGTT TAAACATAA ATCATGCTTA
 7101 AAGTACTTTT AGTGATAAAA CAACTTACAA CAAATAAAT TATACTTACC
 7151 TAATTTTTT TAATAARTCG AATGG

09263373 412605

1 TTATACCATG TGAGAAAGGC TGGAAGCATA TGCTCTTAGC AGGGACGCGT
51 GCATGTTTAT ATAGGAGGCA TAAGCCGAAG AGATATACAT GAGGAGAGGT
101 TTAAGATCAG TCTATCTTAT TTACAGTTA AACACAAGGA GATAGAAAGA
151 GATCCTAACCA ACCACATGTT ATACAAGTCA CGTATAATAC AAGAGTTATT
201 TCGTCTAACCA CCCTCCCCTC TGATATGATA AGTCGCCGGG AGAGAGAGAG
251 AGTGTGTGGC TGCCCTCGCT GCACTGCACG CACATGTTA CTTCTCCGAC
301 TGAAACCACG GTGAAACCGG CGGCGGTGTC GCACTCCCCT GACTTTCCCTC
351 GCCGGGGTCC CGTCCGGACA ATTAAACCGT CTGTACCTGC CGGGCGTCGA
401 CCCGATCGTG ATGTGGCGCC GCTTTGTCTG CAGCGAGCTG CGTGGCCGAT
451 GGCAACAAAA CTGCGGTAC ATACATGCAT ACCCCGCATA CCCCACGCT
501 CACCAAGTAAG TAGGCTGTGG TGCGGCACCA CGGGCTCGCC GCCATTGATG
551 CCATGCATGG GCCACCCGCC GGCGAAACCG CGGGCGCTGCT GCCTGCCACC
601 CCGCCGCCGT TGACGAAGAC TTCGCCCCGC CATCCATAAA AGCATGCATG
651 GCTTGCTCTC ACCGGTCCGG CCACACACAC CACACTTCAC TTGCGCCATTC
701 GCACCACCGA GAGCGTAGCG TAACGTGTGT TTGAAGTCCT ACCATTAATT
751 TTGCTGGATC GATGGCTGGG CGGGCGGGAG GTCGGGAGCT GTGGACACG
801 CCGACGTGGG CGGTGGCGGT AGTCTGCGCC GTCATGATAC TCGTCTCCGT
851 CGCCATGGAG CACCGCTCC ACAAGCTCGG CCACGTACGT GCTCTCGGTT
901 CACTAGTGCT TAACTGTTT TGATGTTTC GGGCGTGTGTT GGTAGCCTGC
951 ATGGAGAGTG TATGAGCCCA AAAGTTCCCT CCCCACCCA CTTTCGCTG
1001 TTTGGTAGGG TGTATGGGCT GAGGAGAGCA TGCATCAACT GATGCAAAA
1051 GGGCCTCAGC ATAGCTGAGC CCAGCACCCC CGCAGAGGCG AGCTGAGGCG
1101 AGTTATGCTG AGCCCATGCA CCCTGCCCGT GTGCCCGGT CGCCCCGTG
1151 CTCCCCCCCCT GCACCTCTTC CTCCCTCCCTC TTCCCTACCAA ACACAGTCTC
1201 ATCCAAACAT GTAACAAACAC ATGCATGACC ACCAAACAAAC TGAAGATGAA
1251 TGTATTTCATC ATGTCTATAC TTACCATGCA TCAACAGGGA ACAACTATGC
1301 TAGGGTGAGA ACAGCTGCCA AACACACCCG TGACACCTACT CATGCTGTGC
1351 CGGCGCTGGC GTACGTGTGC AGTGGTTCCA CAAGTGGCGC AAGAAGGCC
1401 TGGGGGAGGC GCTGGAGAAG ATGAAGGCAGG AGCTCATGCT GGTGGCTTC
1451 ATATCCCTGC TCCTCATCGT CACGCAGGAT CCCGTCTCCA GGATCTGCAT
1501 CTCCAAGGAG GCCGGCGAGA AGATGCTCCC GTGCAAGCCT TACGACGGCG
1551 CCGGCGGTGG CAAAGGCAAG GACAATCACC GGAGGCTTCT CTGGCTCCAA
1601 GGCAGAGCG AGACCCACCG CCGGTTCCCGT GCTGCCCGGG CCGGAGTGG
1651 CGTCTGCGCC AAACAGGTGA GCACCTAGCG TCGCCACAAA CCACAAACTA
1701 GCTAATGAGC ATGGACCTGA ATTTCTCTC TTCTTGGCTT GGCTTGACTA
1751 AATTGGTTGT GCAGGGCAAG GTGGCGCTGA TGTCAAGCGGG AAGCATGCAC
1801 CAACTGCACA TATTGATCTT CGTGCTCGCC GTCTTCCACG TCTTGTACAG
1851 CGTCGTCACC ATGACCCCTAA GCCGTCTCAA AGTGAAGCATT ATACTCGAGC

1901 TGTTTGTCAA TAATCCTTGG TTTCCAATCC AATTCCAAAG CTGGCACTGA
1951 TCCTGCTCCG GCTTCCTGCA GATGAAGCAA TGGAAAGAAGT GGGAGTCGGA
2001 GACCGCCTCG CTGGAGTATC AGTTCGCGAA TGGTCAGCTT CAACTTTCT
2051 TACTGAAACC GGATGCATTT ACAACAAACG CACGCACGAT CAATCATCAC
2101 AGTGTGAGCC GATACTGTTGA ACCGATTGAA TCCTCGCAGA TCCATCGCGG
2151 TGCCGGTTCA CGCACCAAGAC GACGTTGGTG AGGCGGCACC TGGGCCTCTC
2201 CAGCACCCCCC GGCGTCAGAT GGGTGGTGGC CTTCTTCAGG CAGTTCTTCA
2251 CGTCGGTGAC CAAGGTGGAC TACCTGACCT TGCAGGCAGGG CTTCATCAAC
2301 GCGCATCTCT CGCAGGGCAA CAGGTTCGAC TTCCACAAGT ACATCAAGAG
2351 GTCTGGAG GACGACTTCA AAGTCGTCGT CCGCATTAGG TACGCGCCAT
2401 TCCTTTCTCT GCACAAATTAA ATACATCCAC CACCACATAG GTAGATAGAT
2451 AGATCGATAG ATAGATTATA CAAGTGCCGG TACGTACGTA CGTCTCATAT
2501 GATCTTGACA CATCTGCTT CTTGCCGAG TCTCAGCTC TGGTTCGTGG
2551 CGGTCCAT CCTCTTCCTT GATTTCGACG GTAGCCGCCT TGTCCATGCC
2601 CTGCTCGCCC TCTCCTCCGC TTCTCTCCAT AATTTGTGAA CTTGTCCCGT
2651 ATATAACCAC ACCACCGTCG TCTTCTCGCA GGGATCGGCA CTCTTCTCTG
2701 GATGTCCGTG GTTCCTCTCG TGGTAAGTCC ACAATTGAA TAGACAACCT
2751 GTCCAATTGT GATGTACAGT ACCTCCAAAC TTAATTAAACA TGTCAATTG
2801 TGATGTCTTG CGTGTAAACAT TAGATCCTCT TGTGGTTGG GACCAAGCTG
2851 GAGATGGTGA TCATGGAGAT GGCCCAGGAG ATCCATGACC GGGAGAGCGT
2901 CGTCAAGGGT GCTCCCGCCG TCGAGCCAG CAACAAGTAC TTCTGGTTCA
2951 ACCGGCCTGA CTGGGTCTC TTCTCATGC ACCTCACACT CTTCCAGAAC
3001 GCGTTTCAGA TGGCTCATTT CGTGTGGACA GTGGTACGTA CAAGTACTTG
3051 TCACTTCACT TAGGCTAACT CCAACAAACG ACCCCAAATT AATGGTCCGT
3101 CGCGTCTGTT TGGGGTATGT TTGGGGTAAA CGGACACAAA ACTCAATCCA
3151 ACGCGCGGT ACAAACGAAC GTTTTCCGT ACGTTTCGT CCGCTTCGC
3201 CCCATCCCAG CCCAAATTG TGACGTTGT TGCATCGCAG GCCACGCCCG
3251 GCTTGAAGAA ATGCTACAC GAGAAAATGG CAATGAGGCAT CGCCAAGGTC
3301 GTGCTGGGGG TAGCCGCCA GATCTGTGC AGCTACATCA CCTTCCCGCT
3351 CTACCGCTC GTCACGCAGA TGGGCTCACA CATGAAGAGA AGCATCTTCG
3401 ACGAGCAGAC GGCCAAGGCG CTGACCAACT GGCAGAAAGAT GGCCAAGGAG
3451 AAGAAGAAGG CCCGAGACGC GGCCATGCTG ATGGCGCAGA TGGCGGGCGG
3501 CGCGACGCCG AGCGTCGGCT CGTCGCCGGT GCACCTGCTC CACAAGGCCG
3551 GGGCGCGGTC CGACGACCCC CAGAGCGTGC CGGCGTCCCC GAGGGCCGAG
3601 AAGGAAGGCG GCGGCGTGCA GCATCCGGCG CGCAAGGTAC CTCCCTGTGA
3651 CGGGTGGAGG TCGGCCTCGT CGCCGGCGCT CGACGCTCAC ATCCCCGGTG
3701 CAGATTTGG CTTCAGCACG CAACGTGAC CGATCAGACA AGTTCCCTTT
3751 TTTTTCGGTG AATAGAAGCG TATCATTTCA TTGATAGACA GTAGAAATTAA
3801 CAGGAATGGC TGTCCCTACTA CTATGTACAC AAGGGCACAG CAAAGGATCA

20/28

Figure 9 cont'd

3851 TTGATCTTGT TACAAGAGCA GTAGAAAGGG ATTGCTCTCC ATTGATCTTG
3901 TTAAGTTGTA TGTCACAAAT TGTTGCAGAA AAAAGTGTAT GTCATCCCAA
3951 CCAAGAGCTG AGTTTGTGAT GATTCGTGCA ATAAGAATTG CAAGTTTCAC
4001 CGAGTCAAAA ATGAAGCTTC TAAGTACGCCA CCACACCAACG GACTCTTTCA
4051 TCTCAACAAA AGAACTGTAA ATGGCAATAA TTCTGATAAC ATCGGAAGGG
4101 AGCTC

Figure 10

1 ATGGCAGGTG GGAGATCGGG ATCGCGGGAG TTGCCGGAGA CGCCGACGTG
51 GGCGGTGGCC GTCGTCTGCG CCGTCCTCGT GTCGTCTCC GCCGCCATGG
101 AGCAGGGCCT CCACAAACCTTC AGCCATAAAA CCACCGCAGA AGTTCTCATTA
151 TTTCTTGTC TATCTCCACT TGCAGAGCTG ATGCTGCTGG GCTTCATATC
201 CCTGCTCTC ACCGTGGCAC AGGCGCCCAT CTCCAAGATC TGCATCCCCA
251 AGTCGGCTGC CAACATCTTG TTGCCGTGCA AGGCAGGCCA AGATGCCATC
301 GAAGAAGAAG CAGCAAGTGG TCGCCGGTCC TTGCCCGGGCG CGGGCGGGCG
351 GGACTACTGC TCGAAATTG ATGGCAAGGT GGCGCTGATG TCGGCAAAGA
401 GCATGCACCA GCTGCACATT TTCATCTTG TGCTCGCCGT GTTCCATGTT
451 ACCTACTGCA TCATCACCAT GGGTTTACGG CGCCTCAAAA TGAAGAAATG
501 GAAGAAGTGG QAGTCACAGA CCAACTCATT GGAGTATCAG TTGGCAATCG
551 ATCCTTCACG ATTCAAGGTT ACACATCAGA CGTCGTTCGT GAAGCGGCAT
601 CTGGGATCAT TCTCAAGCAC CCCTGGCTC AGATGGATCG TAGCATTCTT
651 CAGGCAGTTC TTTGGGTCCG TCACCAAAGGT GGACTACCTG ACCATGCGGC
701 AAGGCTTCAT CAATGCGCAT TTGTCGAGA ATAGCAAGTT CGACTTCCAC
751 AAATACATCA AGAGGTCTTT GGAGGACGAC TTCAAAGTTG TCGTTGGCAT
801 CAGCCTCCCT CTGTGGTTCG TCGGAATCCT TGTACTCTTC CTCGATATCC
851 ACGGTCTTGG CACACTTATT TGGATCTCTT TIGTTCCTCT CATCATCGTC
901 TTGTTAGTTG GGACCAAGCT AGAGATGGTG ATCATGGAGA TGGCCCAAGA
951 GATACAGGAC AGGGCCACTG TGATCCAGGG AGCACCTATG GTTGAACCAA
1001 GCAACAAGTA CTTCTGGTTC AACCGCCCTG ACTGGGTCTT GTTTTTCATA
1051 CACCTGACAC TCTTCCATAA CGCATTTCAG ATGGCGCATT TCGTATGGAC
1101 TATGGCAACA CCTGGTCTGA AGAAATGCTT CCATGAAGAT ATTTGGCTGA
1151 GCATCGTGG A GTCAATTGGTG GGGATCTCTC TTCAGGTGCT ATGCAGCTAC
1201 ATCACCTTCC CGCTCTACGC GCTCCTCACA CAGATGGGAT CGAACATGAA
1251 GAAGACAATT TTCGAGGAGC AACCGATGAA GGGCTGATG AACTGGAGGA
1301 AGNAGGCAT GGAGAAGAAG AAGGTCCGGG ACGCCGACCC GTTCCCTGGCG
1351 CAGATGAGCG TCGACTTCGC GACGCCGGCG TCGACCCGGT CGCGTGC
1401 GGTGCACCTG CTGCAGGTCA CAGGGGGGT CGGACGCCCG CGAGGCCAA
1451 TCACGGTGGC CTCACCACCG GCACCGGAGG AGGACATGTA CCCGGTGC
1501 GCGGCGGCTG CGTCTCGCCA GCTGCTAGAC GACCCGCCGG ACAGGAGGTG
1551 GATGGCATCC TCGTCGGCCG ACATGCCGA TTCTGATTTT TCCTTCAGCG
1601 CACAACGGTG A

22/28

Figure 11

1 ATGGCTGGGC CGGCGGGAGG TCGGGACCTG TCGGACACGC CGACGTGGGC
51 GGTGGCGGTA GTCTGCCCG TCATGATACT CGTCCTCCGTC GCCATGGACC
101 ACCGCGCTCCA CAAGCTCGGC CACTGGTCC ACAACTGGCG CAAGAAGGCC
151 CTGGGGGAGG CGCTGGAGAA GATGAAGGCG GAGCTCATGC TGCTGGCCTT
201 CATATCCCTG CTCCCTCATCG TCACCGAGGA TCCCGTCTCC AGGATCTGCA
251 TCTCCAAGGA GGCCGGCGAG AAGATGCTCC CGTGCAAGCC TTACGACGGC
301 GCCGGCGGTG GCAAAGGCAA GGACAATCAC CGGAGGCTTC TCTGGCTCCA
351 AGGCGAGAGC GAGACCCACC CCCGGTTCCCT GGCTGCCCG GCGGGAGTGG
401 ACGTCTGCAC CAAACAGGGC AAGGTGGCCC TGATGTCAGC GGGAAAGCATG
451 CACCAACTGC ACATATTCACT CCTCGTCTCC GCGCTCTTCC ACGTCTTGTAA
501 CAGCGTCGTC ACCATGACCC TAAGCCCTCT CAAAATGAAG CAATGGAAGA
551 AGTGGGAGTC GGAGACCGCC TCGCTGGAGT ATCAGTTCGC GAATGATCCA
601 TCGGCGGTGCC CGTTCACGCA CCAGACGACG TTGGTGAGGC GGACACCTGGG
651 CCTCTCCAGC ACCCCCCGGCG TCAGATGGGT GGTGGCCTTC TTCAGGCAGT
701 TCTTCACGTC GGTGACCAAG GTGGACTACC TGACCTTGCCT GCAGGGCTTC
751 ATCAACGCGC ATCTCTCGCA GGGCAACAGG TTGCACTTCC ACAAGTACAT
801 CAAGAGGTCC TTGGAGGACG ACTTCAAAGT CGTCGTCCGC ATCAGTCTCA
851 AGCTCTGGTT CGTGGCGGTC CTCATCCCTCT TCCCTGATTT CGACGGGATC
901 GGCACTCTTC TCTGGATGTC CGTGGTTCCCT CTCGTGATCC TCTTGTGGGT
951 TGGGACCAAG CTGGAGATGG TGATCATGGA GATGGCCCGAG GAGATCCATG
1001 ACCGGGAGAG CGTCGTCAAG GGTGCTCCCG CCGTCGAGCC CACCAACAAG
1051 TACTTCTGGT TCAACCCGCC TGACTGGTC CTCTTCCCTCA TGCAACCTCAC
1101 ACTCTTCCAG AACGGCTTTC AGATGGCTCA TTTCTGTGTCG ACAGTGGCCA
1151 CCCCCGGCTT GAAGAAATGC TACCACGAGA AAATGGCAAT GAGCAGTCGCC
1201 AAGGTCGTGC TGGGGGTAGC CGCCCGAGTC TTGTGCGAGCT ACATCACCTT
1251 CCCGCTCTAC CGCCTCGTCA CGCAGATGGG CTCACACATC AAGAGAACCA
1301 TCTTCGACGA GCAGACGGCC AAGGCCCTGA CCAACTGGCG AAAAGATGGCC
1351 AAGGAGAAGA AGAAGGCCCG AGACGGCCGC ATGCTGATGG CGCAGATGGG
1401 CGGGCGGCCG ACGCCGAGCG TCGGCTCGTC GCCGGTGCAC CTGCTCCACA
1451 ACGGCGGGGC CGGCTCCGAC GACCCCGAGA CGGTGCCGGC GTCCCCGAGG
1501 CCCGAGAAGC AAGGCCGGCG CGTGCAGCCTT CCGGCGCCCA AGGTACCTCC
1551 TTGTGACGGG TGGAGGTCGG CCTCGTCGCC GGCGCTCGAC GCTCACATCC
1601 CCGGTGCAGA TTTTCCCTTC AGCACGCAAC GTTCA

1 GTTGGTACAT AAAAGACTCT TCCTTTGTCT GTTTTTGTT CCCAGATTCA
51 TCTTTACTTA TTGACTAAAT TCTCTCTGGT GTGAGAAGTA AAATGGGTCA
101 CGGAGGAGAA GGGATGTCGC TTGAATTCAC TCCGACGTGG GTCGTCGCCG
151 GAGTTTGTAC GGTCATCGTC GCGATTTCAC TGGCGGTGGA GCGTTTGCTT
201 CACTATTCG GTACTGTCT TAAGAAGAAG AAGCAAAAAC CCCTTACGA
251 AGCCCTTCAA AAGGTTAAAG AAGAGCTGAT GTTGTAGGG TTTATATCGC
301 TGTTACTGAC GGTATTCCAA GGGCTCATTT CCAAATTCTG TGTGAAAGAA
351 AATGTGCTTA TGCATATGCT TCCATGTCT CTCGATTCAA GACGAGAACG
401 TGGGGCAAGT GAACATAAAA ACGTTACAGC AAAAGAACAT TTTCAGACTT
451 TTTTACCTAT TGTTGGAACC ACTAGGGCGTC TACTTGCTGA ACATGCTGCT
501 GTGCAAGTTG GTTACTGTAG CGAAAAGGTT AAAGTACCAT TGCTTTCGCT
551 TGAGGCATTG CACCATCTAC ATATTTCAT CTTCGTCCCTC GCCATATCCC
601 ATGTGACATT CTGTGTCCTT ACCGTGATTT TTGGAAGCAC AAGGATTCAC
651 CAATGGAAAGA AATGGGAGGA TTGATCGCA GATGAGAAGT TTGACCCCCGA
701 AACAGCTCTC AGGAAAAGAA GGGTCACTCA TGTACACAAC CATGCTTTTA
751 TTAAAGAGCA TTTTCTTGGT ATTGGCAAAG ATTCAAGTCAT CCTCGGATGG
801 ACGCAATCCT TTCTCAAGCA ATTCTATGAT TCTGTGACGA AATCAGATTA
851 CGTGACTIONA CGTCTTGGTT TCATTATGAC ACATTGTAAG GGAAACCCCA
901 AGCTTAATT CCACAAGTAT ATGATGCGCG CTCTAGAGGA TGATTTCAA
951 CAAGTTGTTG GTATTAGTTG GTATCTTGG ATCTTGCTCG TCATCTTTT
1001 GCTGCTAAAT GTTAACGGAT GGCACACATA TTTCTGGATA GCATTTATTC
1051 CCTTTGCTTT GCTTCTTGGCT GTGGGAACAA AGTTGGAGCA TGTGATTGCA
1101 CAGTTAGCTC ATGAAGTTGC AGAGAAACAT GTAGCCATTG AAGGAGACTT
1151 AGTGGTGAAA CCCTCAGATG AGCATTTCTG GTTCAGCAAA CCTCAAATTG
1201 TTCTCTACTT GATCCATTTC ATCCTCTTCC AGAATGCTTT TGAGATTGCG
1251 TTTTCTTTT GGATTTGGGT TACATACGGC TTGACTCGT GCATTATGGG
1301 ACAGGTGAGA TACATTGTTCAAGATTGGT TATCGGGGTC TTCATTCAAG
1351 TGCTTGCAG TTACAGTACA CTGCCTCTT ACGCCATCGT CTCACAGATG
1401 GGAAGTAGCT TCAAGAAAGC TATATTGAG GAGAATGTGC AGGTTGGTCT
1451 TGTTNGTTGG GCACAGAAAG TGAAACAAAA GAGAGACCTA AAAGCTGCAG
1501 CTAGTAATGG AGACGAAGGA AGCTCTCAGG CTGGTCCTGG TCCTGATTCT
1551 GGTCTGGTT CTGCTCCTGC TGCTGGCCT GGTGCAGGTT TTGCAGGAAT
1601 TCAGCTCAGC AGAGTAACAA GAAACAACGC AGGGGACACA ACAATGAGA
1651 TTACACCTGA TCATAACAAAC TGAGCAGAGA TATTATCTTT TCCATTAGA
1701 GGATCATCAT CAGATTTAG CTTCAAGGTC CGGTTTGTG GTTTATACAT
1751 AAGTTATAGT GACTTGATTT TTTTGTGTTG TTACAAAGTT ACCATCTTTG
1801 GATTAGAATT GGGAAATTGA ATCTGTTGAT ATATTGTATT ATTTGGAACA
1851 TTGTGGATGC CCATGGATAT GTTCTGTTTC

1 MAGGRSGSRE LPETPTWAVA VVCAVLVLVS AAMEHGLHNL SHKTTAEVLI
51 FLVLSALAEI MLLGFISLLL TVAQAPISKI CIPKSAANIL LPCKAGQDAI
101 EEEAASGRRS LAGAGGGDYC SKFDGKVALM SAKSMHQLHI FIFVLAVFHV
151 TYCIITMGLG RLKMKKWKKW ESQTNLEYQ FAIDPSRFRF THQTSFVKRH
201 LGSFSSTPGL RWIVAFFRQF FGSVTKVDYL TMRQGFINAH LSQNSKFDFH
251 KYIKRSLEDD FKVVVGISLP LWFGILVLF LDIHGLGTLL WISFVPLIIIV
301 LLVGTKLEMV IMEMAQEIQD RATVIQGAPM VEPSNKYFWF NRPDWVLFFI
351 HLTLFHNAFQ MAHFVWTMAT PGLKKCFHEN IWLSIVEVIV GISLQVLCSY
401 ITFPLYALVT QMGSNMKTI FEEQTMKALM NWRKKAMEKK KVRDADAFLA
451 QMSVDFATPA SSRSASPVHL LQVTGRVGRP PSPITVASPP APEEDMYPVP
501 AAAASRQLLD DPPDRRWMAS SSADIADSDF SFSAQR*

1 MAGPAGGREL SDTPTWAVAV VCAVMILVSV AMEHALHKLG HWFHKWRKKA
51 LGEALEKMKA EMLVGFISL LLIVTQDPVS RICISKEAGE KMLPCKPYDG
101 AGGGKGKDNH RRLWLQGES ETHRRFLAAP AGVDVCAKQG KVALMSAGSM
151 HQLHIFIFVL AVFHVLYSVV TMTLSRLKMK QWKKWESETA SLEYQFANDP
201 SRCRFTHQTT LVRHLGLSS TPGVRWVVAF FRQFFTSVTK VDYLTLRQGF
251 INAHLSQGNR FDFHKYIKRS LEDDFKVVR ISLKLWFVAV LILFLDFDGI
301 GTLLWMSVVP LVILLWVGTK LEMVIMEMAQ EIHDRESVK GAPAVEPSNK
351 YFWFNRPDWV LFLMHLTQ NAFQMAHFVW TVATPGLKKC YHEKMAMSIA
401 KVVLGVAAQI LCSYITFPLY ALVTQMGSHM KRSIFDEQTA KALTNWRKMA
451 KEKKKARDAA MLMAQMGGGA TPSVGSSPVH LLHKAGARSD DPQSVPASPR
501 AEKEGGGVQH PARKVPPCDG WRSASSPALD AHIPGADFGF STQR*

26 / 28

Figure 15

1 MGHGGEGMSL EFTPTWVVAG VCTVIVAIISL AVERLLHYFG TVLKKKKOKP
51 LYEAALQKVKE EMLLIGFISL LLTVFQGLIS KFCVKENVLM HMLPCSLDSR
101 REAGASEHICN VTAKEHFQTF LPIVGTTRRL LAEEAAVQVG YCSEKGKVPL
151 LSLEALMHLH IFIFVLAISH VTFCVLTIVF GSTRIHQWKK WEDSIADEKF
201 DPETALRKRR VTIIVHNHAFI KEHFLGIGKD SVILGWTQSF LKQFYDSVTK
251 SDYVTLRLGF IMTHCKGNPK LNFKYMMRA LEDDFKQVVG ISWYLWIFVV
301 IFLLLNVNGW HTYFWIAFIP FALLLAVGPK LEHVIAQLAH EVAEKHVAIE
351 GDLVVVKPSDE HFWFSKPQIV LYLIHFILFQ NAFELAFFFW IWVITYGFDSC
401 IMGQVRYIVP RLVIQVFQIV LCSYSTLPIY AIVSQMGSSF KKAILEENVO
451 VGLVGWAQKV KQKRDLKAAA SNGDEGSSQA GPGPDSGSGS APAAGPGAGF
501 AGIQLSRVTR NNAGDTNNEI TPDHNN*

092233774400

FIGURE 16

Hymlo-H1	MAGPAG	GR	ELS DTT P T W A V	AVV C A V U M M L V	S V A M E H A L H K	L G H W F H K W R K	K A L G E A L E K M
Mlo	NSD KKG	V PAR	EL PET T P S W A V	AVV F A M V L V	S V L M E H G L H K	L G H W F Q H R H K	K A L W E A L E K M
Osmlo-H1m	MAGGRE	GSR	SEE F T P T W A V	AVV C A V U V L V	S A M E H G E H N	L E S H V I K T A	E V L I F L W S A
Atnlo-H1	M G H G E G M		SEE F T P T W A V	AVV C A V U V L V	S L A M E H R L L H Y	E F G T V L K R K Q	K P L Y E A L Q K V
Consensus	M - - - G - - - R	EL - - T P T W A V	AVV C A V U V L V	S - A M E H L H -	L G H - - - K - -	R - L - E A L - K -	-
Hymlo-H1	KAELMLVGF		S L L I V T Q D P	W S R I C I S K E	A G E K M L P C .	. K P Y D A G G	G K G K D N H R R L
Mlo	KAELMLVGF		S L L I V T Q D P	I I S K I C I S E D	A A D M W P C .	. K .	R G T E G R K P S
Osmlo-H1m	LAELMLLGFI		S L L I V T Q D P	I I S K I C I P K S	A A N E H P C .	. K .	E E A A S G R R S
Atnlo-H1	KEELMLLGF		S L L I V T Q D P	I I S K I C I W K E N	V L M H M L P C S L	D S K R E A G A S E	H K N V T A K E H F
Consensus	KAELML - GFI		S L L I V T Q D P	- I S K I C I -	A - - M L P C -	- K - - - A -	-
Hymlo-H1	LWLOGESETH	B R F L A P A G V	D V . C A K . Q G K	V A L M S A G S M H	Q L H I F I F V L A	V E H V L Y S V V T	-
Mlo	KYVD . . .		W K K W E S E T T S	LE Y Q F A N D P S	R C R F T . . H O T	S S T P G V . R W V	
Osmlo-H1m	TA S R L K M K Q		W K K W E S E T T S	LE Y Q F A N D P A	R E F T . . H O T	S S T P G I . R W V	
Atnlo-H1	MGGRLLKMKQ		W K K W E S E T T S	LE Y Q F A N D P S	R E F T . . H O T	S S T P G L . R G I	
Consensus	- L - R L K E -		W K K W E S E T T S	LE Y Q F A N D P S	R E F T . . H O T	S S T P G F . C V T	
Hymlo-H1	MTLSR4LKMKQ		W K K W E S E T T S	LE Y Q F A N D P S	R E F T . . H O T	S S T P G L . R G I	
Mlo	TA S R L K M K Q		W K K W E S E T T S	LE Y Q F A N D P A	R E F T . . H O T	S S T P G L . R G I	
Osmlo-H1m	MGGRLLKMKQ		W K K W E S E T T S	LE Y Q F A N D P S	R E F T . . H O T	S S T P G L . R G I	
Atnlo-H1	VGESTENHQ		W K K W E S E T T S	LE Y Q F A N D P S	R E F T . . H O T	S S T P G L . R G I	
Consensus	- L - R L K E -		W K K W E S E T T S	LE Y Q F A N D P S	R E F T . . H O T	S S T P G L . R G I	
Hymlo-H1	VAFFRQFFTS		V T K V D Y L T L R	Q G F I N A H L S Q	K R S L E D D F K V	V U R I S L K L W F	-
Mlo	VAFFRQFFRS		V T K V D Y L T L R	A G F I N A H L S Q	K R S M E D D F K V	V V G I S L P L W G	
Osmlo-H1m	VAFFRQFFGS		V T K V D Y L T L R	Q G F I N A H L S Q	K R S L E D D F K V	V V G I S L P L W G	
Atnlo-H1	QSEFWKQFEDS		V T K V D Y L T L R	N S K F D F H K Y I	M R A L E D D F K Q	V V G I S M Y L W F	
Consensus	VAFFRQFF - S		V T K V D Y L T L R	N P K ^{top} N F H K Y I	K R S L E D D F K V	V V G I S M Y L W F	
Hymlo-H1	VA V L L F L D F		D G I G T L W M S	G T K L E V V I N E	M A C E I H D R E S	V V K G A P A V E P	-
Mlo	VA V L L F L D I		D G I G T L W M S	G T K L E V V I N E	M A C E I Q D R A S	V I K G A P V V E P	
Osmlo-H1m	UGILVLFEMKV		D G I G T L W M S	G T K L E V V I N E	M A C E I Q D R A T	V I Q G A P M V E P	
Atnlo-H1	F V V F E M K V		D G I G T L W M S	G T K L E V V I N E	M A H E M A E R H V	A I E G D L V V K P P	
Consensus	V - - L - L E D D -		D G I G T L W M S	G T K L E V V I N E	M A - E I - D R - -	V I - G A P - V E P	
Hymlo-H1	SNK YFWFNRP		D W V L F L W M S	V V P L V I L L W V	G T K L E V V I N E	M A C E I H D R E S	-
Mlo	SNK YFWFHRP		D W V L F L W M S	F I P L V I L L W V	G T K L E V V I N E	M A C E I Q D R A S	
Osmlo-H1m	SNK YFWFNRP		D W V L F L W M S	F I P L V I L L W V	G T K L E V V I N E	M A C E I Q D R A T	
Atnlo-H1	SEEHFWFSNP		D W V L F L W M S	F I P L V I L L W V	G T K L E V V I N E	M A C E I H D R E S	
Consensus	SNK - F W F - R P		D W V L F L W M S	F I P L V I L L W V	G T K L E V V I N E	M A C E I Q D R A T	

FIGURE 16 (CONT/D)

28/28

Hymlo-H1	A C I L C S Y I T F	P L Y A L V T Q M G	S H M K R S I F D E	Q T A K A L T N W R	K M A K E K K K A R	D A A M L M A Q M G
Mlo	L C F F L C S Y M T F	P L Y A L V T Q M G	S N M M K R S I F D E	Q T M K A L M N W R	N T A K E K K K V R	D T D M L M A Q M I
Osmlo-H1m	L Q V L C S Y I T F	P L Y A L V T Q M G	S N M M K R S I F D E	Q T M K A L M N W R	K K A M E K K K V R	D A D A F L A Q M S
Atmlo-H1	I Q V L C S Y S T F	P L Y A H V S Q M G	S S F K K A I F F E	N V Q V G L V G W A	Q K V K Q K R D L K	A A A S N G D E G S
Consensus	- Q - L C S Y - T F	P L Y A L V T Q M G	S - M K - - T F - E	Q T - K A L - N W R	- A K E K K K - R	D A - - - A Q E M -
Hymlo-H1	G G A T - - - -	P S V G G S S P V	H L E H K A G A R S	D D P Q S V P A S P	R A E K E G - - -	G G V Q H P A R K
Mlo	G D A T P S R G S S	P M P S R G S S P V	H L E H K G M G R S	D D P Q S A P T S P	R T Q Q E A R D M Y	P V V V A H P V H R
Osmlo-H1m	V D - - - -	P A S S R S A S P V	H L E Q - V T G R V	G R E P S P I T V A	S P P A P E E D M Y	P V P A A A S R Q
Atmlo-H1	S Q A G P G P D S G	S G S A P A A G P	· · · G A G F A	G I Q L S R V T R N	N A G D T N N E I T	P D H N N * . . .
Consensus	- A - - - -	- - S - - S P V	H L E - - - G R -	- - P - S - - T -	- - - - - - - -	P - - - - - - -
Hymlo-H1	V - - P F C D G W R	S A S S P A L D A H	I P G A D F G F S T	Q R *		
Mlo	L - - N P N D R R R	S A S S S A L E A D	I P S A D F S F S Q	G * .		
Osmlo-H1m	L L D D P P D R R W	M A S S S . . . A D	I I A D S D F S F S A	Q R *		
Atmlo-H1	·	·	·	·		
Consensus	- - E - D - -	- A S S - - - A -	I - - D F - F S -	- - - - -		